Diagnostic and therapeutic approaches used to treat breast cancer

By determining the estrogen receptor pathway activity score in breast cancer patients, identifying and treating patients who may benefit, using endocrine therapy such as SERD, the problem of uncertain breast cancer treatment effect in the prior art is solved, and more efficient treatment is achieved Effect.

CN113490850BActive Publication Date: 2024-12-06GENENTECH INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN201980067809.7
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2018-08-17
Filing Date
2019-08-16
Publication Date
2024-12-06
Estimated Expiration
2039-08-16

AI Technical Summary

Technical Problem

The prior art is difficult to effectively diagnose and treat breast cancer, especially due to insufficient prediction of estrogen receptor (ER) pathway activity, resulting in uncertain therapeutic effects of endocrine therapy.

Method used

By identifying the estrogen receptor pathway activity score from individual samples, patients with breast cancer who may benefit from endocrine therapy and monitor treatment responses using endocrine therapies such as selective estrogen receptor modulators (SERDs).

Benefits of technology

It improves the accuracy and effectiveness of breast cancer treatment, ensures the effectiveness of endocrine therapy, and enhances the predictive ability of treatment response to breast cancer patients.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN113490850B_ABST
    Figure CN113490850B_ABST
Patent Text Reader

Abstract

In particular, predictive diagnostic methods, pharmacodynamic methods, and therapeutic methods for treating breast cancer are provided herein. In an embodiment, the methods and compositions are based at least in part on the following findings: an estradiol (E2) induction score or an estrogen receptor (ER) pathway activity score determined from a sample from an individual (e.g., a tissue sample, such as a tumor tissue sample, such as a FFPE, FF, archived, fresh, or frozen tumor tissue sample) can be used to determine whether the individual with breast cancer is likely to respond to a treatment including endocrine therapy; can be used in a method for selecting a therapy for an individual with breast cancer; can be used in a method for treating an individual with breast cancer; can be used in a method for monitoring the therapeutic effect of endocrine therapy, and can be used in a related kit.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] Cross-references to related applications

[0002] This application claims priority to U.S. Provisional Application No. 62 / 719,545, filed August 17, 2018, the disclosure of which is incorporated herein by reference in its entirety for all purposes.

[0003] Refer to the "Sequence List"

[0004] The sequence listing file format is 048893-517001WO_SEQUENCE_LISTING_ST25. TXT Created on August 13, 2019, 560,154 bytes, machine format IBM-PC, MS-W INDOWS Operating systems, the full text of which is incorporated herein by reference for all purposes. Technical Field

[0005] This article provides, in particular, diagnostic and treatment methods for breast cancer. For example, it provides methods for predicting treatment response, monitoring treatment response, selecting treatment, treatment methods, and diagnostic kits. Background Technology

[0006] Cancer remains one of the deadliest threats to human health. In the United States, cancer afflicts nearly 1.3 million new patients each year, making it the second leading cause of death after heart disease, accounting for about a quarter of all deaths. Solid tumors are the primary cause of these deaths. Despite significant advances in the medical treatment of some cancers, the overall 5-year survival rate for all cancers has improved by only about 10% in the past 20 years.

[0007] The estrogen receptor (“ER”) is a ligand-activated transcriptional regulatory protein that mediates the induction of a variety of biological effects through its interaction with endogenous estrogen. Estrogen and the estrogen receptor are associated with cancers such as breast cancer, lung cancer, ovarian cancer, colon cancer, prostate cancer, endometrial cancer, uterine cancer, and other diseases or conditions. However, estrogen receptor degradation as measured by immunohistochemistry (IHC) is insufficient as a predictor of ER pathway activity or a pharmacodynamic (PD) biomarker for endocrine therapy; ER protein levels are not always correlated with ER pathway status. For example, activators of ER signaling, such as the ER ligand estradiol (E2), promote ER degradation. Furthermore, the progesterone receptor (PR) is a recognized ER target gene and is often used as a readout measure of ER pathway activity; however, PR is not always present in ER+ breast tumors, and even when present, PR inhibition may not fully capture ER pathway status.

[0008] Therefore, there is an unmet need for biomarkers (e.g., transcriptional signatures) that comprehensively reflect ER pathway activity and can be used for diagnosis and treatment. Summary of the Invention

[0009] This article provides, in particular, diagnostic methods, treatment methods, kits for informing individuals with breast cancer about treatment, and kits for predicting an individual's response to breast cancer treatment.

[0010] In one aspect, a method is provided for identifying individuals with breast cancer who may benefit from treatments including endocrine therapy, the method comprising determining an estrogen receptor (ER) pathway activity score from a sample from the individual, wherein an ER pathway activity score from the sample that reaches or exceeds a reference ER pathway activity score identifies the individual as an individual who may benefit from treatments including endocrine therapy.

[0011] In one aspect, a method for selecting a therapy for an individual with breast cancer is provided, the method comprising determining an ER pathway activity score from a sample from the individual, wherein an ER pathway activity score from the sample that reaches or exceeds a reference ER pathway activity score identifies the individual as an individual who may benefit from a treatment including endocrine therapy.

[0012] In one aspect, a method for treating an individual with breast cancer is provided, the method comprising administering an effective amount of endocrine therapy to the individual, wherein the individual has been identified as an individual more likely to benefit from treatment including the endocrine therapy described herein.

[0013] In one aspect, a method is provided for treating an individual with breast cancer who is identified as having an ER pathway activity score that meets or exceeds a reference ER pathway activity score, the method comprising administering an effective amount of endocrine therapy to the individual.

[0014] In one aspect, a method for treating an individual with breast cancer is provided, the method comprising: (a) determining an ER pathway activity score from a sample from the individual, wherein the ER pathway activity score from the sample is determined to be at or above a reference ER pathway activity score; and (b) administering an effective amount of endocrine therapy to the individual.

[0015] In one aspect, a method is provided for monitoring the response of an individual with breast cancer to treatment with endocrine therapy, the method comprising: (a) determining a first ER pathway activity score from a sample from the individual at a first time point; (b) determining a second ER pathway activity score from a sample from the individual at a second time point after administration of endocrine therapy, following step (a); and (c) comparing the first ER pathway activity score with the second ER pathway activity score, wherein a decrease in the second ER pathway activity score relative to the first ER pathway activity score predicts that the individual may respond to endocrine therapy.

[0016] On one hand, a method is provided for identifying individuals with breast cancer who may benefit from treatment, including endocrine therapy, the method comprising determining an estradiol (E2) induction score from a sample from the individual, wherein an E2 induction score from the sample that reaches or exceeds a reference E2 induction score identifies the individual as an individual who may benefit from treatment, including endocrine therapy.

[0017] In one aspect, a method for selecting a therapy for an individual with breast cancer is provided, the method comprising determining an E2-inducing score from a sample from the individual, wherein an E2-inducing score from the sample that reaches or exceeds a reference E2-inducing score identifies the individual as an individual who may benefit from a treatment including endocrine therapy.

[0018] In one aspect, a method for treating an individual with breast cancer is provided, the method comprising administering an effective amount of endocrine therapy to the individual, wherein the individual has been identified as an individual more likely to benefit from treatment including the endocrine therapy described herein.

[0019] In one aspect, a method is provided for treating an individual with breast cancer who is identified as having an E2 induction score that reaches or exceeds a reference E2 induction score, the method comprising administering an effective amount of endocrine therapy to the individual.

[0020] In one aspect, a method for treating an individual with breast cancer is provided, the method comprising: (a) determining an E2-inducing score from a sample from the individual, wherein the E2-inducing score from the sample is determined to be at or above a reference E2-inducing score; and (b) administering an effective amount of endocrine therapy to the individual.

[0021] In one aspect, a method is provided for monitoring the response of an individual with breast cancer to treatment with endocrine therapy, the method comprising: (a) determining a first E2-induced score from a sample from the individual at a first time point; (b) determining a second E2-induced score from a sample from the individual at a second time point after the administration of endocrine therapy, following step (a); and (c) comparing the first E2-induced score with the second E2-induced score, wherein a decrease in the second E2-induced score relative to the first E2-induced score predicts that the individual may respond to treatment with endocrine therapy.

[0022] In one aspect, a method is provided for detecting estrogen receptor (ER) pathway activity in subjects with breast cancer, the method comprising detecting the expression levels of at least five genes listed in Table 1 and at least five genes listed in Table 4; at least five genes listed in Table 2 and at least five genes listed in Table 5; or at least five genes listed in Table 3 and at least five genes listed in Table 6.

[0023] In one aspect, a method is provided, comprising: detecting first expression levels of at least five genes listed in Table 1, at least five genes listed in Table 2, or at least five genes listed in Table 3 by one or more processors; detecting second expression levels of at least five genes listed in Table 4, at least five genes listed in Table 5, or at least five genes listed in Table 6 by one or more processors; and detecting estrogen receptor (ER) pathway activity in a subject with cancer based at least on the first expression level and / or the second expression level.

[0024] In one aspect, a kit is provided comprising a plurality of nucleic acids, wherein the plurality of nucleic acids are at least 5 nucleotides in length and have at least 95% identity with a 5-nucleotide sequential sequence within at least five genes listed in Table 1 and at least five genes listed in Table 4, at least five genes listed in Table 2 and at least five genes listed in Table 4, or at least five genes listed in Table 3 and at least five genes listed in Table 6, or a sequence complementary to the 5-nucleotide sequential sequence has 95% identity. Attached Figure Description

[0025] This application contains at least one color drawing. Upon request and payment of the necessary fees, the Patent Office will provide a copy of this patent or patent application with color drawings.

[0026] Figure 1A This is an overview of estradiol (E2)-inducible genes shown in red (columns) in seven breast cancer cell lines (rows). E2 induction is defined as a ≥2-fold change in E2 expression after treatment compared to DMSO treatment (p-value ≤0.05).

[0027] Figure 1B This is an overview of the E2 repressor genes shown in blue (columns) in seven breast cancer cell lines (rows). E2 repression is defined as a change in E2 expression ≤ 1 / 2 fold compared to DMSO treatment (p ≤ 0.05).

[0028] Figure 1C It is a heatmap showing the z-score expression of 23 E2-inducing genes and 18 E2-repressing genes in 989 breast tumors from the Cancer Genome Atlas (TGCA), annotated with estrogen receptor (ER) immunohistochemical (IHC) status and PAM50 subtype.

[0029] Figure 1D This shows the E2 induction score (defined as E2 induction score) of 726 ER IHC+ and 213 ER IHC- breast tumors from TCGA RNA-seq data. Figure 1C The graph shows the overlap reference density curves of the average z-score expression of the 23 E2-induced genes.

[0030] Figure 1E This shows the E2 inhibition score (defined as E2 suppression score) of 726 ER IHC+ and 213 ER IHC- breast tumors from TCGA RNA-seq data. Figure 1C The graph shows the overlap reference density curves of the average z-score expression of the 18 E2 repressor genes.

[0031] Figure 1F This is a graph showing the overlapping reference density curves of ER pathway activity scores (defined as the difference between E2 induction scores and E2 inhibition scores) for 726 ER IHC+ and 213 ER IHC- breast tumors from TCGA RNA-seq data.

[0032] Figure 2A This is a graph showing the in vivo efficacy of treatment with compound A (selective estrogen receptor degrader (SERD)) at specified compound A concentrations in a mouse model of hormone receptor (HR)-positive breast cancer derived from HCI-013 patients, assessed by changes in tumor volume over time.

[0033] Figure 2B This is a heatmap showing the relative changes in z-score expression of 20 E2-inducing genes and 14 E2-repressing genes in HCI-013 tumors after treatment with compound A. The treatment regimen is annotated above.

[0034] Figure 2C This is relative to the animal treated with the medium, in HCI-013 tumors after exposure to compound A, expressed as mean log10 A set of bar graphs showing the fold change in E2 induction score, E2 inhibition score, and ER pathway activity score. The bar graphs show the mean relative score and standard error, n=4. One-sided t-test: *, p<0.05; **, p<0.01; ***, p<0.001; comparisons in black (1 mg / kg vs. 0.1 mg / kg); comparisons in red (10 mg / kg vs. 1 mg / kg).

[0035] Figure 2D This is a graph showing the in vivo efficacy of treatment in an HR-positive breast cancer HCI-013PDX mouse model, using a mediator or compound B (SERD), compound C (SERD / hybrid SERM), or compound F (SERD) at a specified concentration, assessed by changes in tumor volume over time.

[0036] Figure 2E This is a heatmap showing the relative changes in z-score expression of 20 E2-inducing genes and 14 E2-repressing genes in HCI-013 tumors after treatment with the specified therapies. The treatment regimen is annotated above.

[0037] Figure 2F The mean log is expressed as a percentage in HCI-013 tumors in animals treated with the specified compound after exposure to the medium. 10 A set of bar charts showing the fold changes in E2 induction score, E2 inhibition score, and ER pathway activity score. The bar charts show the mean relative score and standard error, n=4. One-sided t-test: *, p<0.1; **, p<0.05; ***, p<0.01; ****, p<0.001; Comparisons between compound E and the mediator, compound C and compound E, compound D and compound C, and compound B and compound D.

[0038] Figure 2G This is a graph showing the in vivo efficacy of treatment in an HCI-011PDX mouse model of HR-positive breast cancer, assessed by changes in tumor volume over time at specified endocrine therapy concentrations, using a mediator, compound B, compound C, or compound F.

[0039] Figure 2H This is a heatmap showing the relative changes in z-score expression of 20 E2-inducing genes and 14 E2-repressing genes in HCI-011 tumors after treatment with the specified therapies. The treatment regimen is annotated above.

[0040] Figure 2I The mean log is expressed as a percentage in HCI-011 tumors in animals treated with the specified compound after exposure to the medium. 10A set of bar charts showing the changes in E2 induction score, E2 inhibition score, and ER pathway activity score. The bar charts show the mean relative score and standard error, n=4. One-sided t-test: *, p<0.1; **, p<0.05; ***, p<0.01; ****, p<0.001; Comparisons between compound E and the mediator, compound C and compound E, compound B and compound C, and compound A and compound B.

[0041] Figure 3A This is a heatmap showing the relative changes in z-score expression of 21 indicated E2-inducing genes and 17 indicated E2-repressing genes from a collection of 139 hormone receptor-positive / human epidermal growth factor receptor 2-negative (HR+ / HER2-) breast tumors.

[0042] Figure 3B-3D E2 induction score in a set of 139 HR+ / HER2- breast tumors ( Figure 3B E2 inhibition score Figure 3C ) and ER pathway activity score ( Figure 3D A series of reference density curves were generated. Expression data from six patients before and after treatment with compound B were covered: pre-treatment scores are represented by diamonds; post-treatment scores are represented by circles. Arrows indicate the magnitude and direction of changes in ER pathway activity scores for each patient.

[0043] Figure 3E This is a scatter plot comparing the pre-treatment ER pathway activity score and pre-treatment ESR1 expression level of six patients treated with compound B.

[0044] Figure 3F This is a scatter plot comparing the treatment-induced differences in ER pathway activity from before to after treatment in six patients treated with compound B, with the pre-treatment ER pathway activity level.

[0045] Figure 3G This is a scatter plot comparing the treatment-induced differences in E2-induced scores from before to after treatment with the pre-treatment E2-induced scores of six patients treated with compound B.

[0046] Figure 3H-3J E2 induction score in a set of 139 HR+ / HER2- breast tumors ( Figure 3H E2 inhibition score Figure 3I ) and ER pathway activity score ( Figure 3J A series of reference density curves were generated. Expression data from seven patients before and after treatment with compound A were covered: pre-treatment scores are represented by diamonds; post-treatment scores are represented by circles. Arrows indicate the magnitude and direction of changes in ER pathway activity scores for each patient.

[0047] Figure 3K This is a scatter plot comparing the pre-treatment ER pathway activity score with the pre-treatment ESR1 expression level in seven patients treated with compound A.

[0048] Figure 3L This is a scatter plot comparing the treatment-induced differences in ER pathway activity from before to after treatment in seven patients treated with compound A, with the pre-treatment ER pathway activity level.

[0049] Figure 3M This is a scatter plot comparing the treatment-induced differences in E2-induced scores from before to after treatment with the pre-treatment E2-induced scores of seven patients treated with compound A.

[0050] Figures 4A-4C This is based on the complete 41-gene signature in HCI-013PDX breast tumors after exposure to compound A. Figure 4A ), 19 gene characteristics ( Figure 4B ), or 14 gene characteristics ( Figure 4C Animals treated with a medium are represented as average log 10 A series of bar graphs showing the fold change in E2 induction score, E2 inhibition score, and ER pathway inhibition. The bar graphs show the mean relative score and standard error, n=4. One-sided t-test: *, p<0.05; **, p<0.01; ***, p<0.001; comparisons in black (1 mg / kg vs. 0.1 mg / kg); comparisons in red (10 mg / kg vs. 1 mg / kg).

[0051] Figure 4D-4F Based on 41 gene features in a set of 139 HR+ / HER2- breast tumors ( Figure 4D ), 19 gene characteristics ( Figure 4E ), or 14 gene characteristics ( Figure 4F A series of reference density curves for ER pathway activity scores are presented. Expression data from six patients before and after treatment are covered: pre-treatment scores are represented by diamonds; post-treatment scores are represented by circles. Arrows indicate the magnitude and direction of changes in ER pathway activity scores for each patient.

[0052] Figure 4G-4I Based on 41 gene features in a set of 139 HR+ / HER2- breast tumors ( Figure 4G ), 19 gene characteristics ( Figure 4H ), or 14 gene characteristics ( Figure 4IA series of reference density curves for the E2-induced score are presented. Expression data from six patients before and after treatment are covered: pre-treatment scores are represented by diamonds; post-treatment scores are represented by circles. Arrows indicate the magnitude and direction of change in the E2-induced score for each patient.

[0053] Figure 4J This is a table showing the characteristics of 41 genes (23 E2-inducing genes and 18 E2-repressing genes).

[0054] Figure 4K This is a table showing the characteristics of 19 genes (11 E2-inducing genes and 8 E2-repressing genes).

[0055] Figure 4L This is a table showing the characteristics of 14 genes (8 E2-inducing genes and 6 E2-repressing genes).

[0056] Figure 5 This is a scatter plot of ER pathway activity scores in 60 tissue samples, where expression data were obtained using RIBO-ZERO. or RNA Prepared. Formalin-fixed and paraffin-embedded (FFPE) samples are shown as triangles; fresh frozen samples are shown as circles. Breast tumors are shown as pink; other tissues are shown as black.

[0057] Figure 6 This is a graph showing the E2 induction score of ER+ / HER2- breast cancer cell lines.

[0058] Figure 7 This is a comparison of the effects of E2 induction score and fulvestrant on cell growth rate. Detailed Implementation

[0059] I. General Technology

[0060] Those skilled in the art will readily understand and generally use conventional methods to employ the techniques and procedures described or referenced herein, such as, for example, Sambrook et al., Molecular Cloning: A Laboratory Manual 3rd Edition (2001), Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY; Current Protocols in Molecular Biology (edited by F.M. Usubel et al., (2003)); Methods in Enzymology series (Academic Press, Inc.): PCR 2: A Practical Approach (edited by M.J. MacPherson, B.D. Hames, and G.R. Taylor, (1995)); Harlow and Lane (edited by Harlow and Lane, (1988); Antibodies, A Laboratory Manual and Animal Cell Culture (edited by R.R. Freshney, (1987)); Oligonucleotide Synthesis (edited by M.J. Gait, 1984); Methods in Molecular Biology, Humana Press; Cell Biology: A Laboratory Manual Notebook (edited by J.E.C. Elis, 1998) Academic Press; Animal Cell Culture (edited by R.R. Freshney, 1987); Introduction to Cell and Tissue Culture (edited by J.M. Pather and P.E. Roberts, 1998) Plenum Press; Cell and Tissue Culture: Laboratory Procedures (edited by A. Doyle, J.B. Griffiths, and D.G. Newell, 1993–8) J. Wiley and Sons; Handbook of Experimental Immunology (edited by D.M. Weir and C.C. Blackwell); Gene Transfer Vectors for Mammalian Cells (edited by J.M. Miller and M.P. Roberts, 1998)Calos, ed., 1987; PCR: The Polymerase Chain Reaction, (Mullis et al., ed., 1994); Current Protocols in Immunology (JEColigan et al., ed., 1991); Short Protocols in Molecular Biology (Wiley and Sons, 1999); Immunobiology (CA Janeway and P. Travers, 1997); Antibodies (P. Finch, 1997); Antibodies: A Practical Approach (D. Catty, ed., IRL Press, 1988-1989); Monoclonal Antibodies: A Practical Approach (P. Shepherd and C. Dean, ed., Oxford University Press, 2000); Using Antibodies: A Laboratory Manual (E. Harlow and D. Lane, Cold Spring Harbor Laboratory). The widely used methods described in *The Antibodies* (M. Zanetti and JD Capra, eds., Harwood Academic Publishers, 1999), and *Cancer: Principles and Practice of Oncology* (VT DeVita et al., eds., JBLippincott Company, 1993) are as follows.

[0061] II. Definition

[0062] It should be understood that the aspects and embodiments described herein include those referred to as “comprising,” “consisting of,” and “substantially consisting of.” Unless otherwise indicated, the singular forms “a / an” and “the” used herein include the plural of the referred to items.

[0063] As used herein, the term "about" refers to a common range of error for a corresponding value that is readily known to those skilled in the art. References to "about" values ​​or parameters herein include (and describe) embodiments relating to that value or parameter itself. For example, a description referring to "about X" includes a description of "X".

[0064] As used herein, “administration” means the method of giving a dose of a compound (e.g., the endocrine therapy or composition described herein (e.g., a pharmaceutical composition, such as a pharmaceutical composition comprising an endocrine therapy (e.g., a selective estrogen receptor modulator (SERM) (e.g., a selective estrogen receptor degrader (SERD)), a gonadotropin-releasing hormone (GnRH) agonist, and / or an aromatase inhibitor (AI))) to a subject. The compounds and / or compositions used in the methods described herein may be administered via, for example, orally, intramuscularly, or intravenously (e.g., by intravenous infusion). Note: Administration methods include subcutaneous, intradermal, percutaneous, intra-arterial, intraperitoneal, intralesional, intracranial, intra-articular, intraprostatic, intrapleural, intratracheal, intranasal, intravitreal, intravaginal, intrarectal, local, intratumoral, intraperitoneal, subconjunctival, intracystic, mucosal, intraperitoneal, intraumbilical, intraocular, local, by inhalation, by injection, by infusion, by continuous infusion, by local perfusion to directly immerse target cells, by catheter, by irrigation, as a cream or lipid composition. The method of administration can vary depending on various factors (e.g., the compound or composition to be administered and the severity of the condition, disease, or symptom to be treated).

[0065] The term "anticancer therapy" refers to a therapy that can be used to treat cancer (e.g., breast cancer, such as HR+ breast cancer (e.g., ER+ breast cancer (e.g., luminal A or luminal B breast cancer)) and / or metastatic or locally advanced breast cancer). Examples of anticancer therapeutic agents include, but are not limited to, endocrine therapies described herein, growth inhibitors, cytotoxic agents, agents used in radiotherapy, anti-angiogenic agents, apoptotic agents, anti-microtubule agents and other agents used to treat cancer (e.g., anti-CD20 antibodies), platelet-derived growth factor inhibitors (e.g., GLEEVEC). TM (imatinib mesylate), COX-2 inhibitors (e.g., celecoxib), interferons, cytokines, antagonists (e.g., neutralizing antibodies), other biologically active and organic chemical agents, etc. Combinations of these are also included herein. Anticancer therapies as used herein may also be referred to as “non-endocrine therapies,” which in turn refers to any anticancer therapy that does not include endocrine therapies as defined herein.

[0066] The term "endocrine therapy" refers to a therapy or treatment that modulates (e.g., regulates, reduces, blocks, or inhibits) the expression, level, or amount of one or more hormones found to cause or otherwise contribute to the progression of breast cancer as described herein. Endocrine therapies described herein include non-hormonal and hormonal therapies such as, for example, selective estrogen receptor modulators (SERMs) described herein and understood in the art, selective estrogen receptor degraders (SERDs) described herein and understood in the art, gonadotropin-releasing hormone (GnRH) agonists described herein and understood in the art, selective estrogen receptor covalent antagonists (SERCAs) described herein and understood in the art, selective local human estrogen receptor agonists (ShERPA) described herein and understood in the art; aromatase inhibitors (AIs) as described herein, or combinations thereof. In one embodiment, an endocrine therapy comprises one or more compounds from Section IV-A of this document.

[0067] Other exemplary endocrine therapies used in the methods described herein include, but are not limited to: anti-estrogens, such as tamoxifen (including...). Tamoxifen, raloxifene, droloxifen, 4-hydroxytamoxifen, trivoxifen, naloxifene, LY117018, onanasone (Toremifene citrate), Nafoxitin, Clomiphene, Diacetylcholine, Bardoxifene, Bromhexetine, Cyclofennig, Lasoxifene, Omexifen, Acobifene, Ilestron (RAD1901), Oflomiphene, Etisul (etacstil), Opelimiphene, Fluvestrant EM800, brilanestrant (GDC-0810), LX-039, AZ9496, GDC-0927 (SRN-0927); GDC-9545, G1T48 (G1 Therapeutics), H3B 6545 (H3 Biomedicine), SAR439859 (Sanofi), aromatase inhibitors that can inhibit aromatase, which regulate the production of estrogen in the adrenal glands, such as, for example, 4(5)-imidazole, aminoglutethimide, Megestrol acetate, (Exemestane), Formexane, Fatrazole (Volchlorazole) (letrozole), and (Anastrozole); antiandrogens such as flutamide, nilumet, bicalutamide, leuprorelin and goserelin; and trisatabine (a 1,3-dioxolane cytosine analog); antisense oligonucleotides, especially those that inhibit gene expression in signaling pathways involved in abnormal cell proliferation, and combinations of two or more of the above.

[0068] Examples of chemotherapy agents (and applicable non-endocrine therapies) include, but are not limited to, targets of mammalian rapamycin (mTOR) inhibitors such as sirolimus (also known as rapamycin), tamsulosin (also known as CCI-779 or... ), everolimus (also known as RAD001 or ), deforolimus (also known as AP-23573, MK-8669 or 42-(dimethylphosphono)rapamycin), OSI-027, AZD8055 and INK128; phosphatidylinositol 3-kinase (PI3K) inhibitors such as ederalipix (also known as GS-1101 or CAL-101), BKM120 and pelifosine (also known as KRX-0401); dual phosphatidylinositol 3-kinase (PI3K) / mTOR inhibitors such as XL765, GDC-0980, BEZ235 (also known as NVP-BEZ235), BGT226, GSK2126458, PF-04691502 and PF-05212384 (also known as PKI-587); and cyclin-dependent protein kinase (CDK) 4 / 6 inhibitors such as pomarcillin Pabosini Rebocillin Trilacridone (G1T28); anthracyclines such as daunorubicin, doxorubicin, epirubicin, idarubicin, mitoxantrone, pentorubicin; taxanes, including paclitaxel and docetaxel; podophyllotoxin; gemcitabine 5-Fluorouracil (5-FU); Cyclophosphamide Platinum analogues such as cisplatin and carboplatin; Changchun Ruibin Capecitabine Isaspiron ; and Eriblin ; Ribozymes such as VEGF expression inhibitors (e.g., (ribozymes) and HER2 expression inhibitors; vaccines such as gene therapy vaccines, for example, vaccine, Vaccines and vaccine; rIL-2; Topoisomerase 1 inhibitors; rmRH; vinorelbine and esperamicins (see U.S. Patent No. 4,675,187), any compound described in Sections IV-A below, and any of the pharmaceutical salts, acids or derivatives thereof; and combinations of two or more thereof.

[0069] Other exemplary chemotherapeutic agents (and non-endocrine therapies) include alkylating agents such as thiotepa and cyclophosphamide. Alkyl sulfonates such as busulfan, indomethacin, and piperosulfan; aziridines such as benzoxetine, carbaquinone, methotrexate, and uratetipa; ethyleneimines and methylmelamines, including tratamidoamine, ethylphosphamide, ethylthiophosphamide, and trimethylolamine; polyacetyl (especially bratacin and bratacinone); δ-9-tetrahydrocannabinol (drocannabinol, ); β-lapaquinone; laparol; colchicine; betulinic acid; camptothecin (including its synthetic analogue topotecan) CPT-11 (irinotecan) Acetylcamptothecin, scopolamine, and 9-aminocamptothecin; bryostatin; callystatin; CC-1065 (including its synthetic analogs adorelasin, calcelacin, and bicelecin); podophyllotoxin; podophyllic acid; teniposide; nostocin (especially nostocin 1 and nostocin 8); dolastatin; pyroxine (including synthetic analogs, KW-2189, and CB1-TM1); eleutheroside; *Philodendron simsii* Bases; *Cyperitoneol; *Spongistatin; *Nitrogen mustards such as chlorambucil, naphthylambucil, chlorphosphamide, estradiol, ifosfamide, nitrogen mustard, nitrogen mustard oxide hydrochloride, melphalan, sine emblica, benzyl mustard cholesterol, prednimustine, tralophosphamide, uramustine; *Nitrosoureas such as carmustine, chloramphenicol, fomomustine, lomustine, nimustine, and ramustine; *Antibiotics such as enediyne antibiotics (e.g., chachiin, especially chachiin γ1). I And chachiin ωI1 (see, e.g., Nicolaou et al., Angew. Chem Intl. Ed. Engl., 33: 183-186 (1994)); CDP323, oral α-4 integrin inhibitors; danexycin, including danexycin A; esperamycin; and new carcinogen chromophores and associated chromogen ethynylene antibiotic chromophores), akanamycin, actinomycin, atrazomycin, diazoserine, bleomycin, actinomycin C, carabixin, erythromycin, chromomycin, actinomycin D, daunorubicin, detoxin, 6-diazo-5-oxo-leucine, doxorubicin (including Morpholin-doxorubicin, cyanomorpholin-doxorubicin, 2-pyrrolino-doxorubicin, doxorubicin hydrochloride liposome injection Liposomedoxorubicin TLC D-99 PEGylated liposomal doxorubicin And deoxydoxorubicin), epirubicin, isorubicin, idarubicin, mesorcinol, mitomycin such as mitomycin C, mycophenolic acid, nogamycin, oligomycin, pepromycin, pofibromycin, puromycin, triamcinolone acetonide, rodorubicin, streptozotocin, streptozotocin, tuberculin, ubenmex, fenestrated statin, zoleobacillus; antimetabolites such as methotrexate, gemcitabine Tegafur Capecitabine Epothilone and 5-fluorouracil (5-FU); folic acid analogs, such as folate, methotrexate, pteroxate, trimethyltraxa; purine analogs, such as fludarabine, 6-mercaptopurine, thioimidine, thioguanine; pyrimidine analogs, such as ancitabine, azacitidine, 6-azauridine, carmoflurane, vidarabine, dideoxyuridine, deoxyfluorouridine, enoxabin, and fluorouridine; androgens, such as capprotestone, drotalbutone propionate, cyclothionol, meandrolone, and testrolide; antiadrenergics, such as aminoglutethimide, mitotane, and triamcinolone. Stan; Folic acid supplements, such as folinic acid; glucuronolactone; aldehyde phosphoramide glycoside; aminolevulinic acid; enuramicin; acridine; amustine; bisacodyl; idatraxa; defraudin; colchicine; defraudin; enoxamethonol; hydroxypyrrolizazole acetate; epothilone; itogluconol; gallium nitrate; hydroxyurea; lentinan; clonidine; maytansine compounds, such as maytansine and anthraquinone; mitoxantrone; mitoxantrone; moparinol; diaminonitroacin; pentostatin; methamidophos; pirarubicin; loxoantrone; 2-ethylhydrazine; mebenzylhydrazine; Polysaccharide complexes (JHS Natural Products, Eugene, Oreg.); Razosen; Rhizomycin; Cizonan; Germ-spiroamine; Alternaria solanilic acid; Triaminoquinone; 2,2',2'-Trichlorotriethylamine; Trichothecene toxins (especially T-2 toxin, Verrucosporin A, Bacitracin A, and Serpentin); Urethane; Vinpocetine ; Dacarbazine; Mannitol mustard; Dibromomannitol; Dibromoeutherol; Piperobromide; Gasetucin; Cytarabine (“Ara-C”); Triaminethione; Taxanes, such as paclitaxel ( Bristol-Myers Squibb Oncology, Princeton, NJ), and albumin-engineered nanoparticle formulations of paclitaxel (ABRAXANE). TM ) and Dorsetas ( Rhome-Poulene Rorer, Antony, France); chlorambucil; 6-thioguanine; mercaptopurine; methotrexate; platinum analogs, such as cisplatin, platinum oxalate (e.g., ) and carboplatin; periwinkle, to prevent tubulin polymerization and microtubule formation, including vincristine. , Changchun New Alkali Changchun Dixin and vinorelbine Etoposide (VP-16); isophosphoramide; mitoxantrone; folate; norfloxacin; idatraxa; danomycin; aminopterin; iban phosphate; topoisomerase inhibitor RFS 2000; difluoromethylornithine (DMFO); visual pigments such as retinoic acid, including bexarotine. ; diphosphates, such as chlorophosphates (e.g., or ethidium phosphate NE-58095, Zoledronic Acid / Zolephosphate alendronate Pamir phosphate Tiruphosphate or risperidone phosphate ; and trisatabine (a 1,3-dioxolane cytosine analog); antisense oligonucleotides, especially those that inhibit gene expression in signaling pathways involved in abnormal cell proliferation and reduce cell proliferation, such as PKC-α, Raf, H-Ras, and epidermal growth factor receptor (EGF-R) (e.g., erlotinib (TARCEVA)). TM )); and VEGF-A; vaccines, such as Vaccines and gene therapy vaccines, such as vaccine, Vaccines and Vaccines; topoisomerase 1 inhibitors (e.g., );rmRH (for example, ); BAY439006 (Sorafenib; Bayer); SU-11248 (Sunitinib, Pfizer); pelifoxine, COX-2 inhibitors (e.g., celecoxib or etoricoxib), proteasome inhibitors (e.g., PS341); bortezomib CCI-779; tilpifanib (R11577); sorafenib, ABT510; Bcl-2 inhibitors such as oliganin sodium Pifuran; EGFR inhibitors; tyrosine kinase inhibitors; serine-threonine kinase inhibitors such as rapamycin (sirolimus); Farnesyltransferase inhibitors such as lonafamib (SCH 6636, SARASAR) TM ); and any of the above-mentioned pharmaceutical salts, acids, or derivatives; and combinations of two or more of the above, such as CHOP (an abbreviation for combination therapy of cyclophosphamide, doxorubicin, vincristine, and prednisolone) and FOLFOX (oxaliplatin). TM (abbreviation for a treatment regimen combining 5-FU and leucovorin), and any of the above-mentioned medicinal salts, acids or derivatives; and combinations of two or more of the above.

[0070] As used herein, the term "cytotoxic agent" refers to a substance that inhibits or prevents cell function and / or causes cell death or destruction. Cytotoxic agents include, but are not limited to, radioactive isotopes (e.g., At). 211 , I 131 , I 125 Y 90 、Re 186 、Re 188 、Sm 153 、Bi 212 、P 32 , Pb 212 Radioactive isotopes of Lu; chemotherapeutic agents or drugs (e.g., methotrexate, doxorubicin, vinblastine alkaloids (vincristine, vinblastine, etoposide), doxorubicin, melphalan, mitomycin C, chlorambucil, daunorubicin or other intercalating agents); growth inhibitors; enzymes and fragments thereof such as lysozymes; antibiotics; toxins such as small molecule toxins or enzyme-active toxins of bacterial, fungal, plant or animal origin, including fragments and / or variants thereof; and various antitumor or anticancer drugs disclosed below. Cytotoxic agents may be non-endocrine agents.

[0071] "Article" means any article (e.g., packaging or container) or kit that contains at least one reagent, such as a medicine for treating a disease or condition (e.g., cancer, e.g., breast cancer, e.g., HR+ breast cancer (e.g., ER+ breast cancer (e.g., luminal A or luminal B breast cancer)), DCIS, and / or metastatic or locally advanced breast cancer), and / or a probe for specifically detecting the biomarkers described herein. In some embodiments, the article or kit is marketed, distributed, or sold as a unit for performing the methods described herein.

[0072] As used herein, the term "biomarker" refers to an indicator (e.g., a predictive, prognostic, and / or pharmacodynamic indicator) that can be detected in a sample (e.g., a tissue sample, such as a tumor tissue sample, such as formalin-fixed and paraffin-embedded (FFPE), fresh-frozen (FF), archived, fresh, or frozen tumor tissue sample). Biomarkers can be used as indicators of specific subtypes of diseases or conditions (e.g., breast cancer, HR+ breast cancer (e.g., ER+ breast cancer (e.g., luminal type A or luminal type B breast cancer)), DCIS, and / or metastatic or locally advanced breast cancer), characterized by certain molecular, pathological, histological, and / or clinical features. In some embodiments, a biomarker is a gene or a group of genes. Biomarkers include, but are not limited to, polynucleotides (e.g., DNA and / or RNA), polynucleotide copy number alterations (e.g., DNA copy number), peptides, peptide and polynucleotide modifications (e.g., post-translational modifications), carbohydrates, and / or glycolipid-based molecular markers. An exemplary collection of biomarkers is listed in Tables 1-6.

[0073] The terms “biomarker signature,” “signature,” “biomarker expression signature,” or “expression signature” are used interchangeably herein and refer to a combination of biomarkers expressed as indicators (e.g., predictive, prognostic, and / or pharmacodynamic indicators) (e.g., a combination of 41 gene signatures (e.g., combinations of genes listed in Tables 3 and 6), 19 gene signatures (e.g., combinations of genes listed in Tables 2 and 5), or 14 gene signatures (e.g., combinations of genes listed in Tables 1 and 4)). A biomarker signature can be used as an indicator of a specific subtype of a disease or condition (e.g., cancer, e.g., breast cancer, e.g., HR+ breast cancer (e.g., ER+ breast cancer (e.g., luminal type A or luminal type B breast cancer)), DCIS, and / or metastatic or locally advanced breast cancer), characterized by certain molecular, pathological, histological, and / or clinical features. In some embodiments, a biomarker signature is a “gene signature.” The term “gene signature” is used interchangeably with “gene expression signature” and refers to a combination of polynucleotides expressed as indicators (e.g., predictive, diagnostic, and / or prognostic indicators). In some embodiments, the biomarker characteristic is a “protein characteristic.” The terms “protein characteristic” and “protein expression characteristic” are used interchangeably and refer to a combination of peptides that are expressed as indicators (e.g., predictive, prognostic, and / or pharmacodynamic indicators).

[0074] Unless otherwise specified, the term "AGR3" refers to any naturally occurring member of the end-gradient 3 protein disulfide isomerase family from any vertebrate source, including mammals such as primates (e.g., humans) and rodents (e.g., mice and rats). The term includes "full-length" unprocessed AGR3, as well as any form of AGR3 produced through cellular processing. The term also covers naturally occurring variants of AGR3, such as splice variants or allelic variants. AGR3 is also referred to in the art in the form of protein disulfide isomerase family A member 18, breast cancer membrane protein 11, BCMP11, PDIA18, HAG-3, HAG3, AG-3, AG3, and pre-gradient protein 3 homologs. An exemplary nucleic acid sequence of human AGR3 is shown in the following NCBI reference sequence: NM_176813.4 or in SEQ ID NO:1. An exemplary amino acid sequence of a protein encoded by human AGR3 is shown in UniProt accession number Q8TD06 or SEQ ID NO:2.

[0075] Unless otherwise specified, the term "AMZ1" refers to any naturally occurring lysozyme family metallopeptidase 1 from any vertebrate source, including mammals such as primates (e.g., humans) and rodents (e.g., mice and rats). The term covers "full-length" unprocessed AMZ1, as well as any form of AMZ1 produced through cellular processing. The term also covers naturally occurring variants of AMZ1, such as splice variants or allelic variants. AMZ1 is also known in the art as archaea metalloproteinase-like protein 1, archaea-1, metalloproteinase-like protein, and KIAA1950. An exemplary nucleic acid sequence of human AMZ1 is shown in the following NCBI reference sequence: NM_133463.3 or in SEQ ID NO:3. An exemplary amino acid sequence of a protein encoded by human AMZ1 is shown in UniProt accession number Q400G9 or SEQ ID NO:4.

[0076] Unless otherwise specified, the term “AREG” refers to any naturally occurring bimodal protein from any vertebrate source, including mammals such as primates (e.g., humans) and rodents (e.g., mice and rats). The term covers “full-length” unprocessed AREG, as well as any form of AREG produced through cellular processing. The term also covers naturally occurring variants of AREG, such as splice variants or allelic variants. AREG is also known in the art as colorectal cell-derived growth factor, schwannoma-derived growth factor, bimodal protein B, AREGB, CRDGF, and SDGF. An exemplary nucleic acid sequence of human AREG is shown in the following NCBI reference sequence: NM_001657.3 or in SEQ ID NO:5. An exemplary amino acid sequence of a protein encoded by human AREG is shown in UniProt accession number P15514 or in SEQ ID NO:6.

[0077] Unless otherwise specified, the term “C5AR2” refers to any naturally occurring complement component 5a receptor 2 from any vertebrate source, including mammals such as primates (e.g., humans) and rodents (e.g., mice and rats). The term includes “full-length” unprocessed C5AR2, as well as any form of C5AR2 produced through cellular processing. The term also covers naturally occurring variants of C5AR2, such as splice variants or allelic variants. C5AR2 is also referred to in the art as complement component 5a receptor 2, G protein-coupled receptor 77, GPR77, C5L2, C5a anaphylatoxin chemokine receptor C5L2, and GPF77. An exemplary nucleic acid sequence of human C5AR2 is shown in the following NCBI reference sequence: NM_001271749.1 or in SEQ ID NO:7. An exemplary amino acid sequence of a protein encoded by human C5AR2 is shown in UniProt accession number Q9P296 or SEQ ID NO:8.

[0078] Unless otherwise specified, the term "CELSR2" refers to any naturally occurring cadherin EGF LAG heptacortex G-type receptor 2 from any vertebrate source, including mammals such as primates (e.g., humans) and rodents (e.g., mice and rats). The term includes "full-length" unprocessed CELSR2, as well as any form of CELSR2 produced through cellular processing. The term also covers naturally occurring variants of CELSR2, such as splice variants or allelic variants. CELSR2 is also referred to in the art in the form of multiepidermal growth factor-like domain protein 3, multiepidermal growth factor-like domain protein 3, adhesion G protein-coupled receptor C2, epidermal growth factor-like protein 2, multi-EGF-like domain protein 3, cadherin family member 10, flamingo homolog 3, EGF-like protein 2, CDHF10, EGFL2, MEGF3, flamingol, KIAA0279, and ADGRC2. The exemplary nucleic acid sequence of human CELSR2 is shown in the following NCBI reference sequence: NM_001408.2 or in SEQ ID NO:9. The amino acid sequence of an exemplary protein encoded by human CELSR2 is shown in UniProt accession number Q9HCU4 or in SEQ ID NO:10.

[0079] Unless otherwise specified, the term "CT62" refers to any naturally occurring cancer / testis antigen 62 from any vertebrate source, including mammals such as primates (e.g., humans) and rodents (e.g., mice and rats). The term includes "full-length" unprocessed CT62, as well as any form of CT62 produced through cellular processing. The term also covers naturally occurring variants of CT62, such as splice variants or allelic variants. An exemplary nucleic acid sequence of human CT62 is shown in the following NCBI reference sequence: XM_006720429 or in SEQ ID NO:11. An exemplary amino acid sequence of a protein encoded by human CT62 is shown in UniProt accession number P0C5K7 or in SEQ ID NO:12.

[0080] Unless otherwise specified, the term "FKBP4" refers to any naturally occurring FK506-binding protein 4 from any vertebrate source, including mammals such as primates (e.g., humans) and rodents (e.g., mice and rats). The term includes "full-length" unprocessed FKBP4, as well as any form of FKBP4 produced through cellular processing. The term also covers naturally occurring variants of FKBP4, such as splice variants or allelic variants. FKBP4 is also known in the art as gyroisomerase, FKBP51, FKBP52, FKBP59, HBI, peptidylprolyl cis-trans isomerase FKBP4, T-cell FK506-binding protein (59kD), HSP-binding immunoaffinity, immunoaffinity FKBP52, peptidylprolyl isomerase FKBP4, PPIASE, Hsp56, P52, and P59. The exemplary nucleic acid sequence of human FKBP4 is shown in the following NCBI reference sequence: NM_002014.3 or in SEQ ID NO:13. The amino acid sequence of an exemplary protein encoded by human FKBP4 is shown in UniProt accession number Q02790 or in SEQ ID NO:14.

[0081] Unless otherwise specified, the term "FMN1" refers to any naturally occurring FMN1 from any vertebrate source, including mammals such as primates (e.g., humans) and rodents (e.g., mice and rats). The term includes "full-length" unprocessed FMN1, as well as any form of FMN1 produced through cellular processing. The term also covers naturally occurring variants of FMN1, such as splice variants or allelic variants. FMN1 is also referred to in the art as limb malformation protein homolog, FMN, and LD. An exemplary human FMN1 nucleic acid sequence is shown in the following NCBI reference sequence: NM_001277313.1 or in SEQ ID NO:15. An exemplary protein encoded by human FMN1 has an amino acid sequence shown in UniProt accession number Q68DA7 or SEQ ID NO:16.

[0082] Unless otherwise specified, the term "GREB1" refers to any naturally occurring breast cancer estrogen growth regulator protein 1 from any vertebrate source, including mammals such as primates (e.g., humans) and rodents (e.g., mice and rats). The term includes "full-length" unprocessed GREB1, as well as any form of GREB1 produced through cellular processing. The term also covers naturally occurring variants of GREB1, such as splice variants or allelic variants. GREB1 is also referred to in the art as breast cancer 1 gene regulator protein and KIAA0575. An exemplary nucleic acid sequence of human GREB1 is shown in the following NCBI reference sequence: NM_014668.3 or in SEQ ID NO:17. An exemplary amino acid sequence of a protein encoded by human GREB1 is shown in UniProt accession number Q4ZG55 or SEQ ID NO:18.

[0083] Unless otherwise specified, the term "IGFBP4" refers to any naturally occurring insulin-like growth factor binding protein 4 from any vertebrate source, including mammals such as primates (e.g., humans) and rodents (e.g., mice and rats). The term includes "full-length" unprocessed IGFBP4, as well as any form of IGFBP4 produced through cellular processing. The term also covers naturally occurring variants of IGFBP4, such as splice variants or allelic variants. IGFBP4 is also referred to in the art as IGF-binding protein 4, IBP-4, HT29-IGFBP, and BP-4. An exemplary nucleic acid sequence of human IGFBP4 is shown in the following NCBI reference sequence: NM_001552.2 or in SEQ ID NO:19. An exemplary amino acid sequence of a protein encoded by human IGFBP4 is shown in UniProt accession number P22692 or in SEQ ID NO:20.

[0084] Unless otherwise specified, the term "NOS1AP" refers to any naturally occurring nitric oxide synthase 1 adaptor protein from any vertebrate source, including mammals such as primates (e.g., humans) and rodents (e.g., mice and rats). The term includes "full-length" unprocessed NOS1AP, as well as any form of NOS1AP produced through cellular processing. The term also covers naturally occurring variants of NOS1AP, such as splice variants or allelic variants. NOS1AP is also referred to in the art as the C-terminal PDZ ligand of the neuronal nitric oxide synthase protein, nitric oxide synthase 1 (neuronal) adaptor protein, CAPON, ligand of neuronal nitric oxide synthase having a C-terminal PDZ domain, 6330408P19Rik, and KIAA0464. An exemplary nucleic acid sequence of human NOS1AP is shown in the following NCBI reference sequence: NM_014697.2 or in SEQ ID NO:21. The amino acid sequence of an exemplary protein encoded by human NOS1AP is shown in UniProt accession number O75052 or SEQ ID NO:22.

[0085] Unless otherwise specified, the term "NXPH3" refers to any naturally occurring extraneurotrophic protein 3 from any vertebrate source, including mammals such as primates (e.g., humans) and rodents (e.g., mice and rats). The term includes "full-length" unprocessed NXPH3, as well as any form of NXPH3 produced through cellular processing. The term also covers naturally occurring variants of NXPH3, such as splice variants or allelic variants. NXPH3 is also known in the art as NPH3 and KIAA1159. An exemplary nucleic acid sequence of human NXPH3 is shown in the following NCBI reference sequence: NM_007225.2 or in SEQ ID NO:23. An exemplary amino acid sequence of a protein encoded by human NXPH3 is shown in UniProt accession number O95157 or SEQ ID NO:24.

[0086] Unless otherwise specified, the term "OLFM1" refers to any naturally occurring olfactory mediator 1 from any vertebrate source, including mammals such as primates (e.g., humans) and rodents (e.g., mice and rats). The term includes "full-length" unprocessed OLFM1, as well as any form of OLFM1 produced through cellular processing. The term also covers naturally occurring variants of OLFM1, such as splice variants or allelic variants. OLFM1 is also referred to in the art as neuronal olfactory mediator-associated ER localizer, Noelin, NOE1, neuroblastoma protein, Pancortin 1, Pancortin, NOELIN1, NOEL1, OlfA, and AMY. An exemplary nucleic acid sequence of human OLFM1 is shown in the following NCBI reference sequence: NM_014279.4 or in SEQ ID NO:25. An exemplary amino acid sequence of a protein encoded by human OLFM1 is shown in UniProt accession number Q99784 or in SEQ ID NO:26.

[0087] Unless otherwise specified, the term “PGR” refers to any natural progesterone receptor from any vertebrate source, including mammals such as primates (e.g., humans) and rodents (e.g., mice and rats). The term covers “full-length” unprocessed PGR, as well as any form of PGR produced through cellular processing. The term also covers naturally occurring variants of PGR, such as splice variants or allelic variants. PGR is also referred to in the art in the form of nuclear receptor subfamily 3 group C member 3, NR3C3, and PR. An exemplary nucleic acid sequence of human PGR is shown in the following NCBI reference sequence: NM_000926.4 or in SEQ ID NO:27. An exemplary amino acid sequence of a protein encoded by human PGR is shown in UniProt accession number P06401 or in SEQ ID NO:28.

[0088] Unless otherwise specified, the term "PPM1J" refers to any naturally occurring Mg2+ / Mn2+ dependent protein phosphatase 1J from any vertebrate source, including mammals such as primates (e.g., humans) and rodents (e.g., mice and rats). The term includes "full-length" unprocessed PPM1J, as well as any form of PPM1J produced through cellular processing. The term also covers naturally occurring variants of PPM1J, such as splice variants or allelic variants. PPM1J is also referred to in the art as protein phosphatase 1J (containing the PP2C domain), protein phosphatase 2Cζ, EC 3.1.3.16, PP2C-ζ, protein phosphatase 2a, catalytic subunit, ζ isotype, protein phosphatase 1J, PP2Cζ, and PP2CZ. An exemplary human PPM1J nucleic acid sequence is shown in the following NCBI reference sequence: NM_005167.5 or in SEQ ID NO:29. The amino acid sequence of an exemplary protein encoded by human PPMIJ is shown in UniProt accession number Q5JR12 or SEQ ID NO:30.

[0089] Unless otherwise specified, the term “RAPGEFL1” refers to any naturally occurring Rap-type guanine nucleotide exchange factor-like 1 from any vertebrate source, including mammals such as primates (e.g., humans) and rodents (e.g., mice and rats). The term includes “full-length” unprocessed RAPGEFL1, as well as any form of RAPGEFL1 produced through cellular processing. The term also covers naturally occurring variants of RAPGEFL1, such as splice variants or allelic variants. RAPGEFL1 is also referred to in the art in connection with Link guanine nucleotide exchange factor II, Rap-type guanine nucleotide exchange factor (GEF)-like 1, and Link GEFII. An exemplary nucleic acid sequence of human RAPGEFL1 is shown in the following NCBI reference sequence: NM_001303533.1 or in SEQ ID NO:31. An exemplary amino acid sequence of a protein encoded by human RAPGEFL1 is shown in UniProt accession number Q9UHV5 or in SEQ ID NO:32.

[0090] Unless otherwise specified, the term "RBM24" refers to any naturally occurring RNA-binding motif protein 24 from any vertebrate source, including mammals such as primates (e.g., humans) and rodents (e.g., mice and rats). The term includes "full-length" unprocessed RBM24, as well as any form of RBM24 produced through cellular processing. The term also covers naturally occurring variants of RBM24, such as splice variants or allelic variants. RBM24 is also referred to in the art as containing an RNA-binding region (RNP1, RRM) containing 6, RNPC6, RNA-binding protein 24, and DJ259A10.1. An exemplary human RBM24 nucleic acid sequence is shown in the following NCBI reference sequence: NM_001143942.1 or in SEQ ID NO:33. An exemplary protein encoded by human RBM24 amino acid sequence is shown in UniProt accession number Q9BX46 or SEQ ID NO:34.

[0091] Unless otherwise specified, the term “RERG” refers to any naturally occurring RAS-like estrogen-regulated growth inhibitory factor from any vertebrate source, including mammals such as primates (e.g., humans) and rodents (e.g., mice and rats). The term covers “full-length” unprocessed RERG, as well as any form of RERG produced through cellular processing. The term also covers naturally occurring variants of RERG, such as splice variants or allelic variants. An exemplary nucleic acid sequence of human RERG is shown in the following NCBI reference sequence: NM_032918.2 or in SEQ ID NO:35. An exemplary amino acid sequence of a protein encoded by human RERG is shown in UniProt accession number Q96A58 or SEQ ID NO:36.

[0092] Unless otherwise specified, the term “RET” refers to any naturally occurring Ret proto-oncogene from any vertebrate source, including mammals such as primates (e.g., humans) and rodents (e.g., mice and rats). The term covers “full-length” unprocessed RET, as well as any form of RET produced through cellular processing. The term also covers naturally occurring variants of RET, such as splice variants or allele variants. RET is also referred to in the art in terms of cadherin-associated family member 16, rearranged during transfection, RET receptor tyrosine kinase, cadherin family member 12, proto-oncogene C-Ret, EC 2.7.10.1, CDHF12, CDHR16, PTC, multiple endocrine adenomas and medullary thyroid carcinoma 1, EC 2.7.10, RET-ELE1, HSCR1, MEN2A, MEN2B, RET51, and MTC1. The nucleic acid sequence of an exemplary human RET is shown in the following NCBI reference sequence: NM_020975.5 or in SEQ ID NO:37. The amino acid sequence of an exemplary protein encoded by human RET is shown in UniProt accession number P07949 or in SEQ ID NO:38.

[0093] Unless otherwise specified, the term “SGK3” refers to any naturally occurring serum / glucocorticoid-regulated kinase family member 3 from any vertebrate source, including mammals such as primates (e.g., humans) and rodents (e.g., mice and rats). The term includes “full-length” unprocessed SGK3, as well as any form of SGK3 produced through cellular processing. The term also covers naturally occurring variants of SGK3, such as splice variants or allelic variants. SGK3 is also referred to in the art as cytokine-independent survival kinase, EC 2.7.11.1, SGKL, CISK, EC 2.7.11, serine / threonine protein kinase Sgk3, and SGK2. An exemplary human SGK3 nucleic acid sequence is shown in the following NCBI reference sequence: NM_001033578.2 or in SEQ ID NO:39. An exemplary protein encoded by human SGK3 has an amino acid sequence shown in UniProt accession number Q96BR1 or in SEQ ID NO:40.

[0094] Unless otherwise specified, the term "SLC9A3R1" refers to any naturally occurring SLC9A3 regulatory factor 1 from any vertebrate source, including mammals such as primates (e.g., humans) and rodents (e.g., mice and rats). The term includes "full-length" unprocessed SLC9A3R1, as well as any form of SLC9A3R1 produced through cellular processing. The term also covers naturally occurring variants of SLC9A3R1, such as splice variants or allelic variants. SLC9A3R1 is also referred to in the art as solute carrier family 9, subfamily A (NHE3, cation proton reverse transporter 3), member 3 regulatory factor 1, regulatory cofactor of the Na(+) / H(+) exchange pump, NHERF-1, EBP50, NHERF, EZ protein / root protein / membrane spike protein binding phosphoprotein 50, sodium-hydrogen exchange pump regulatory factor 1, and NPHLOP2. The exemplary nucleic acid sequence of human SLC9A3R1 is shown in the following NCBI reference sequence: NM_004252.4 or in SEQ ID NO:41. The amino acid sequence of the exemplary protein encoded by human SLC9A3R1 is shown in UniProt accession number O14745 or in SEQ ID NO:42.

[0095] Unless otherwise specified, the term "TFF1" refers to any naturally occurring trefoil factor 1 from any vertebrate source, including mammals such as primates (e.g., humans) and rodents (e.g., mice and rats). The term includes "full-length" unprocessed TFF1, as well as any form of TFF1 produced through cellular processing. The term also covers naturally occurring variants of TFF1, such as splice variants or allelic variants. TFF1 is also known in the art as breast cancer estrogen-inducing protein, polypeptide P1.A, protein PS2, HP1.A, PNR-2, BCEI, PS2, gastrointestinal trefoil protein PS2, D21S21, and HPS2. An exemplary human TFF1 nucleic acid sequence is shown in the following NCBI reference sequence: NM_003225.2 or in SEQ ID NO:43. An exemplary protein encoding human TFF1 amino acid sequence is shown in UniProt accession number P04155 or SEQ ID NO:44.

[0096] Unless otherwise specified, the term "ZNF703" refers to any naturally occurring zinc finger protein 703 from any vertebrate source, including mammals such as primates (e.g., humans) and rodents (e.g., mice and rats). The term includes "full-length" unprocessed ZNF703, as well as any form of ZNF703 produced through cellular processing. The term also covers naturally occurring variants of ZNF703, such as splice variants or allelic variants. ZNF703 is also referred to in the art in the form of zinc finger elbow-associated proline domain protein 1, ZEPPO1, ZPO1, ZNF503L, and NLZ1. An exemplary human ZNF703 nucleic acid sequence is shown in the following NCBI reference sequence: NM_025069.2 or in SEQ ID NO:45. An exemplary protein encoded by human ZNF703 has an amino acid sequence shown in UniProt accession number Q9H7S9 or in SEQ ID NO:46.

[0097] Unless otherwise specified, the term “BAMBI” refers to any naturally occurring BMP and activin membrane-binding repressor from any vertebrate source, including mammals such as primates (e.g., humans) and rodents (e.g., mice and rats). The term covers “full-length” unprocessed BAMBI, as well as any form of BAMBI produced through cellular processing. The term also covers naturally occurring variants of BAMBI, such as splice variants or allelic variants. BAMBI is also referred to in the art as a homolog of the presumed transmembrane protein NMA, the nontransferable gene A protein NMA, and BMP with the activin membrane-binding repressor. An exemplary nucleic acid sequence of human BAMBI is shown in the following NCBI reference sequence: NM_012342.2 or in SEQ ID NO:47. An exemplary amino acid sequence of a protein encoded by human BAMBI is shown in UniProt accession number Q13145 or SEQ ID NO:48.

[0098] Unless otherwise specified, the term “BCAS1” refers to any naturally occurring breast cancer amplification sequence 1 from any vertebrate source, including mammals such as primates (e.g., humans) and rodents (e.g., mice and rats). The term includes “full-length” unprocessed BCAS1, as well as any form of BCAS1 produced through cellular processing. The term also covers naturally occurring variants of BCAS1, such as splice variants or allelic variants. BCAS1 is also referred to in the art as breast cancer amplification and overexpression, novel breast cancer amplification 1, AIBC1, and NABC1. An exemplary nucleic acid sequence of human BCAS1 is shown in the following NCBI reference sequence: NM_003657.3 or in SEQ ID NO:49. An exemplary amino acid sequence of a protein encoded by human BCAS1 is shown in UniProt accession number O75363 or in SEQ ID NO:50.

[0099] Unless otherwise specified, the term “CCNG2” refers to any naturally occurring cyclin G2 from any vertebrate source, including mammals such as primates (e.g., humans) and rodents (e.g., mice and rats). The term includes “full-length” unprocessed CCNG2, as well as any form of CCNG2 produced through cellular processing. The term also covers naturally occurring variants of CCNG2, such as splice variants or allelic variants. An exemplary nucleic acid sequence of human CCNG2 is shown in the following NCBI reference sequence: XM_011532399.2 or in SEQ ID NO:51. An exemplary amino acid sequence of a protein encoded by human CCNG2 is shown in UniProt accession number Q16589 or SEQ ID NO:52.

[0100] Unless otherwise specified, the term “DDIT4” refers to any naturally occurring DNA damage-inducing transcript 4 from any vertebrate source, including mammals such as primates (e.g., humans) and rodents (e.g., mice and rats). The term includes “full-length” unprocessed DDIT4, as well as any form of DDIT4 produced through cellular processing. The term also covers naturally occurring variants of DDIT4, such as splice variants or allelic variants. DDIT4 is also referred to in the art in the form of developmental and DNA damage response regulator 1, HIF-1 response protein RTP801, REDD1, RTP801, and Dig2. An exemplary human DDIT4 nucleic acid sequence is shown in the following NCBI reference sequence: NM_019058.3 or in SEQ ID NO:53. An exemplary protein encoded by human DDIT4 amino acid sequence is shown in UniProt accession number Q9NX09 or SEQ ID NO:54.

[0101] Unless otherwise specified, the term "EGLN3" refers to any naturally occurring Egl-9 family hypoxia-inducible factor 3 from any vertebrate source, including mammals such as primates (e.g., humans) and rodents (e.g., mice and rats). The term includes "full-length" unprocessed EGLN3, as well as any form of EGLN3 produced through cellular processing. The term also covers naturally occurring variants of EGLN3, such as splice variants or allelic variants. EGLN3 is also referred to in the art as prolyl hydroxylase domain-containing protein 3, hypoxia-inducible factor prolyl hydroxylase 3, HIF prolyl hydroxylase 3, HPH-1, HPH-3, PHD3, Egl nine-like protein 3 isoform, Egl nine homolog 3, EC 1.14.11.29, EC 1.14.11, HIFP4H3, and HIFPH3. The exemplary nucleic acid sequence of human EGLN3 is shown in the following NCBI reference sequence: NM_022073.3 or in SEQ ID NO:55. The amino acid sequence of an exemplary protein encoded by human EGLN3 is shown in UniProt accession number Q9H6Z9 or SEQ ID NO:56.

[0102] Unless otherwise specified, the term "FAM171B" refers to any naturally occurring sequence-similar member of family 171B from any vertebrate source, including mammals such as primates (e.g., humans) and rodents (e.g., mice and rats). The term includes "full-length" unprocessed FAM171B, as well as any form of FAM171B produced through cellular processing. The term also covers naturally occurring variants of FAM171B, such as splice variants or allelic variants. FAM171B is also known in the art as KIAA1946 and protein FAM171B. An exemplary nucleic acid sequence of human FAM171B is shown in the following NCBI reference sequence: NM_177454.3 or in SEQ ID NO:57. An exemplary amino acid sequence of a protein encoded by human FAM171B is shown in UniProt accession number Q6P995 or SEQ ID NO:58.

[0103] Unless otherwise specified, the term “GRM4” refers to any naturally occurring metabolized glutamate receptor 4 from any vertebrate source, including mammals such as primates (e.g., humans) and rodents (e.g., mice and rats). The term includes “full-length” unprocessed GRM4, as well as any form of GRM4 produced through cellular processing. The term also covers naturally occurring variants of GRM4, such as splice variants or allelic variants. GRM4 is also known in the art as GPRC1D, MGLUR4, and MGlu4. An exemplary nucleic acid sequence of human GRM4 is shown in the following NCBI reference sequence: NM_000841.4 or in SEQ ID NO:59. An exemplary amino acid sequence of a protein encoded by human GRM4 is shown in UniProt accession number Q14833 or in SEQ ID NO:60.

[0104] Unless otherwise specified, the term "IL1R1" refers to any naturally occurring interleukin-1 receptor type 1 from any vertebrate source, including mammals such as primates (e.g., humans) and rodents (e.g., mice and rats). The term includes "full-length" unprocessed IL1R1, as well as any form of IL1R1 produced through cellular processing. The term also covers naturally occurring variants of IL1R1, such as splice variants or allelic variants. IL1R1 is also referred to in the art as CD121 antigen-like family member A, interleukin-1 receptor α, IL-1R-α, IL1RA, IL1R, P80, CD12la antigen, D2S1473, CD121A, and IL1RT1. An exemplary nucleic acid sequence of human IL1R1 is shown in the following NCBI reference sequence: NM_001288706.1 or in SEQ ID NO:61. The amino acid sequence of an exemplary protein encoded by human IL1R1 is shown in UniProt accession number P14778 or SEQ ID NO:62.

[0105] Unless otherwise specified, the term "LIPH" refers to any naturally occurring lipase H from any vertebrate source, including mammals such as primates (e.g., humans) and rodents (e.g., mice and rats). The term covers "full-length" unprocessed LIPH, as well as any form of LIPH produced through cellular processing. The term also covers naturally occurring variants of LIPH, such as splice variants or allelic variants. LIPH is also referred to in the art as membrane-associated phosphatidic acid selective phospholipase A1-α, PD lipase-associated protein, phospholipase A1 member B, MPA-PLA1α, LPDLR, membrane-bound phosphatidic acid selective phospholipase A1, lipase member H, EC 3.1.1.3, C 3.1, ARWH2, HYPT7, LAH2, and AH. An exemplary human LIPH nucleic acid sequence is shown in the following NCBI reference sequence: XM_006713529.4 or in SEQ ID NO:63. The amino acid sequence of an exemplary protein encoded by human LIPH is shown in UniProt accession number Q8WWY8 or SEQ ID NO:64.

[0106] Unless otherwise specified, the term "NBEA" refers to any naturally occurring protein kinase-anchored protein from any vertebrate source, including mammals such as primates (e.g., humans) and rodents (e.g., mice and rats). The term covers "full-length" unprocessed NBEA, as well as any form of NBEA produced through cellular processing. The term also covers naturally occurring variants of NBEA, such as splice variants or allelic variants. NBEA is also known in the art as lysosomal transport regulator 2, BCL8B, LYST2, protein BCL8B, EC 1.14.14.5, EC 6.1.1.11, and KIAA1544. An exemplary nucleic acid sequence of human NBEA is shown in the following NCBI reference sequence: NM_015678.4 or in SEQ ID NO:65. An exemplary amino acid sequence of a protein encoded by human NBEA is shown in UniProt accession number Q8NFP9 or SEQ ID NO:66.

[0107] Unless otherwise specified, the term "PNPLA7" refers to any naturally occurring PNPLA7 containing the potato glycoprotein-like phospholipase domain 7 from any vertebrate source, including mammals such as primates (e.g., humans) and rodents (e.g., mice and rats). The term includes "full-length" unprocessed PNPLA7, as well as any form of PNPLA7 produced through cellular processing. The term also covers naturally occurring variants of PNPLA7, such as splice variants or allelic variants. PNPLA7 is also known in the art as C9orf111, protein 7 containing the potato glycoprotein-like phospholipase domain, chromosome 9 open reading frame 111, EC 3.1.1.5, NTE-R1, and NTEL1. An exemplary human PNPLA7 nucleic acid sequence is shown in the following NCBI reference sequence: NM_001098537.2 or in SEQ ID NO:67. The amino acid sequence of an exemplary protein encoded by human PNPLA7 is shown in UniProt accession number Q6ZV29 or SEQ ID NO:68.

[0108] Unless otherwise specified, the term "PSCA" refers to any naturally occurring prostate stem cell antigen from any vertebrate source, including mammals such as primates (e.g., humans) and rodents (e.g., mice and rats). The term covers "full-length" unprocessed PSCA, as well as any form of PSCA produced through cellular processing. The term also covers naturally occurring variants of PSCA, such as splice variants or allelic variants. PSCA is also known in the art as PRO232. An exemplary nucleic acid sequence of human PSCA is shown in the following NCBI reference sequence: NM_005672.4 or in SEQ ID NO:69. An exemplary amino acid sequence of a protein encoded by human PSCA is shown in UniProt accession number O43653 or in SEQ ID NO:70.

[0109] Unless otherwise specified, the term "SEMA3E" refers to any naturally occurring semacin 3E from any vertebrate source, including mammals such as primates (e.g., humans) and rodents (e.g., mice and rats). The term includes "full-length" unprocessed SEMA3E, as well as any form of SEMA3E produced through cellular processing. The term also covers naturally occurring variants of SEMA3E, such as splice variants or allelic variants. SEMA3E is also referred to in the art as the Sema domain, immunoglobulin domain (Ig), basic short domain, secreted (semacin) 3E, SEMAH, semacin-3E, M-Sema H, KIAA0331, M-SemaK, and Coll-5. An exemplary human SEMA3E nucleic acid sequence is shown in the following NCBI reference sequence: NM_012431.2 or in SEQ ID NO:71. The amino acid sequence of an exemplary protein encoded by human SEMA3E is shown in UniProt accession number O15041 or SEQ ID NO:72.

[0110] Unless otherwise specified, the term "SSPO" refers to any naturally occurring SCO-vertebral protein from any vertebrate source, including mammals such as primates (e.g., humans) and rodents (e.g., mice and rats). The term covers "full-length" unprocessed SSPO, as well as any form of SSPO produced through cellular processing. The term also covers naturally occurring variants of SSPO, such as splice variants or allelic variants. SSPO is also known in the art as SCO protein, platelet-reactive protein domain-containing septal vertebral protein, EC 3.4.24.82, EC 3.4.21.9, and KIAA2036. An exemplary human SSPO nucleic acid sequence is shown in the following NCBI reference sequence: BN000852.1 or in SEQ ID NO:73. An exemplary protein encoded by human SSPO is shown in UniProt accession number A2VEC9 or SEQ ID NO:74.

[0111] Unless otherwise specified, the term "STON1" refers to any naturally occurring lithin 1 from any vertebrate source, including mammals such as primates (e.g., humans) and rodents (e.g., mice and rats). The term includes "full-length" unprocessed STON1, as well as any form of STON1 produced through cellular processing. The term also covers naturally occurring variants of STON1, such as splice variants or allelic variants. STON1 is also known in the art as stone B-like factor, SALF, SBLF, STN1, stone B homolog 1, and STNB1. An exemplary nucleic acid sequence of human STON1 is shown in the following NCBI reference sequence: NM_001198595.1 or in SEQ ID NO:75. An exemplary amino acid sequence of a protein encoded by human STON1 is shown in UniProt accession number Q9Y6Q2 or SEQ ID NO:76.

[0112] Unless otherwise specified, the term "TGFB3" refers to any naturally occurring transforming growth factor β3 from any vertebrate source, including mammals such as primates (e.g., humans) and rodents (e.g., mice and rats). The term includes "full-length" unprocessed TGFB3, as well as any form of TGFB3 produced through cellular processing. The term also covers naturally occurring variants of TGFB3, such as splice variants or allelic variants. TGFB3 is also referred to in the art as precursor transforming growth factor β-3, arrhythmogenic right ventricular dysplasia 1, TGF-β-3, ARVD1, LDS5, RNHF, and ARVD. An exemplary nucleic acid sequence of human TGFB3 is shown in the following NCBI reference sequence: NM_003239.4 or in SEQ ID NO:77. An exemplary amino acid sequence of a protein encoded by human TGFB3 is shown in UniProt accession number Pl0600 or SEQ ID NO:78.

[0113] Unless otherwise specified, the term "TP53INP1" refers to any naturally occurring tumor protein P53-inducible nucleoprotein 1 from any vertebrate source, including mammals such as primates (e.g., humans) and rodents (e.g., mice and rats). The term includes "full-length" unprocessed TP53INP1, as well as any form of TP53INP1 produced through cellular processing. The term also covers naturally occurring variants of TP53INP1, such as splice variants or allelic variants. TP53INP1 is also referred to in the art as P53-dependent damage-inducible nucleoprotein 1, stress-inducible protein, P53DINP1, SIP, P53-inducible P53DINP1, TP53DINP1, TP53INP1A, TP53INP1B, and Teap. An exemplary human TGFB3 nucleic acid sequence is shown in the following NCBI reference sequence: NM_033285.3 or in SEQ ID NO:79. The amino acid sequence of an exemplary protein encoded by human TP53INP1 is shown in UniProt accession number Q96A56 or SEQ ID NO:80.

[0114] Unless otherwise specified, the term "TP53INP2" refers to any naturally occurring tumor protein P53-inducible nucleoprotein 2 from any vertebrate source, including mammals such as primates (e.g., humans) and rodents (e.g., mice and rats). The term includes "full-length" unprocessed TP53INP2, as well as any form of TP53INP2 produced through cellular processing. The term also covers naturally occurring variants of TP53INP2, such as splice variants or allelic variants. TP53INP2 is also referred to in the art as P53-inducible protein U, C20orf110, PIG-U, PINH, DOR, chromosome 20 open reading frame 110, diabetes and obesity regulatory gene, and DJ1181N3.1. An exemplary human TP53INP2 nucleic acid sequence is shown in the following NCBI reference sequence: NM_021202.2 or in SEQ ID NO:81. The amino acid sequence of an exemplary protein encoded by human TP53INP2 is shown in UniProt accession number Q8IXH6 or SEQ ID NO:82.

[0115] Unless otherwise specified, the term “GUSB” refers to any naturally occurring glucuronidase β from any vertebrate source, including mammals such as primates (e.g., humans) and rodents (e.g., mice and rats). The term covers “full-length” unprocessed GUSB, as well as any form of GUSB produced through cellular processing. The term also covers naturally occurring variants of GUSB, such as splice variants or allelic variants. GUSB is also referred to in the art as EC 3.2.1.31, β-G1, β-D-glucuronidase, MPS7, and BG. An exemplary human GUSB nucleic acid sequence is shown in the following NCBI reference sequence: NM_000181.3 or in SEQ ID NO:83. An exemplary protein encoded by human GUSB has an amino acid sequence shown in UniProt accession number P08236 or in SEQ ID NO:84.

[0116] Unless otherwise specified, the term "PPIA" refers to any naturally occurring peptidyl proline isomerase A from any vertebrate source, including mammals such as primates (e.g., humans) and rodents (e.g., mice and rats). The term covers "full-length" unprocessed PPIA, as well as any form of PPIA produced through cellular processing. The term also covers naturally occurring variants of PPIA, such as splice variants or allelic variants. PPIA is also known in the art as cyclosporine A-binding protein, cyclophilin A, gyroisomerase A, EC 5.2.1.8, peptidyl prolyl isomerase A, CYPA, epididymal secretory sperm-binding protein Li 69p, peptidyl prolyl cis-trans isomerase A, T-cell cyclophilin, HEL-S-69p, and CYPH. An exemplary human PPIA nucleic acid sequence is shown in the following NCBI reference sequence: NM_021130.4 or in SEQ ID NO:85. The amino acid sequence of an exemplary protein encoded by human PPIA is shown in UniProt accession number P62937 or SEQ ID NO:86.

[0117] Unless otherwise specified, the term “UBC” refers to any naturally occurring ubiquitin C from any vertebrate source, including mammals such as primates (e.g., humans) and rodents (e.g., mice and rats). The term covers “full-length” unprocessed UBC, as well as any form of UBC produced through cellular processing. The term also covers naturally occurring variants of UBC, such as splice variants or allelic variants. UBC is also known in the art as polyubiquitin-C and HMG20. An exemplary nucleic acid sequence of human UBC is shown in the following NCBI reference sequence: NM_021009.6 or in SEQ ID NO:87. An exemplary amino acid sequence of a protein encoded by human UBC is shown in UniProt accession number P0CG48 or SEQ ID NO:88.

[0118] Unless otherwise specified, the term "SDHA" refers to the flavoprotein subunit A of the succinate dehydrogenase complex from any vertebrate source, including mammals such as primates (e.g., humans) and rodents (e.g., mice and rats). The term covers "full-length" unprocessed SDHA, as well as any form of SDHA produced through cellular processing. The term also covers naturally occurring variants of SDHA, such as splice variants or allelic variants. An exemplary nucleic acid sequence of human SDHA is shown in the following NCBI reference sequence: NM_001330758 or in SEQ ID NO:89. An exemplary amino acid sequence of a protein encoded by human SDHA is shown in UniProt accession number P31040 or in SEQ ID NO:90.

[0119] The terms “cancer” and “cancerous” refer to or describe a physiological condition in mammals typically characterized by uncontrolled cell growth. Examples of cancer include, but are not limited to, carcinoma, lymphoma, blastoma, sarcoma, and leukemia or lymphoid malignancies. More specific examples of such cancers include, but are not limited to, breast cancer (e.g., HR+ breast cancer (e.g., ER+ breast cancer (e.g., luminal type A breast cancer or luminal type B breast cancer)), DCIS, and / or metastatic or locally advanced breast cancer); lung cancer, including small cell lung cancer, non-small cell lung cancer, lung adenocarcinoma, and lung squamous cell carcinoma; bladder cancer (e.g., urothelial bladder cancer (UBC), muscle-invasive bladder cancer (MIBC), and BCG-refractory non-muscle-invasive bladder cancer (NMIBC)); kidney or renal cell carcinoma (e.g., renal cell carcinoma (RCC)); urinary tract cancer; prostate cancer, such as castration-resistant prostate cancer (CRPC); peritoneal cancer; hepatocellular carcinoma; gastric cancer; and gastric cancer. Stomach cancer, including gastrointestinal cancer and gastrointestinal stromal cancer; pancreatic cancer; glioblastoma; cervical cancer; ovarian cancer; liver cancer; hepatocellular carcinoma; colon cancer; rectal cancer; colorectal cancer; endometrial or uterine cancer; salivary gland cancer; prostate cancer; vulvar cancer; thyroid cancer; primary liver cancer; anal cancer; penile cancer; melanoma, including superficial diffuse melanoma, malignant lentigines melanoma, peripheral maculopapular melanoma, and nodular malignant melanoma; multiple myeloma and B-cell lymphoma (including low-grade / follicular non-Hodgkin lymphoma (NHL); small lymphocytic (SL) NHL; intermediate / follicular NHL; intermediate diffuse NHL; high-grade immunoblastic NHL; high-grade lymphocytic NHL; high-grade small non-lytic NHL). NHL; giant mass NHL; mantle cell lymphoma; AIDS-related lymphoma; Waldenstrom's macroglobulinemia; chronic lymphocytic leukemia (CLL); acute lymphoblastic leukemia (ALL); acute myeloid leukemia (AML); hairy cell leukemia; chronic myeloid leukemia (CML); post-transplant lymphoproliferative disorder (PTLD); myelodysplastic syndrome (MDS); and abnormal angiogenesis associated with maculopapular hamartomatosis, edema (such as that associated with brain tumors), Meigs' syndrome, brain cancer, head and neck cancer, and related metastases.

[0120] As used herein, the term "breast cancer" refers to breast cancer that has been histologically or cytologically confirmed. In some embodiments, breast cancer is epithelial carcinoma. In some embodiments, breast cancer is adenocarcinoma. In some embodiments, breast cancer is sarcoma. In some embodiments, breast cancer is HR+ breast cancer. In some embodiments, HR+ breast cancer is ER+ breast cancer. In some embodiments, ER+ breast cancer is luminal type A breast cancer. In some embodiments, ER+ breast cancer is luminal type B breast cancer. In some embodiments, breast cancer is metastatic or locally advanced breast cancer.

[0121] The term "locally advanced breast cancer" refers to cancer that starts in the breast and spreads to nearby tissues or lymph nodes, but has not spread to other parts of the body.

[0122] The term "metastatic breast cancer" refers to cancer that has spread from the breast to other parts of the body, such as bone, liver, lungs, or brain. Metastatic breast cancer can also be called stage IV breast cancer.

[0123] As understood in the art, the term "ductal carcinoma in situ breast cancer" or (DCIS cancer) refers to breast cancer characterized by an intraductal, non-avoided, and pre-invasive primary tumor.

[0124] The terms "cellular proliferative disorder" and "proliferative disease" refer to conditions associated with some degree of abnormal cell proliferation. In one embodiment, a cellular proliferative disorder is breast cancer (e.g., HR+ breast cancer (e.g., ER+ breast cancer (e.g., luminal type A breast cancer or luminal type B breast cancer)), DCIS, and / or metastatic or locally advanced breast cancer). In another embodiment, a cellular proliferative disorder is a tumor.

[0125] As used herein, the term "simultaneous" refers to the administration of two or more therapeutic agents, wherein at least some of the administration overlaps in time. Therefore, simultaneous administration includes a dosing regimen in which administration of one or more other agents is continued after the administration of one or more agents has been discontinued.

[0126] As used herein, “delayed progression” of a condition or disease means the postponement, impediment, mitigation, slowing, stabilization, and / or delay of the development of a disease or condition (e.g., breast cancer, such as HR+ breast cancer (e.g., ER+ breast cancer (e.g., luminal A-type or luminal B-type breast cancer)), DCIS, and / or metastatic or locally advanced breast cancer). Such delay can vary in length depending on medical history and / or the subject to be treated. It will be apparent to those skilled in the art that adequate or significant delay can effectively encompass prevention, as the subject will not develop the disease.

[0127] The terms “determination,” “determining,” “detection,” and “detecting,” and their grammatical variations, include any means of determination or detection, including direct and indirect determination or detection.

[0128] “Symptom” or “disease” means any condition that can benefit from treatment, including but not limited to chronic and acute symptoms or diseases, which include those pathological conditions that make mammals susceptible to said symptoms (e.g., cancer, e.g., breast cancer, e.g., HR+ breast cancer (e.g., ER+ breast cancer (e.g., luminal type A breast cancer or luminal type B breast cancer)), DCIS and / or metastatic or locally advanced breast cancer).

[0129] As used herein, the term “diagnosis” refers to the identification or classification of a molecular or pathological state, disease, or symptom (e.g., cancer, e.g., breast cancer, e.g., HR+ breast cancer (e.g., ER+ breast cancer (e.g., luminal type A or luminal type B breast cancer)), DCIS, and / or metastatic or locally advanced breast cancer). For example, “diagnosis” can refer to the identification of a specific type of breast cancer. “Diagnosis” can also refer to the classification of a specific subtype of breast cancer, e.g., by histopathological criteria or molecular characteristics (e.g., a subtype characterized by a combination of biomarkers expressed (e.g., a specific gene or a protein encoded by said gene)).

[0130] An “effective amount” of a compound (e.g., an endocrine therapy described herein) or a combination thereof (e.g., a pharmaceutical composition) is at least the minimum amount required to achieve a desired therapeutic or preventative outcome, such as measurable overall survival (OS) or progression-free survival (PFS) for a specific disease or condition (e.g., breast cancer, such as HR+ breast cancer (e.g., ER+ breast cancer (e.g., luminal type A or luminal type B breast cancer)), DCIS, and / or metastatic or locally advanced breast cancer). The effective amount described herein can vary depending on factors such as an individual’s disease state, age, sex, and weight, and the ability of the antibody to elicit the expected response in a subject. An effective amount is also the amount at which the beneficial effects of treatment outweigh any toxic or adverse effects of treatment. For preventative use, beneficial or anticipated outcomes include elimination or reduction of risk, lessening of severity, or delay of disease onset, including biochemical, histological, and / or behavioral symptoms of the disease, its complications, and intermediate pathological phenotypes that occur during disease development. An effective amount may be administered once or multiple times. For the purposes provided herein, an effective amount of a drug, compound, or pharmaceutical composition is an amount sufficient to provide direct or indirect prevention or treatment. As understood in a clinical context, an effective amount of a drug, compound, or pharmaceutical composition may or may not be achieved when combined with another drug, compound, or pharmaceutical composition. Therefore, an "effective amount" may be considered when administering one or more therapeutic agents, and an effective amount of a single agent may be considered if the desired outcome can be obtained or achieved when combined with one or more other agents. For example, an effective amount of endocrine therapy as described herein for cancer treatment may reduce the number of cancer cells; reduce the size of the primary tumor; inhibit (i.e., to some extent slow down and preferably stop) the infiltration of cancer cells into surrounding organs; inhibit (i.e., to some extent slow down and preferably stop) tumor metastasis; inhibit tumor growth to some extent; and / or alleviate one or more symptoms associated with the disease to some extent. To some extent, a drug may stop the growth of and / or kill existing cancer cells; it may inhibit cell growth and / or be cytotoxic. For cancer therapies, efficacy in vivo can be measured, for example, by assessing survival time, time to progression of disease (TTP), response rate (RR), duration of response, and / or quality of life.

[0131] The terms “expression level,” “amount,” or “level,” or interchangeably herein, refer to the detectable level in a biological sample. “Expression” generally refers to the process by which information (e.g., genetically encoded and / or epigenetically inherited) is converted into structures present and functioning within the cell. Therefore, as used herein, “expression” can refer to transcription into a polynucleotide, translation into a polypeptide, or even polynucleotide and / or polypeptide modification (e.g., post-translational modification of a polypeptide). Fragments of transcribed polynucleotides, translated polypeptides, or polynucleotide and / or polypeptide modifications (e.g., post-translational modifications of a polypeptide) should also be considered expressed, regardless of whether they originate from transcripts generated by alternative splicing or degradation of transcripts, or from post-translational processing of polypeptides (e.g., by proteolysis). “Expressed genes” include those polynucleotides transcribed into mRNA and then translated into polypeptides, as well as those transcribed into RNA but not translated into polypeptides (e.g., transfer RNA and ribosomal RNA). Expression levels can be measured using methods known to those skilled in the art and disclosed herein. The expression levels or amounts of biomarkers can be used to identify / characterize subjects with breast cancer (e.g., HR+ breast cancer (e.g., ER+ breast cancer (e.g., luminal A or luminal B breast cancer)), DCIS, and / or metastatic or locally advanced breast cancer) who may respond to or benefit from specific therapies (e.g., therapies that include endocrine therapy, such as SERMs (e.g., SERDs), GnRH agonists, and / or AIs). In subjects with breast cancer described herein, the expression levels or amounts of the biomarkers provided herein can also be used to determine and / or track the benefit of endocrine therapy administered over a period of time.

[0132] Expression levels can be measured using assays and techniques suitable for measuring RNA levels. For example, RNA-Seq kits can be used to measure expression levels and are applicable to the kits described herein. Exemplary techniques that can be used to measure expression levels herein include, but are not limited to, RNA... plan or plan RT-qPCR, qPCR, multiplex qPCR (e.g., fluidigm), nanostring technology, microarray analysis, SAGE, or MassARRAY.

[0133] As used herein, the term “E2 induction score” refers to a numerical value reflecting the aggregated expression level of a predetermined genome, the induction of which reflects estrogen receptor (ER) pathway activity. For example, an E2 induction score may reflect at least five, six, seven, or eight genes listed in Table 1 (i.e., AMZ1, C5AR2, CELSR2, FKBP4, GREB1, OLFM1, SLC9A3R1, and TFF1), at least five, six, seven, eight, nine, ten, or eleven genes listed in Table 2 (i.e., AMZ1, AREG, C5AR2, CELSR2, FKBP4, FMN1, GREB1, OLFM1, RBM24, SLC9A3R1, and TFF1), or at least five, six, seven, eight, nine, or ten genes listed in Table 3. The aggregated expression levels of 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, or 23 genes (i.e., AGR3, AMZ1, AREG, C5AR2, CELSR2, CT62, FKBP4, FMN1, GREB1, IGFBP4, NOS1AP, NXPH3, OLFM1, PGR, PPM1J, RAPGEFL1, RBM24, RERG, RET, SGK3, SLC9A3R1, TFF1, and ZNF703) were induced, reflecting estrogen receptor (ER) pathway activity. The aggregated expression level of a predetermined genome can be determined, for example, as the mean z-score expression of the predetermined genome detected in a sample (e.g., a tissue sample, such as a tumor tissue sample, such as FFPE, FF, archived, fresh, or frozen tumor tissue sample) obtained from an individual (e.g., an individual with cancer, such as breast cancer (e.g., HR+ breast cancer (e.g., ER+ breast cancer (e.g., luminal type A or luminal type B breast cancer)), DCIS, and / or metastatic or locally advanced breast cancer). However, it should be understood that aggregated expression levels can be determined using methods known in the art, such as, for example, the average gene expression plotted over a reference population space, or, for example, as the average gene expression relative to untreated or drug-treated tumors, which optionally express as a fold change.

[0134] As used herein, the “E2 suppression score” refers to a numerical value reflecting the aggregated expression level of a predetermined genome, the suppression of which reflects estrogen receptor (ER) pathway activity. For example, the E2 suppression score may reflect at least three, four, five, or six genes listed in Table 4 (i.e., BCAS1, CCNG2, IL1R1, PNPLA7, SEMA3E, and STON1), at least four, five, six, seven, or eight genes listed in Table 5 (i.e., BCAS1, CCNG2, IL1R1, NBEA, PNPLA7, SEMA3E, STON1, and TP53INP1), or at least four, five, six, seven, or eight genes listed in Table 6. Aggregated expression levels of 9, 10, 11, 12, 13, 14, 15, 16, 17, or 18 genes (i.e., BAMBI, BCAS1, CCNG2, DDIT4, EGLN3, FAM171B, GRM4, IL1R1, LIPH, NBEA, PNPLA7, PSCA, SEMA3E, SSPO, STON1, TGFB3, TP53INP1, and TP53INP2) were calculated, with suppression reflecting estrogen receptor (ER) pathway activity. E2-induced scores for aggregated expression levels of predetermined genomes in HR+ breast cancer (e.g., ER+ breast cancer (e.g., luminal A or luminal B breast cancer)), DCIS, and / or metastatic or locally advanced breast cancer can be calculated as described above.

[0135] As used herein, the terms “estrogen receptor pathway activity score,” “ER pathway activity score,” and “comprehensive ER pathway activity score” refer to numerical values ​​that reflect the mathematical difference between the E2 induction score and the E2 inhibition score. The ER pathway activity score can be used as a predictive, prognostic, and / or pharmacodynamic biomarker (e.g., to identify individuals with breast cancer who may benefit from treatments including endocrine therapy, or to monitor the response of individuals with breast cancer to treatments including endocrine therapy).

[0136] The terms “reference estrogen receptor pathway activity score” and “reference ER pathway activity score” refer to an ER pathway activity score that is compared with another ER pathway activity score for, for example, to make predictive, prognostic, and / or therapeutic determinations. For example, the reference ER pathway activity score could be the ER pathway activity score in a reference sample, the ER pathway activity score in a reference population (e.g., a patient population with HR+ breast cancer), and / or a predetermined value. In some cases, the reference ER pathway activity score is a critical value that clearly distinguishes breast cancer individuals with ER pathway activity from those with low or no ER pathway activity (e.g., a reference ER pathway activity score of -1.0 or higher (e.g., -1.0, -0.9, -0.8, -0.7, -0.6, -0.5, -0.4, -0.3, -0.2, or higher). In other cases, the reference ER pathway activity score is a critical value that clearly distinguishes breast cancer individuals who are likely to respond to therapies, including the endocrine therapies described herein, from those who are unlikely to respond to therapies, including endocrine therapies (e.g., a reference ER pathway activity score of -1.0 or higher (e.g., -1.0, -0.9, -0.8, -0.7, -0.6, -0.5, ...). -0.4, -0.3, -0.2, or higher). Those skilled in the art will understand that the reference ER pathway activity score may vary depending on the type of breast cancer (e.g., HR+ breast cancer (e.g., ER+ breast cancer (e.g., luminal A or luminal B breast cancer)), DCIS, and / or metastatic or locally advanced breast cancer), the method used to measure the ER pathway activity score, the specific gene signature examined (e.g., the gene combinations listed in Tables 1-6), and / or the statistical method used to generate the ER pathway activity score. For example, the activity score described herein can be calculated by calculating the z-score of a reference population and recalibrating the expression of each gene in all samples to a mean of 0 and a standard deviation of 1 using the following formula. Expression data for a given patient can then be overlaid onto the z-score reference space described herein.

[0137] The Z-score can be described by the following formula: z = (x - μ) / σ, where z is the recalibrated score, x is the measured gene expression level, μ is the mean gene expression calculated based on the reference population, and σ is the standard deviation of gene expression calculated based on the reference population.

[0138] In some embodiments, a reference estrogen receptor pathway activity score is calculated with reference to a standard control as defined herein.

[0139] The term "reference E2-inducible activity score" refers to an E2-inducible activity score that is compared with another E2-inducible activity score for, for example, to make predictive, prognostic, and / or therapeutic determinations. For example, the reference E2-inducible activity score could be the reference E2-inducible activity score in a reference sample, the reference E2-inducible activity score in a reference population (e.g., a patient population with HR+ breast cancer), and / or a predetermined value. In some cases, the reference E2 induction activity score is a critical value that clearly distinguishes breast cancer individuals with E2 induction activity from those with low or no E2 induction activity (e.g., a reference E2 induction activity score of -2.0 or higher (e.g., -2.0, -1.9, -1.8, -1.7, -1.6, -1.5, -1.4, -1.3, -1.2, -1.1, 1.0, -0.9, -0.8, -0.7, -0.6, -0.5, -0.4, -0.3, -0.2 or higher). In other cases, the reference E2 induction activity score is a critical value that clearly distinguishes breast cancer individuals who are likely to respond to therapies, including the endocrine therapies described herein, from those who are unlikely to respond to therapies, including endocrine therapies (e.g., a reference E2 induction activity score of -2.0 or higher (e.g., -2.0, -1.9, -1.5, -1.4, -1.3, -1.2, -1.1, 1.0, -0.9, -0.8, -0.7, -0.6, -0.5, -0.4, -0.3, -0.2 or higher). -1.8, -1.7, -1.6, -1.5, -1.4, -1.3, -1.2, -1.1, 1.0, -0.9, -0.8, -0.7, -0.6, -0.5, -0.4, -0.3, -0.2 or higher). Those skilled in the art will understand that the reference E2-inducible activity score may vary depending on the type of breast cancer (e.g., HR+ breast cancer (e.g., ER+ breast cancer (e.g., luminal A or luminal B breast cancer)), DCIS, and / or metastatic or locally advanced breast cancer), the method used to measure the E2-inducible activity score, the specific genetic characteristics examined (e.g., gene combinations listed herein and, for example, in Tables 1-6), and / or the statistical methods used to generate the E2-inducible activity score. As described herein, the E2-inducible activity score can be calculated using the estrogen receptor pathway activity score. In some embodiments, the E2-inducible activity score is calculated with reference to a standard control as defined herein.

[0140] The ability to discriminate (e.g., by calculating an activity score as defined herein) is relative to the identification / characterization / quantification of gene expression as described herein, rather than by a form of measurement used to determine gene expression levels.

[0141] As used herein, a “reference gene” refers to a gene or group of genes (e.g., one, two, three, or more genes) used for comparison purposes, such as housekeeping genes. A “housekeeping gene” herein refers to a gene or group of genes (e.g., one, two, three, or more genes) that encode proteins whose activity is essential for maintaining cellular function and is generally similarly present in all cell types. Exemplary housekeeping genes include SDHA, GUSB, PPIA, and UBC.

[0142] As used herein, the terms “individual,” “patient,” and “subject” are used interchangeably and refer to any single animal, more preferably a mammal (including non-human animals such as dogs, cats, horses, rabbits, zoo animals, cattle, pigs, sheep, and non-human primates). In some embodiments, the individual, patient, or subject is a human.

[0143] "Isolated" nucleic acids refer to nucleic acid molecules that have been isolated from components of their natural environment. Isolated nucleic acids include nucleic acid molecules that are contained in cells that normally contain said nucleic acid molecules, but which are located outside chromosomes or at chromosomal locations different from their natural chromosomal locations.

[0144] When used herein, the term “label” refers to a detectable compound or composition. Labels are typically conjugated or fused directly or indirectly to reagents, such as polynucleotide probes or antibodies, and facilitate the detection of the conjugated or fused reagent. The label itself may be detectable (e.g., radioisotope labeling or fluorescent labeling), or, in the case of enzyme labeling, may catalyze a chemical change in the substrate compound or composition to produce a detectable product.

[0145] As used herein, the term "modulator" refers to an agent that interacts directly or indirectly with a target. Interactions include, but are not limited to, interactions between agonists, partial agonists, inverse agonists, antagonists, degraders, or combinations thereof. In some embodiments, the modulator is an antagonist. In some embodiments, the modulator is a degrader.

[0146] As used herein, the term "degrading agent" refers to an agent that binds to a nuclear hormone receptor and subsequently reduces the homeostatic protein level of said receptor. In some embodiments, the degrading agents described herein reduce homeostatic estrogen receptor levels by at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%. In some embodiments, the degrading agents described herein reduce homeostatic estrogen receptor levels by at least 65%. In some embodiments, the degrading agents described herein reduce homeostatic estrogen receptor levels by at least 85%.

[0147] The term "nucleic acid" refers to deoxyribonucleotides or ribonucleotides and their polymers in single-stranded or double-stranded form, as well as their complement. The term "polynucleotide" refers to a linear sequence of nucleotides. The term "nucleotide" generally refers to a single unit of a polynucleotide, i.e., a monomer. Nucleotides can be ribonucleotides, deoxyribonucleotides, or modified forms thereof. Examples of polynucleotides considered herein include single-stranded and double-stranded DNA, single-stranded and double-stranded RNA (including siRNA), and hybrid molecules having mixtures of single-stranded and double-stranded DNA and RNA. Nucleic acid as used herein also refers to nucleic acids having the same basic chemical structure as naturally occurring nucleic acids. Such analogs have modified sugars and / or modified ring substituents, but retain the same basic chemical structure as naturally occurring nucleic acids. Nucleic acid mimics are compounds having a structure different from the general chemical structure of nucleic acids but functioning in a manner similar to naturally occurring nucleic acids. Examples of such analogs include, but are not limited to, thiophosphates, aminophosphates, methylphosphates, chiral methylphosphates, 2-O-methylribonucleotides, and peptide-nucleic acids (PNAs). The term "oligonucleotide" refers to relatively short polynucleotides (e.g., less than about 250 nucleotides in length), including but not limited to single-stranded deoxyribonucleotides, single-stranded or double-stranded ribonucleotides, RNA:DNA hybrids, and double-stranded DNA. Oligonucleotides, such as single-stranded DNA probe oligonucleotides, are typically synthesized by chemical methods, such as using commercially available automated oligonucleotide synthesizers. However, oligonucleotides can be prepared by a variety of other methods, including in vitro recombinant DNA-mediated techniques and through expression of DNA in cells and organisms.

[0148] The term "packaging insert" is used to refer to the instruction leaflet typically included in the commercial packaging of a therapeutic product, which contains information concerning the indications, usage, dosage, administration, combination therapy, contraindications, and / or warnings related to the use of such therapeutic products.

[0149] The term "pharmaceutical formulation" refers to a formulation in which the bioactive ingredient contained therein is in a form in which the activity is effective and which does not contain any additional components that would have unacceptable toxicity to a subject to whom the formulation will be administered.

[0150] "Pharmaceutical carriers" refer to components in a pharmaceutical preparation that are non-toxic to the test subject, excluding the active ingredient. Pharmaceutical carriers include, but are not limited to, buffers, excipients, stabilizers, or preservatives.

[0151] Unless otherwise specified, as used herein, the term "protein" means any naturally occurring protein from any vertebrate source, including mammals such as primates (e.g., humans) and rodents (e.g., mice and rats). The term includes "full-length" unprocessed proteins, as well as any form of protein produced through cellular processing. The term also covers naturally occurring protein variants, such as splice variants or allele variants.

[0152] The “sequence identity percentage (%)” relative to a reference polynucleotide or polypeptide sequence is defined as the percentage of nucleic acid or amino acid residues in the candidate sequence that are identical to those in the reference polynucleotide or polypeptide sequence after aligning the candidate sequence with the reference polynucleotide or polypeptide sequence and introducing vacancies (if necessary) to achieve the maximum sequence identity percentage, without considering any conserved substitutions as part of sequence identity. Alignment used to determine the nucleic acid or amino acid sequence identity percentage can be performed in various ways within the scope of the art, such as using publicly available computer software, such as BLAST, BLAST-2, ALIGN, or Megalign (DNASTAR) software. Those skilled in the art can determine appropriate parameters for aligning sequences, including any algorithm required to achieve maximum alignment across the full length of the sequences being compared. However, for the purposes of this document, the sequence comparison computer program ALIGN-2 is used to generate the sequence identity % value. The ALIGN-2 sequence comparison computer program was written by Genentech, and the source code has been submitted with user documentation to the US Copyright Office, Washington DC, 20559, where it is registered under US Copyright Registry No. TXU510087. The ALIGN-2 program is publicly available from Genentech (South San Francisco, California, USA) or can be compiled from the source code. The ALIGN-2 program should be compiled for use on a UNIX operating system, including Digital UNIX V4.0D. All sequence comparison parameters are set by the ALIGN-2 program and remain unchanged.

[0153] When comparing nucleic acid or amino acid sequences using ALIGN-2, the percentage of sequence similarity between a given nucleic acid or amino acid sequence A and a given nucleic acid or amino acid sequence B (which can be alternatively expressed as a given nucleic acid or amino acid sequence A having or containing a certain percentage of sequence similarity with a given nucleic acid or amino acid sequence B) is calculated as follows:

[0154] 100 multiplied by the fraction X / Y,

[0155] Where X is the number of nucleic acid or amino acid residues that are scored as identical matches by the sequence alignment program ALIGN-2 in the alignment of A and B, and Y is the total number of nucleic acid or amino acid residues in B. It should be understood that if the length of nucleic acid or amino acid sequence A is not equal to the length of nucleic acid or amino acid sequence B, the sequence identity percentage of A to B will not be equal to the sequence identity percentage of B to A. Unless otherwise specifically stated, all sequence identity percentage values ​​used herein were obtained using the ALIGN-2 computer program as described in the preceding paragraph.

[0156] "Correlate" or "correlating" means comparing the performance and / or results of a first analysis or protocol with the performance and / or results of a second analysis or protocol in any way. For example, the results of the first analysis or protocol may be used when performing the second protocol, and / or the results of the first analysis or protocol may be used when performing the second protocol. Regarding examples of peptide analyses or protocols, the results of peptide expression analyses or protocols may be used to determine whether a specific treatment regimen should be performed. Regarding examples of polynucleotide analyses or protocols, the results of polynucleotide expression analyses or protocols may be used to determine whether a specific treatment regimen should be performed.

[0157] The terms “polynucleotide” or “nucleic acid” used interchangeably in this document refer to a polymer of nucleotides of any length, including DNA and RNA. Nucleotides can be deoxyribonucleotides, ribonucleotides, modified nucleotides or bases, and / or their analogues, or any substrate that can be incorporated into the polymer by DNA or RNA polymerases or by a synthetic reaction.

[0158] Polynucleotides can contain modified nucleotides, such as methylated nucleotides and their analogues. If present, the nucleotide structure can be modified before or after polymer assembly. The sequence of the nucleotide can be interrupted by non-nucleotide components. Polynucleotides can be further modified post-synthesized, for example, by conjugation with tags. Other types of modification include, for example, “termination,” with similar internucleotide modifications, such as those with uncharged bonds (e.g., methyl phosphate, triphosphate, amino phosphate, carbamate) and those with charged bonds (e.g., thiophosphate, dithiophosphate, etc.), those containing side groups, such as, for example, proteins (e.g., nucleases, toxins, antibodies, signal peptides, ply-L-lysine, etc.), those containing intercalating agents (e.g., acridine, psoralen, etc.), those containing chelating agents (e.g., metals, radioactive metals, boron, oxidizing metals, etc.), those containing alkylating agents, those with modified bonds (e.g., α-anomeric nucleic acids, etc.), and the substitution of one or more naturally occurring nucleotides with unmodified forms of polynucleotides. Furthermore, any hydroxyl groups typically present in the sugar can be substituted (e.g., phosphate ester groups, phosphate groups), protected by standard protecting groups, or activated to prepare additional linkages with other nucleotides, or can be conjugated to a solid or semi-solid support. The OH groups at the 5' and 3' ends can be phosphorylated or partially substituted by amine or organic end-capping groups of 1-20 carbon atoms. Other hydroxyl groups can also be derived as standard protecting groups. Polynucleotides can also contain similar forms of ribose or deoxyribose known in the art, including, for example, 2'-O-methyl-, 2'-O-allyl, 2'-fluoro-, or 2'-azido-ribose, carbocyclic sugar analogs, α-anomeric sugars, epimeric sugars (such as arabinose, xylose, or lythose, pyranose, furanose, heptacaphesose), acyclic analogs, and non-base nucleoside analogs such as methylriboside. One or more phosphodiester bonds can be substituted with alternative linking groups. These alternative linking groups include, but are not limited to, embodiments in which the phosphate ester is replaced by P(O)S (“thioester”), P(S)S (“dithioester”), (O)NR2 (“amic acid ester”), P(O)R, P(O)OR', CO, or CH2 (“methylal”), wherein each R or R' is independently H or a substituted or unsubstituted alkyl group (1-20C). Optionally, an ether (-O-) bond, aryl, alkenyl, cycloalkyl, cycloalkenyl, or aryl substituted group may be included. Not all links in a polynucleotide need to be identical. The preceding description applies to all polynucleotides referred to herein, including RNA and DNA.

[0159] As used herein, “polymerase chain reaction” or “PCR” generally refers to a procedure for amplifying trace amounts of specific nucleic acid, RNA, and / or DNA fragments, as described in U.S. Patent No. 4,683,195, granted July 28, 1987. Typically, sequence information is required from the ends or regions outside the target region so that oligonucleotide primers can be designed; these primers are identical or similar in sequence to the opposite strand of the template to be amplified. The 5' nucleotides of the two primers may coincide with the ends of the amplified material. PCR can be used to amplify specific RNA sequences and specific DNA sequences from total genomic DNA, as well as cDNA transcribed from total cellular RNA, bacteriophage, or plasmid sequences, etc. See also Mullis et al., Cold Spring Harbor Symp. Quant. Biol., 51:263 (1987); Erlich, ed., PCR Technology, (Stockton Press, NY, 1989). As used in this article, PCR is considered one type of nucleic acid polymerase reaction method for amplifying nucleic acid test samples, but not the only example. Other examples include using known nucleic acids (DNA or RNA) as primers and utilizing nucleic acid polymerases to amplify or generate specific nucleic acid fragments, or amplifying or generating specific nucleic acid fragments complementary to specific nucleic acids.

[0160] As used herein, the terms “reverse transcriptase polymerase chain reaction” or “RT-PCR” refer to the replication and amplification of an RNA sequence. In this method, for example, as described in U.S. Patent No. 5,322,770, the reverse transcription is coupled to PCR, the entire text of which is incorporated herein by reference. In RT-PCR, an RNA template is converted to cDNA due to the reverse transcriptase activity of an enzyme, which is then amplified using the polymerase activity of the same or different enzymes. Thermostable and thermolabile reverse transcriptases and polymerases can be used. “Reverse transcriptase” (RT) can include reverse transcriptases derived from retroviruses, other viruses, and DNA polymerases that exhibit reverse transcriptase activity.

[0161] As used herein, the terms “reverse transcriptase quantitative polymerase chain reaction” or “RT-qPCR” refer to a form of PCR in which the nucleic acid to be amplified is RNA that is first reverse transcribed into cDNA, and the amount of PCR product is measured at each step of the PCR reaction.

[0162] "Quantitative real-time polymerase chain reaction" or "qRT-PCR" refers to a form of PCR in which the amount of PCR product is measured at each step of the PCR reaction. This technique has been described in various publications, including Cronin et al., Am. J. Pathol. 164(l):35-42 (2004); and Ma et al., Cancer Cell 5:607-616 (2004).

[0163] The term "multiplex PCR" refers to a single PCR reaction using one or more primer sets on nucleic acids obtained from a single source (e.g., an individual) with the aim of amplifying two or more DNA sequences in a single reaction.

[0164] The term “RNA-seq,” also known as “whole transcriptome shotgun sequencing (WTSS),” refers to the use of high-throughput sequencing technology to sequence and / or quantify cDNA to obtain information about the RNA content of a sample. Publications describing RNA-seq include: Wang et al., “RNA-Seq: a revolutionary tool for transcriptomics,” Nature Reviews Genetics 10(1):57-63 (January 2009); Ryan et al., BioTechniques 45(1):81-94 (2008); and Maher et al., “Transcriptome sequencing to detect gene fusions in cancer,” Nature 458(7234):97-101 (January 2009). Exemplary RNA-seq protocols include the use of RNA… plan or plan .

[0165] "Response to a treatment," "responsiveness to treatment," or "benefit from treatment" can be assessed using any endpoint that indicates benefit to an individual, including but not limited to (1) inhibiting disease progression (e.g., progression of breast cancer) to some extent, including slowing and completely stopping it; (2) reducing tumor size; (3) inhibiting (i.e., reducing, slowing, or completely stopping) cancer cell infiltration into adjacent peripheral organs and / or tissues; (4) inhibiting (i.e., reducing, slowing, or completely stopping) metastasis; (5) alleviating one or more symptoms associated with the disease or condition (e.g., cancer) to some extent; (6) increasing or prolonging survival, including recurrence-free survival (RFS), disease-free survival (DFS), overall survival (OS HR < 1), and progression-free survival (PFS HR < 1); and / or (9) reducing mortality at a given time point following treatment (e.g., treatment with endocrine therapy, SERM (e.g., SERD), GnRH agonists, and / or AIs). The response to treatment can also refer to a pharmacodynamic response or a pathway response (e.g., the ER pathway), and can be assessed using methods known in the art.

[0166] As used herein, “progression-free survival” or “PFS” refers to the length of time during and after treatment during which the disease to be treated (e.g., breast cancer, e.g., HR+ breast cancer, e.g., ER+ breast cancer, e.g., luminal A or luminal B breast cancer, e.g., advanced or metastatic breast cancer) does not progress or worsen. Progression-free survival may include the amount of time an individual experiences a complete or partial response, as well as the amount of time an individual experiences stable disease.

[0167] As used in this article, “overall survival” or “OS” refers to the percentage of a group of subjects who are likely to survive after a specific time period (e.g., 6 months, 1 year, 2 years, 3 years, 4 years, 5 years, 10 years, 15 years, 20 years or more from the start of diagnosis or treatment).

[0168] As used in this article, “recurrence-free survival” or “RFS” refers to the length of time a patient survives in the same local or localized area without any signs, symptoms or recurrence of tumor after the initial treatment.

[0169] As used in this article, “disease-free survival” or “DFS” refers to the length of time a patient has remained free of any signs, symptoms, or recurrence of tumors in any region after initial treatment, including the development of distant metastases.

[0170] As used in this article, "complete response" or "CR" refers to the disappearance of all signs of cancer in response to treatment. This does not necessarily mean that the cancer has been cured.

[0171] As used in this article, "partial response" or "PR" refers to a response to treatment of a reduction in the size of one or more tumors or lesions or a reduction in the degree of cancer in the body.

[0172] As used herein, “hazard ratio” or “HR” is a statistical definition of the incidence of an event. For the purposes of this article, the hazard ratio is defined as the probability of an event (e.g., PFS or OS) in the experimental (e.g., treatment) group / arm divided by the probability of the event in the control group / arm. An HR of 1 indicates that the relative risk of the endpoint (e.g., death) is equal in the treatment and control groups; a value greater than 1 indicates a greater risk in the treatment group relative to the control group; and a value less than 1 indicates a greater risk in the control group relative to the treatment group. The hazard ratio in a progression-free survival analysis (i.e., PFS HR) summarizes the difference between two progression-free survival curves, representing the reduced risk of death in the treatment group compared to the control group during the follow-up period. The hazard ratio in an overall survival analysis (i.e., OS HR) summarizes the difference between two overall survival curves, representing the reduced risk of death in the treatment group compared to the control group during the follow-up period.

[0173] "Extended survival" refers to an increase in overall survival or progression-free survival relative to untreated individuals (i.e., individuals not receiving drug treatment) or individuals not expressing a specified level of biomarker and / or individuals receiving an approved anticancer therapy. Objective response refers to a measurable response, including complete response (CR) or partial response (PR).

[0174] "Reduction or inhibition" refers to the ability to cause an overall reduction of 20%, 30%, 40%, 50%, 60%, 70%, 75%, 80%, 85%, 90%, 95%, or more. Reduction or inhibition can refer to the symptoms of the treated condition (e.g., breast cancer, such as HR+ breast cancer (e.g., ER+ breast cancer (e.g., luminal A or luminal B breast cancer)), DCIS and / or metastatic or locally advanced breast cancer), the presence or size of metastases, or the size of the primary tumor. When tumor pathways are involved, reduction or inhibition refers to a decrease in the expression or activity of any component of that pathway (e.g., decreased ER expression, decreased ER activity, or ER degradation).

[0175] As used herein, “reference sample,” “reference cell,” “reference tissue,” “control sample,” “control cell,” or “control tissue” refers to a sample, cell, tissue, standard, or level used for comparative purposes. In one embodiment, the reference sample, reference cell, reference tissue, control sample, control cell, or control tissue is obtained from the same subject or individual. In another embodiment, the reference sample is obtained from one or more individuals who are not the subject or individual. In any of the foregoing embodiments, one or more individuals from whom the reference sample, reference cell, reference tissue, control sample, control cell, or control tissue is obtained have breast cancer (e.g., HR+ breast cancer (e.g., ER+ breast cancer (e.g., luminal A-type or luminal B-type breast cancer)), DCIS, and / or metastatic or locally advanced breast cancer). In some embodiments, one or more individuals from whom the reference sample, reference cell, reference tissue, control sample, control cell, or control tissue is obtained have breast cancer and have previously been treated with anticancer therapies (e.g., one or more doses of endocrine therapy, e.g., SERM (e.g., SERD), GnRH agonists, and / or AI). In other embodiments, one or more individuals who obtained the reference sample, reference cell, reference tissue, control sample, control cell, or control tissue had breast cancer and were treatment-naïve. In any of the foregoing embodiments, the subject / individual and one or more individuals who were not subjects or individuals had the same breast cancer.

[0176] As used herein, a “standard control” for the expression level of one or more genes refers to the expression level measured in a control subject (e.g., in a sample from a control subject) or a population of control subjects. In embodiments, a control subject is a healthy control subject relative to a test subject, wherein the healthy control subject does not have breast cancer. In embodiments, a control subject is a test subject prior to treatment of the test subject, wherein both the test subject and the control subject have breast cancer. For example, in embodiments, the test subject has been treated with an anticancer agent for breast cancer, while the control subject is the test subject prior to treatment. In embodiments, a population of control subjects is a diverse collection of healthy and diseased subjects, wherein the expression level of the test subject is compared to the expression level of the control subject population (e.g., the mean expression level of the control subject population). In embodiments, a population of control subjects is a collection of healthy subjects without breast cancer, wherein the expression level of the test subject is compared to the expression level of the control subject population (e.g., the mean expression level of the control subject population). In this embodiment, the control group is a collection of subjects who have already received treatment for breast cancer, wherein the expression levels of the subjects being tested are compared with the expression levels of the control group (e.g., the average expression levels of the control group).

[0177] As used herein, the term "sample" means a composition obtained from or derived from a subject and / or individual intended for the purpose of the study, which contains, for example, cells and / or other molecular entities to be characterized and / or identified based on physical, biochemical, chemical, and / or physiological characteristics. For example, the phrase "disease sample" and variations thereof refer to any sample obtained from a subject intended for the purpose of the study, which is expected or known to contain cells and / or molecular entities to be characterized. Samples include, but are not limited to, tissue extracts such as homogenized tissue, tumor tissue, cell extracts, primary or cultured cells or cell lines, cell supernatants, cell lysates, platelets, serum, plasma, vitreous fluid, lymph, synovial fluid, follicular fluid, semen, amniotic fluid, breast milk, whole blood, blood-derived cells, urine, cerebrospinal fluid, saliva, sputum, tears, sweat, mucus, tumor lysis products, and tissue culture media, and combinations thereof.

[0178] A “tissue sample” or “cell sample” refers to a collection of similar cells obtained from the tissue of a subject or individual. The source of the tissue or cell sample can be solid tissue from FFPE, FF, fresh, frozen, and / or preserved organs, tissue samples, biopsies, and / or aspirates; blood or any blood component, such as plasma; body fluids, such as cerebrospinal fluid, amniotic fluid, peritoneal fluid, or interstitial fluid; or cells from any time during the subject’s pregnancy or development. The tissue sample can also be primary or cultured cells or cell lines. Optionally, the tissue or cell sample is obtained from tissue / organ of a disease (e.g., breast cancer, such as HR+ breast cancer (e.g., ER+ breast cancer (e.g., luminal type A or luminal type B breast cancer)), DCIS, and / or metastatic or locally advanced breast cancer). The tissue sample may contain compounds that are naturally occurring and do not mix with the tissue, such as preservatives, anticoagulants, buffers, fixatives, nutrients, antibiotics, etc.

[0179] For the purposes of this article, a “slice” of a tissue sample refers to a single portion or piece of a tissue sample, such as a thin slice of tissue or cells cut from a tissue sample. It should be understood that multiple slices of a tissue sample can be obtained and analyzed, provided that the same slice of the tissue sample can be analyzed at the morphological and molecular levels, or that analysis can be performed on peptides and polynucleotides.

[0180] As used herein, “treatment” (and its grammatical variations, such as “treat” or “treating”) refers to a clinical intervention that attempts to alter the natural course of a subject being treated, and may be for prevention or in the course of clinicopathology. Desired therapeutic effects include, but are not limited to, preventing the occurrence or recurrence of disease (e.g., breast cancer, such as HR+ breast cancer (e.g., ER+ breast cancer (e.g., luminal A or luminal B breast cancer)), DCIS, and / or metastatic or locally advanced breast cancer), relieving symptoms, mitigating any direct or indirect pathological consequences of the disease, preventing metastasis, slowing disease progression, improving or alleviating the condition, and mitigating or improving prognosis. In some embodiments, the treatments described herein are intended to delay disease development or slow the progression of disease (e.g., breast cancer, such as HR+ breast cancer (e.g., ER+ breast cancer (e.g., luminal A or luminal B breast cancer)), DCIS, and / or metastatic or locally advanced breast cancer). In some cases, treatment can increase overall survival (OS) (e.g., by about 20% or more, about 25% or more, about 30% or more, about 35% or more, about 40% or more, about 45% or more, about 50% or more, about 55% or more, about 60% or more, about 65% or more, about 70% or more, about 75% or more, about 80% or more, about 85% or more, about 90% or more, about 95% or more, about 96% or more, about 97% or more, about 98% or more, or about 99% or more). In some cases, treatment can increase overall survival (OS), for example, by about 5% to about 500%, for example, about 10% to about 450%, for example, about 20% to about 400%, for example, about 25% to about 350%, for example, about 30% to about 400%, for example, about 35% to about 350%, for example, about 40% to about 300%, for example, about 45% to about 250%, for example, about 50% to about 200%, for example, about 55% to about 150%, for example, about 60% to about 100%, for example, about 65% to about 100%, for example, about 70% to about 100%, for example, about 75% to about 100%, for example, about 80% to about 100%, for example, about 85% to about 100%, for example, about 90% to about 100%, for example, about 95% to about 100%, for example, about 98% to about 100%.In some cases, treatment can increase progression-free survival (PFS) (for example, by about 20% or more, about 25% or more, about 30% or more, about 35% or more, about 40% or more, about 45% or more, about 50% or more, about 55% or more, about 60% or more, about 65% or more, about 70% or more, about 75% or more, about 80% or more, about 85% or more, about 90% or more, about 95% or more, about 96% or more, about 97% or more, about 98% or more, or about 99% or more). In some cases, treatment can increase PFS, for example, by about 5% to about 500%, for example, about 10% to about 450%, for example, about 20% to about 400%, for example, about 25% to about 350%, for example, about 30% to about 400%, for example, about 35% to about 350%, for example, about 40% to about 300%, for example, about 45% to about 250%, for example, about 50% to about 200%, for example, about 55% to about 150%, for example, about 60% to about 100%, for example, about 65% to about 100%, for example, about 70% to about 100%, for example, about 75% to about 100%, for example, about 80% to about 100%, for example, about 85% to about 100%, for example, about 90% to about 100%, for example, about 95% to about 100%, for example, about 98% to about 100%.

[0181] As used herein, the term “tumor” refers to all proliferative cell growth and proliferation (whether malignant or benign), as well as all precancerous and cancerous cells and tissues. The terms “cancer,” “cancerous,” “proliferative disorder,” “proliferative lesion,” and “tumor” are not mutually exclusive in this text.

[0182] III. Methods

[0183] This document provides methods and assays for identifying individuals with breast cancer (e.g., HR+ breast cancer (e.g., ER+ breast cancer (e.g., luminal A or luminal B breast cancer)), DCIS and / or metastatic or locally advanced breast cancer, ER+ breast cancer (e.g., luminal A or luminal B breast cancer)), DCIS and / or metastatic or locally advanced breast cancer, who may benefit from treatment including the endocrine therapies described herein; selecting therapies for individuals with breast cancer; treating individuals with breast cancer based on the diagnostic methods provided herein; and monitoring the efficacy of endocrine therapy. In one embodiment, the endocrine therapy is a compound described herein. In another embodiment, the endocrine therapy is a SERM, SERD, AI, or a combination thereof.

[0184] The methods and assays described herein are based on the finding that estradiol (E2) induction scores or estrogen receptor (ER) pathway activity scores determined from samples from an individual (e.g., tissue samples, such as tumor tissue samples, such as FFPE, FF, archived, fresh, or frozen tumor tissue samples) can be used to predict the therapeutic efficacy of the endocrine therapies described herein. Any method may further include administration of endocrine therapy (e.g., as described in Section IV-A below) to the individual.

[0185] Therefore, this article also provides methods and assays for determining E2 induction scores and / or ER pathway activity scores from samples from individuals. Any method provided herein may include administration of anticancer therapies other than endocrine therapy (e.g., as described in Section IV-A below) to the individual. Any method may further include administration of an effective amount of other therapeutic agents described herein to the individual.

[0186] A. Diagnostic methods and measurements

[0187] Predictive diagnostic methods and assays

[0188] In specific circumstances, the methods and assays provided herein can be used to identify individuals with breast cancer (e.g., HR+ breast cancer (e.g., ER+ breast cancer (e.g., luminal A or luminal B breast cancer), DCIS, and / or metastatic or locally advanced breast cancer) who may benefit from treatment including the endocrine therapies described herein. The method includes determining an ER pathway activity score from samples from the individual (e.g., tissue samples, such as tumor tissue samples, such as formalin-fixed and paraffin-embedded (FFPE), fresh-frozen (FF), archived, fresh, or frozen tumor tissue samples), wherein an ER pathway activity score that meets or exceeds a reference ER pathway activity score identifies the individual as an individual who may benefit from treatment including the endocrine therapies described herein.

[0189] In specific circumstances, the methods and assays provided herein can be used to identify individuals with breast cancer (e.g., HR+ breast cancer (e.g., ER+ breast cancer (e.g., luminal type A or luminal type B breast cancer), DCIS, and / or metastatic or locally advanced breast cancer) who may benefit from treatment including the endocrine therapy described herein. The method includes determining an E2 induction score from samples from the individual (e.g., tissue samples, such as tumor tissue samples, such as FFPE, FF, archived, fresh, or frozen tumor tissue samples), wherein an E2 induction score that reaches or exceeds a reference E2 induction score identifies the individual as an individual who may benefit from treatment including the endocrine therapy described herein.

[0190] In specific circumstances, the methods and assays provided herein can be used to select a therapy for an individual with breast cancer (e.g., HR+ breast cancer (e.g., ER+ breast cancer (e.g., luminal A or luminal B breast cancer)), DCIS, and / or metastatic or locally advanced breast cancer). The method includes determining an ER pathway activity score from samples from the individual (e.g., tissue samples, such as tumor tissue samples, such as FFPE, FF, archived, fresh, or frozen tumor tissue samples), wherein an ER pathway activity score that meets or exceeds a reference ER pathway activity score identifies the individual as an individual who may benefit from treatment including the endocrine therapies described herein.

[0191] In specific circumstances, the methods and assays provided herein can be used to select a therapy for an individual with breast cancer (e.g., HR+ breast cancer (e.g., ER+ breast cancer (e.g., luminal type A or luminal type B breast cancer)), DCIS, and / or metastatic or locally advanced breast cancer). The method includes determining an E2 induction score from a sample from the individual (e.g., a tissue sample, such as a tumor tissue sample, such as FFPE, FF, archived, fresh, or frozen tumor tissue sample), wherein an E2 induction score that reaches or exceeds a reference E2 induction score identifies the individual as an individual who may benefit from a treatment including the endocrine therapy described herein.

[0192] In specific circumstances, the methods and assays provided herein can be used to identify individuals with breast cancer (e.g., HR+ breast cancer (e.g., ER+ breast cancer (e.g., luminal A or luminal B breast cancer), DCIS, and / or metastatic or locally advanced breast cancer) who may benefit from treatment including the endocrine therapies described herein. The method includes determining an ER pathway activity score from samples from the individual (e.g., tissue samples, such as tumor tissue samples, such as FFPE, FF, archived, fresh, or frozen tumor tissue samples), wherein an ER pathway activity score lower than a reference ER pathway activity score identifies the individual as unlikely to benefit from treatment including the endocrine therapies described herein.

[0193] In specific circumstances, the methods and assays provided herein can be used to identify individuals with breast cancer who may benefit from treatments including the endocrine therapies described herein. The method involves determining an E2-inducible score from a sample from the individual (e.g., a tissue sample, such as a tumor tissue sample, such as FFPE, FF, archived, fresh, or frozen tumor tissue sample), wherein an E2-inducible score lower than a reference E2-inducible score identifies the individual as unlikely to benefit from treatments including the endocrine therapies described herein.

[0194] In specific circumstances, the methods and assays provided herein can be used to select therapy for individuals with breast cancer (e.g., HR+ breast cancer (e.g., ER+ breast cancer (e.g., luminal A or luminal B breast cancer)), DCIS, and / or metastatic or locally advanced breast cancer). The method involves determining an ER pathway activity score from samples from the individual (e.g., tissue samples, such as tumor tissue samples, such as FFPE, FF, archived, fresh, or frozen tumor tissue samples), wherein an ER pathway activity score below a reference ER pathway activity score identifies the individual as unlikely to benefit from treatment including the endocrine therapies described herein. For example, the method relates to selecting an anticancer therapy for an individual in addition to endocrine therapy.

[0195] In specific circumstances, the methods and assays provided herein can be used to select therapy for individuals with breast cancer (e.g., HR+ breast cancer (e.g., ER+ breast cancer (e.g., luminal A or luminal B breast cancer)), DCIS, and / or metastatic or locally advanced breast cancer). The method involves determining an E2-inducible score from samples from the individual (e.g., tissue samples, such as tumor tissue samples, such as FFPE, FF, archived, fresh, or frozen tumor tissue samples), wherein an E2-inducible score below a reference E2-inducible score identifies the individual as unlikely to benefit from treatment including the endocrine therapies described herein. For example, the method involves selecting an anticancer therapy for an individual in addition to endocrine therapy.

[0196] In specific circumstances, the methods and assays provided herein can be used to identify individuals with breast cancer (e.g., HR+ breast cancer (e.g., ER+ breast cancer (e.g., luminal A or luminal B breast cancer), DCIS, and / or metastatic or locally advanced breast cancer) who may benefit from treatment including anticancer therapies other than endocrine therapy), wherein the method comprises determining an ER pathway activity score from samples from the individual (e.g., tissue samples, such as tumor tissue samples, such as FFPE, FF, archived, fresh, or frozen tumor tissue samples), wherein an ER pathway activity score lower than a reference ER pathway activity score identifies the individual as an individual who may benefit from treatment including anticancer therapies other than endocrine therapy).

[0197] In specific circumstances, the methods and assays provided herein can be used to identify individuals with breast cancer who may benefit from treatment including anticancer therapies other than endocrine therapy. The method involves determining an E2-inducible score from a sample from the individual (e.g., a tissue sample, such as a tumor tissue sample, such as FFPE, FF, archived, fresh, or frozen tumor tissue sample), wherein an E2-inducible score lower than a reference E2-inducible score identifies the individual as potentially benefiting from treatment including anticancer therapies other than endocrine therapy.

[0198] In specific circumstances, the methods and assays provided herein can be used to select a therapy for an individual with breast cancer (e.g., HR+ breast cancer (e.g., ER+ breast cancer (e.g., luminal A or luminal B breast cancer)), DCIS, and / or metastatic or locally advanced breast cancer). The method involves determining an ER pathway activity score from samples from the individual (e.g., tissue samples, such as tumor tissue samples, such as FFPE, FF, archived, fresh, or frozen tumor tissue samples), wherein an ER pathway activity score lower than a reference ER pathway activity score identifies the individual as someone who may benefit from treatment including anticancer therapies other than endocrine therapy.

[0199] In specific circumstances, the methods and assays provided herein can be used to select a therapy for an individual with breast cancer (e.g., HR+ breast cancer (e.g., ER+ breast cancer (e.g., luminal A-type or luminal B-type breast cancer)), DCIS, and / or metastatic or locally advanced breast cancer). The method involves determining an E2 induction score from a sample from the individual (e.g., a tissue sample, such as a tumor tissue sample, such as FFPE, FF, archived, fresh, or frozen tumor tissue sample), wherein an E2 induction score lower than a reference E2 induction score identifies the individual as someone who may benefit from treatment including anticancer therapies other than endocrine therapy.

[0200] In any of the foregoing circumstances, the reference ER pathway activity score can be the ER pathway activity score in a reference population of individuals with HR+ breast cancer (e.g., ER+ breast cancer (e.g., luminal A or luminal B breast cancer)), DCIS, and / or metastatic or locally advanced breast cancer. In some cases, the reference population is a group of individuals who have not received treatment including the endocrine therapy described herein. In some cases, the reference population is a group of individuals who have not received prior endocrine therapy described herein. In some cases, the reference population is a group of individuals who are not currently receiving anticancer treatment (including the endocrine therapy described herein). In some cases, the reference ER pathway activity score can be a pre-assigned reference ER pathway activity score. In some cases, the reference ER pathway activity score can be at or above -1.0 (e.g., -1.0, -0.9, -0.8, -0.7, -0.6, -0.5, -0.4, -0.3, -0.2, or higher). For example, in some cases, the reference ER pathway activity score can be at or above -0.9. In some cases, the reference ER pathway activity score can reach or exceed -0.8. In some cases, the reference ER pathway activity score can reach or exceed -0.7. In some cases, the reference ER pathway activity score can reach or exceed -0.6. In some cases, the reference ER pathway activity score can reach or exceed -0.5. In some cases, the reference ER pathway activity score can reach or exceed -0.4. In some cases, the reference ER pathway activity score can reach or exceed -0.3. In some cases, the reference ER pathway activity score can reach or exceed -0.2. In some cases, the reference ER pathway activity score can be between about -1.0 and about -0.2 (e.g., between about -0.9 and about -0.2, for example, between about -0.8 and about -0.2, for example, between about -0.7 and about -0.2, for example, between about -0.6 and about -0.2, for example, between about -0.5 and about -0.2, for example, between about -0.4 and about -0.2, or for example, between about -0.3 and about -0.2).

[0201] In any of the foregoing circumstances, the ER pathway activity score of samples from an individual (e.g., tissue samples, such as tumor tissue samples, such as FFPE, FF, archived, fresh, or frozen tumor tissue samples) can reach or exceed -1.0 (e.g., -1.0, -0.9, -0.8, -0.7, -0.6, -0.5, -0.4, -0.3, -0.2, or higher). For example, in some cases, the ER pathway activity score can reach or exceed -0.9. In some cases, the ER pathway activity score can reach or exceed -0.8. In some cases, the ER pathway activity score can reach or exceed -0.7. In some cases, the ER pathway activity score can reach or exceed -0.6. In some cases, the ER pathway activity score can reach or exceed -0.5. In some cases, the ER pathway activity score can reach or exceed -0.4. In some cases, the ER pathway activity score can reach or exceed -0.3. In some cases, the ER pathway activity score can reach or exceed -0.2. In some cases, the ER pathway activity score can be between about -1.0 and about -0.2 (e.g., between about -0.9 and about -0.2, for example, between about -0.8 and about -0.2, for example, between about -0.7 and about -0.2, for example, between about -0.6 and about -0.2, for example, between about -0.5 and about -0.2, for example, between about -0.4 and about -0.2, or for example, between about -0.3 and about -0.2). In some cases, the ER activity score from the sample can be less than -1.0.

[0202] In any of the foregoing circumstances, the reference E2-inducible score can be the E2-inducible score in a reference population of individuals with hormone receptor (HR)+ breast cancer (e.g., ER+ breast cancer (e.g., luminal A or luminal B breast cancer)) and / or metastatic or locally advanced breast cancer. In some cases, the reference population is a group of individuals who have not received treatment including the endocrine therapies described herein. In some cases, the reference E2-inducible score can be a pre-assigned reference E2-inducible score. In some cases, the reference E2-inducible score can be at or above -2.0 (e.g., -2.0, -1.0, -0.9, -0.8, -0.7, -0.6, -0.5, -0.4, -0.3, -0.2, or higher). For example, in some cases, the reference E2-inducible score can be at or above -1.0. In some cases, the reference E2-inducible score can be at or above -0.9. In some cases, the reference E2-inducible score can be at or above -0.8. In some cases, the reference E2-induced score can reach or exceed -0.7. In some cases, the reference E2-induced score can reach or exceed -0.6. In some cases, the reference E2-induced score can reach or exceed -0.5. In some cases, the reference E2-induced score can reach or exceed -0.4. In some cases, the reference E2-induced score can reach or exceed -0.3. In some cases, the reference E2-induced score can reach or exceed -0.2. In some cases, the reference E2-induced score can reach or exceed -0.1. In some cases, the reference E2 induced score can be between about -2.0 and about -0.1 (e.g., between about -1.0 and about -0.1, for example, between about -0.7 and about -0.1, for example, between about -0.6 and about -0.1, for example, between about -0.5 and about -0.1, for example, between about -0.4 and about -0.1, for example, between about -0.3 and about -0.1, or for example, between about -0.2 and about -0.1).

[0203] In any of the foregoing circumstances, the E2 induction score of samples from an individual (e.g., tissue samples, such as tumor tissue samples, such as FFPE, FF, archived, fresh, or frozen tumor tissue samples) may be at or above -2.0 (e.g., -2.0, -1.0, -0.9, -0.8, -0.7, -0.6, -0.5, -0.4, -0.3, -0.2, -0.1, or higher). For example, in some cases, the E2 induction score may be at or above -1.0. In some cases, the E2 induction score may be at or above -0.9. In some cases, the E2 induction score may be at or above -0.8. In some cases, the E2 induction score may be at or above -0.7. In some cases, the E2 induction score may be at or above -0.6. In some cases, the E2 induction score may be at or above -0.5. In some cases, the E2 induction score may be at or above -0.4. In some cases, the E2-induced score can reach or exceed -0.3. In some cases, the E2-induced score can reach or exceed -0.2. In some cases, the E2-induced score can reach or exceed -0.1. In some cases, the E2-induced score can be between about -2.0 and about -0.1 (e.g., between about -1.0 and about -0.1, for example, between about -0.7 and about -0.1, for example, between about -0.6 and about -0.1, for example, between about -0.5 and about -0.1, for example, between about -0.4 and about -0.1, for example, between about -0.3 and about -0.1, or for example, between about -0.2 and about -0.1). In some cases, the E2-induced score from the sample can be less than -2.0.

[0204] In any of the predictive methods and assays described above, the methods and assays may further include administering endocrine therapy (e.g., as described in Section IV-A below) to the individual. In specific cases, the method further includes administering endocrine therapy to the individual when the ER pathway activity score of a sample from the individual (e.g., a tissue sample, such as a tumor tissue sample, such as FFPE, FF, archived, fresh, or frozen tumor tissue samples) reaches or exceeds a reference ER pathway activity score. In specific cases, the method further includes administering endocrine therapy to the individual when the E2 induction score of a sample from the individual (e.g., a tissue sample, such as a tumor tissue sample, such as FFPE, FF, archived, fresh, or frozen tumor tissue samples) reaches or exceeds a reference E2 induction score.

[0205] In any of the predictive methods and assays described above, the methods and assays may further include administering anticancer therapy other than endocrine therapy (e.g., as described in Section IV-A below) to the individual. In specific circumstances, when the ER pathway activity score of a sample from the individual (e.g., a tissue sample, such as a tumor tissue sample, such as FFPE, FF, archived, fresh, or frozen tumor tissue samples) is lower than a reference ER pathway activity score, the method further includes administering anticancer therapy other than endocrine therapy to the individual. In specific circumstances, when the E2 induction score of a sample from the individual (e.g., a tissue sample, such as a tumor tissue sample, such as FFPE, FF, archived, fresh, or frozen tumor tissue samples) is lower than a reference E2 induction score, the method further includes administering anticancer therapy other than endocrine therapy to the individual.

[0206] The methods provided herein may include determining ER pathway activity scores from samples from individuals (e.g., tissue samples, such as tumor tissue samples, such as FFPE, FF, archived, fresh, or frozen tumor tissue samples). In some cases, the sample may be an FFPE tumor tissue sample. In some cases, the sample may be an FF tumor tissue sample.

[0207] In any of the aforementioned cases, an individual may have HR+ breast cancer. In some cases, HR+ cancer can be ER+ breast cancer. In some cases, an individual may have ER+ breast cancer, selected from, for example, luminal type A breast cancer or luminal type B breast cancer. In some cases, the breast cancer may be advanced breast cancer or metastatic breast cancer.

[0208] In some of the aforementioned methods or assays involving the determination of ER pathway activity scores and / or E2 induction scores from samples from an individual (e.g., tissue samples, such as tumor tissue samples, such as FFPE, FF, archived, fresh, or frozen tumor tissue samples), the individual has previously been treated with the endocrine therapies described herein. In other cases, the individual has not previously received endocrine therapy. In another embodiment, the individual has received one or more prior therapies prior to performing the methods and assays described herein, wherein such therapy may be an endocrine therapy or a non-endocrine therapy described herein.

[0209] In some cases, the method further includes generating reports for individuals or other individuals or entities, caregivers, physicians, oncologists, hospitals, clinics, third-party payers, insurance companies, pharmaceutical or biotechnology companies, or government agencies, such as electronic reports, web-based reports, or paper reports. In some embodiments, the report includes output from a method that incorporates an assessment of ER pathway activity and / or E2 induction scores.

[0210] Pharmacodynamic diagnostic methods

[0211] This article also provides pharmacodynamic methods. In some cases, these methods may involve monitoring an individual's response to treatment with endocrine therapies as described herein.

[0212] In some cases, the method includes: (a) determining an ER pathway activity score from a sample from the individual at a first time point (e.g., a tissue sample, such as a tumor tissue sample, such as FFPE, FF, archived, fresh, or frozen tumor tissue sample); (b) determining a second ER pathway activity score from the sample from the individual at a second time point after step (a), following administration of endocrine therapy as described herein; and (c) comparing the first ER pathway activity score with the second ER pathway activity score, wherein a decrease in the second ER pathway activity score relative to the first ER pathway activity score (e.g., a decrease in the ER pathway activity score of approximately 0.1, 0.2, 0.3, or greater) predicts that the individual may respond to treatment with endocrine therapy (e.g., SERM (e.g., SERD), GnRH agonists, and / or AI). In some cases, a decrease in the ER pathway activity score is defined as an overall decrease in the ER pathway activity score of at least 0.1. In some cases, a decrease in the ER pathway activity score is defined as an overall decrease in the ER pathway activity score of at least 0.2. In some cases, a decrease in ER pathway activity score is defined as an overall decrease in ER pathway activity score of at least 0.3.

[0213] In some cases, if the second ER pathway activity score is lower than the first ER pathway activity score in a sample from an individual (e.g., a tissue sample, such as a tumor tissue sample, such as formalin-fixed and paraffin-embedded (FFPE), fresh-frozen (FF), archived, fresh, or frozen tumor tissue sample), the method further includes administering one or more additional doses of endocrine therapy. In some cases, a reduced ER pathway activity score is defined as an overall reduction of at least 0.1 in the ER pathway activity score (e.g., a reduction of 0.1, 0.2, 0.3, or greater). In some cases, a reduced ER pathway activity score is defined as an overall reduction of at least 0.2 in the ER pathway activity score. In some cases, a reduced ER pathway activity score is defined as an overall reduction of at least 0.3 in the ER pathway activity score.

[0214] In some of the aforementioned methods, the first ER pathway activity score is determined from a sample (e.g., a tissue sample, such as a tumor tissue sample, e.g., FFPE, FF, archived, fresh, or frozen tumor tissue sample) obtained from the individual prior to administration of the first dose of endocrine therapy as described herein. In other words, the sample may be a baseline sample. In other cases, the first ER pathway activity score is determined from a sample obtained from the individual at a previous time point, wherein the previous time point is after administration of the first dose of endocrine therapy as described herein. In other cases, the first ER pathway activity score is determined from a sample obtained from the individual at a previous time point, wherein the previous time point is after administration of the first dose of non-endocrine therapy as described herein. In other cases, the first ER pathway activity score is a predetermined ER pathway activity score.

[0215] In some cases, the method includes: (a) determining an E2-inducible score from a sample from the individual (e.g., a tissue sample, such as a tumor tissue sample, such as FFPE, FF, archived, fresh, or frozen tumor tissue sample) at a first time point; (b) determining a second E2-inducible score from the sample from the individual at a second time point after step (a), following administration of the endocrine therapy as described herein; and (c) comparing the first E2-inducible score with the second E2-inducible score, wherein a decrease in the second E2-inducible score relative to the first E2-inducible score (e.g., a decrease in the E2-inducible score of at least 0.1, 0.2, 0.3, or greater) predicts that the individual may respond to treatment with the endocrine therapy as described herein. In some cases, a decrease in the E2-inducible score means an overall decrease of at least 0.1. In some cases, a decrease in the E2-inducible score means an overall decrease of at least 0.2. In some cases, a decrease in the E2-inducible score means an overall decrease of at least 0.3.

[0216] In some cases, if the second E2-induced score is lower than the first E2-induced score in a sample (e.g., a tissue sample, such as a tumor tissue sample, such as FFPE, FF, archived, fresh, or frozen tumor tissue sample), the method further includes administering one or more additional doses of the endocrine therapy described herein. In some cases, a lowered E2-induced score means an overall reduction of at least 0.1 in the E2-induced score (e.g., a reduction of 0.1, 0.2, 0.3, or greater). In some cases, a lowered E2-induced score means an overall reduction of at least 0.2 in the E2-induced score. In some cases, a lowered E2-induced score means an overall reduction of at least 0.3 in the E2-induced score.

[0217] In some of the aforementioned methods, the first E2-inducing score is an E2-inducing score determined from a sample obtained from an individual prior to the administration of the first dose of anticancer therapy (e.g., endocrine therapy as described herein, such as a tissue sample, such as a tumor tissue sample, such as FFPE, FF, archived, fresh, or frozen tumor tissue sample). In other words, the sample may be a baseline sample. In other cases, the first E2-inducing score is an E2-inducing score determined from a sample obtained from an individual at a previous time point, wherein the previous time point is after the administration of the first dose of endocrine therapy as described herein. In still other cases, the first E2-inducing score is a predetermined E2-inducing score.

[0218] In some cases, the second ER pathway activity score of a sample from an individual (e.g., a tissue sample, such as a tumor tissue sample, such as FFPE, FF, archived, fresh, or frozen tumor tissue samples) is reduced relative to the first ER pathway activity score, and the method or assay further involves administering an additional dose of the endocrine therapy described herein to the individual. In some cases, the second E2 induction score of a sample from an individual (e.g., a tissue sample, such as a tumor tissue sample, such as FFPE, FF, archived, fresh, or frozen tumor tissue samples) is reduced relative to the first E2 induction score, and the method or assay further involves administering an additional dose of the endocrine therapy described herein to the individual.

[0219] The methods provided herein may include determining ER pathway activity scores from samples from individuals (e.g., tissue samples, such as tumor tissue samples, such as FFPE, FF, archived, fresh, or frozen tumor tissue samples). In some cases, the sample may be an FFPE tumor tissue sample. In some cases, the sample may be an FF tumor tissue sample.

[0220] In any of the aforementioned cases, an individual may have HR+ breast cancer. In some cases, HR+ cancer can be ER+ breast cancer. In some cases, an individual may have ER+ breast cancer, selected from, for example, luminal type A breast cancer or luminal type B breast cancer. In some cases, the breast cancer may be advanced breast cancer or metastatic breast cancer.

[0221] In some of the aforementioned methods or assays involving the determination of ER pathway activity scores and / or E2 induction scores from samples from an individual (e.g., tissue samples, such as tumor tissue samples, such as FFPE, FF, archived, fresh, or frozen tumor tissue samples), the individual has previously been treated with the endocrine therapy described herein. In other cases, the individual has not previously received endocrine therapy. In some cases of any of the methods and assays, the sample (e.g., tissue sample, such as tumor tissue sample, such as FFPE, FF, archived, fresh, or frozen tumor tissue sample) was obtained from the individual prior to the administration of the endocrine therapy described herein (e.g., minutes, hours, days, weeks, months, or years prior). In other words, the sample may be a baseline sample. In some cases of any of the aforementioned methods, the sample was obtained from the individual after the administration of endocrine therapy (e.g., minutes, hours, or days prior). In some cases, the sample from the individual was obtained within thirty hours after the administration of endocrine therapy. In some cases, multiple samples were obtained from the same individual at different time points (e.g., before and after the administration of endocrine therapy).

[0222] In some cases, the method further includes generating reports for individuals or other individuals or entities, caregivers, physicians, oncologists, hospitals, clinics, third-party payers, insurance companies, pharmaceutical or biotechnology companies, or government agencies, such as electronic reports, web-based reports, or paper reports. In some cases, the report includes outputs from a method that incorporates assessments of ER pathway activity and / or E2 induction scores.

[0223] On the one hand, a method is provided for detecting estrogen receptor (ER) pathway activity in subjects with breast cancer. This method includes detecting the expression levels of at least five genes listed in Table 1 and at least five genes listed in Table 4; at least five genes listed in Table 2 and at least five genes listed in Table 5; or at least five genes listed in Table 3 and at least five genes listed in Table 6.

[0224] A control used in the methods provided herein is valuable for determining the significance of the data. For example, if the value of a given parameter varies greatly in a control, the variation in the test sample will not be considered significant. In some examples of the disclosed methods, when assessing the expression level of any gene provided in Tables 1-6, that expression level is compared to the control expression level of that gene. A control expression level refers to the expression level of a gene from samples or subjects lacking breast cancer, at a selected stage of breast cancer or cancer, or without a specific variable such as a treatment agent. Alternatively, a control level includes the amount of a known gene. Such a known amount is associated with the average level of subjects lacking breast cancer, at a selected stage of breast cancer or cancer, or without a specific variable such as a treatment agent. A control level also includes the expression levels of genes from one or more of the selected samples or subjects described herein. For example, a control level includes an assessment of the expression levels of a gene in samples from subjects who do not have breast cancer, are at a selected stage of breast cancer or cancer, or have breast cancer but have not yet received treatment. Another exemplary control level includes an assessment of the expression levels of a gene in samples collected from multiple subjects who have never had breast cancer, are at a selected stage of cancer, or have cancer but have not yet received breast cancer treatment. In this embodiment, the threshold for elevated gene expression levels is higher than the median expression level of a control group, which optionally consists of a group of subjects with breast cancer.

[0225] In one embodiment, the method includes detecting the expression levels of at least five genes (e.g., 5, 6, 7, 8, etc.) listed in Table 1 and at least five genes listed in Table 4. In another embodiment, the method includes detecting the expression levels of at least five genes listed in Table 2 and at least five genes listed in Table 5. In yet another embodiment, the method includes detecting the expression levels of at least five genes listed in Table 3 and at least five genes listed in Table 6.

[0226] In the embodiments, the expression levels of at least five genes listed in Table 1, at least five genes listed in Table 2, or at least five genes listed in Table 3 are all higher than the standard control. In the embodiments, the expression levels of all genes listed in Table 1, all genes listed in Table 2, or all genes listed in Table 3 are all higher than the standard control. In the embodiments, the expression levels of at least five genes listed in Table 1 are all higher than the standard control. In the embodiments, the expression levels of all genes listed in Table 1 are all higher than the standard control. In the embodiments, the expression levels of at least five genes listed in Table 2 are all higher than the standard control. In the embodiments, the expression levels of all genes listed in Table 2 are all higher than the standard control. In the embodiments, the expression levels of at least five genes listed in Table 3 are all higher than the standard control. In the embodiments, the expression levels of all genes listed in Table 3 are all higher than the standard control.

[0227] In this embodiment, the threshold for elevated gene expression levels (e.g., the expression of any of the genes listed in Tables 1-6) is higher than the median expression level of a control group, optionally consisting of subjects with breast cancer. In this embodiment, it is higher than the first quartile of gene expression in a control group, optionally consisting of subjects with breast cancer. In this embodiment, it is higher than the third quartile of gene expression in a control group, optionally consisting of subjects with breast cancer. In this embodiment, it is higher than the fifth percentile of gene expression in a control group, optionally consisting of subjects with breast cancer. In this embodiment, it is higher than the tenth percentile of gene expression in a control group, optionally consisting of subjects with breast cancer. In this embodiment, it is higher than the twentieth percentile of gene expression in a control group, optionally consisting of subjects with breast cancer. In this embodiment, it is higher than the thirtieth percentile of gene expression in a control group, optionally consisting of subjects with breast cancer. In one embodiment, it is above the 40th percentile of gene expression in a set of control samples, wherein the control samples are optionally a group of subjects with breast cancer. In another embodiment, it is above the 45th percentile of gene expression in a set of control samples, wherein the control samples are optionally a group of subjects with breast cancer. In another embodiment, it is above the 50th percentile of gene expression in a set of control samples, wherein the control samples are optionally a group of subjects with breast cancer. In another embodiment, it is above the 60th percentile of gene expression in a set of control samples, wherein the control samples are optionally a group of subjects with breast cancer. In another embodiment, it is above the 70th percentile of gene expression in a set of control samples, wherein the control samples are optionally a group of subjects with breast cancer. In another embodiment, it is above the 80th percentile of gene expression in a set of control samples, wherein the control samples are optionally a group of subjects with breast cancer. In another embodiment, it is above the 90th percentile of gene expression in a set of control samples, wherein the control samples are optionally a group of subjects with breast cancer.

[0228] In the embodiments, the expression levels of at least five genes listed in Table 4, at least five genes listed in Table 5, or at least five genes listed in Table 6 are all lower than the standard control. In the embodiments, the expression levels of all genes listed in Table 4, all genes listed in Table 5, or all genes listed in Table 6 are all lower than the standard control. In the embodiments, the expression levels of at least five genes listed in Table 4 are all lower than the standard control. In the embodiments, the expression levels of all genes listed in Table 4 are all lower than the standard control. In the embodiments, the expression levels of at least five genes listed in Table 5 are all lower than the standard control. In the embodiments, the expression levels of all genes listed in Table 5 are all lower than the standard control. In the embodiments, the expression levels of at least five genes listed in Table 6 are all lower than the standard control. In the embodiments, the expression levels of all genes listed in Table 6 are all lower than the standard control.

[0229] In this embodiment, the threshold for reduced gene expression levels (e.g., the expression level of any of the genes listed in Tables 1-6) is below the median expression level of a control group, optionally consisting of subjects with breast cancer. In this embodiment, it is below the first quartile of gene expression in a control group, optionally consisting of subjects with breast cancer. In this embodiment, it is below the third quartile of gene expression in a control group, optionally consisting of subjects with breast cancer. In this embodiment, it is below the fifth percentile of gene expression in a control group, optionally consisting of subjects with breast cancer. In this embodiment, it is below the tenth percentile of gene expression in a control group, optionally consisting of subjects with breast cancer. In this embodiment, it is below the twentieth percentile of gene expression in a control group, optionally consisting of subjects with breast cancer. In this embodiment, it is below the thirtieth percentile of gene expression in a control group, optionally consisting of subjects with breast cancer. In one embodiment, it is below the 40th percentile of gene expression in a set of control samples, wherein the control samples are optionally a group of subjects with breast cancer. In another embodiment, it is below the 45th percentile of gene expression in a set of control samples, wherein the control samples are optionally a group of subjects with breast cancer. In another embodiment, it is below the 50th percentile of gene expression in a set of control samples, wherein the control samples are optionally a group of subjects with breast cancer. In another embodiment, it is below the 60th percentile of gene expression in a set of control samples, wherein the control samples are optionally a group of subjects with breast cancer. In another embodiment, it is below the 70th percentile of gene expression in a set of control samples, wherein the control samples are optionally a group of subjects with breast cancer. In another embodiment, it is below the 80th percentile of gene expression in a set of control samples, wherein the control samples are optionally a group of subjects with breast cancer. In another embodiment, it is below the 90th percentile of gene expression in a set of control samples, wherein the control samples are optionally a group of subjects with breast cancer.

[0230] In one embodiment, the subject was treated with endocrine therapy prior to the test. In another embodiment, the subject was treated with endocrine therapy after the test.

[0231] In one embodiment, the method includes detecting the expression levels of all genes listed in Table 1 and all genes listed in Table 4. In another embodiment, the method includes detecting the expression levels of all genes listed in Table 2 and all genes listed in Table 5. In another embodiment, the method includes detecting the expression levels of all genes listed in Table 3 and all genes listed in Table 6. In yet another embodiment, the method includes detecting the expression levels of all genes listed in Table 1 and all genes listed in Table 4, but does not detect the expression levels of any other genes in the subject. In yet another embodiment, the method includes detecting the expression levels of all genes listed in Table 2 and all genes listed in Table 5, but does not detect the expression levels of any other genes in the subject. In yet another embodiment, the method includes detecting the expression levels of all genes listed in Table 3 and all genes listed in Table 6, but does not detect the expression levels of any other genes in the subject.

[0232] In one embodiment, the subject was treated with endocrine therapy, wherein the endocrine therapy was a selective estrogen receptor degrader.

[0233] In one embodiment, the method includes determining an estrogen receptor (ER) pathway activity score from a sample from a subject. In another embodiment, an ER pathway activity score from the sample that reaches or exceeds a reference ER pathway activity score identifies an individual as potentially eligible for treatment including endocrine therapy. In yet another embodiment, the method includes comparing ER pathway activity scores from the sample that reach or exceed a reference ER pathway activity score to identify individuals as potentially eligible for treatment including endocrine therapy.

[0234] In one aspect, a method is provided, comprising detecting first expression levels of at least five genes listed in Table 1, at least five genes listed in Table 2, or at least five genes listed in Table 3 by one or more processors; detecting second expression levels of at least five genes listed in Table 4, at least five genes listed in Table 5, or at least five genes listed in Table 6 by one or more processors; and detecting estrogen receptor (ER) pathway activity in a subject with cancer, based at least on the first expression level and / or the second expression level. In one embodiment, the first expression level is increased relative to the second expression level. In another embodiment, the first expression level is decreased relative to the second expression level.

[0235] In this embodiment, the threshold for an elevated first gene expression level (e.g., the first expression level of any of the genes listed in Tables 1-6) is higher than that of a second expression level. In this embodiment, it is higher than the first quartile of the second gene expression level. In this embodiment, it is higher than the third quartile of the second gene expression level. In this embodiment, it is higher than the fifth percentile of the second gene expression level. In this embodiment, it is higher than the tenth percentile of the second gene expression level. In this embodiment, it is higher than the twentieth percentile of the second gene expression level. In this embodiment, it is higher than the thirtieth percentile of the second gene expression level. In this embodiment, it is higher than the fortyth percentile of the second gene expression level. In this embodiment, it is higher than the forty-fifth percentile of the second gene expression level. In this embodiment, it is higher than the fiftyth percentile of the second gene expression level. In this embodiment, it is higher than the sixtyth percentile of the second gene expression level. In this embodiment, it is higher than the seventyth percentile of the second gene expression level. In this embodiment, it is higher than the eightyth percentile of the second gene expression level. In the example, it is above the 90th percentile of the expression level of the second gene.

[0236] In this embodiment, the threshold for reducing the expression level of a first gene (e.g., the first expression level of any of the genes listed in Tables 1-6) is lower than the threshold for the second expression level. In this embodiment, it is lower than the first quartile of the second gene expression level. In this embodiment, it is lower than the third quartile of the second gene expression level. In this embodiment, it is lower than the fifth percentile of the second gene expression level. In this embodiment, it is lower than the tenth percentile of the second gene expression level. In this embodiment, it is lower than the twentieth percentile of the second gene expression level. In this embodiment, it is lower than the thirtieth percentile of the second gene expression level. In this embodiment, it is lower than the fortyth percentile of the second gene expression level. In this embodiment, it is lower than the forty-fifth percentile of the second gene expression level. In this embodiment, it is lower than the fiftyth percentile of the second gene expression level. In this embodiment, it is lower than the sixtyth percentile of the second gene expression level. In this embodiment, it is lower than the seventyth percentile of the second gene expression level. In this embodiment, it is lower than the eightyth percentile of the second gene expression level. In the example, it is below the 90th percentile of the expression level of the second gene.

[0237] In the embodiments, the expression levels of at least five genes listed in Table 1, at least five genes listed in Table 2, or at least five genes listed in Table 3 are all higher than the standard control. In the embodiments, the expression levels of at least five genes listed in Table 4, at least five genes listed in Table 5, or at least five genes listed in Table 6 are all lower than the standard control.

[0238] In one embodiment, the method includes treating the subject with endocrine therapy prior to the test. In another embodiment, the method includes treating the subject with endocrine therapy based at least on estrogen receptor (ER) pathway activity detected in the subject.

[0239] B. Treatment methods

[0240] This document also provides for the treatment of individuals with breast cancer (e.g., HR+ breast cancer (e.g., ER+ breast cancer (e.g., luminal A or luminal B breast cancer)), DCIS, and / or metastatic or locally advanced breast cancer). Therefore, in some cases, the methods provided herein include administering the endocrine therapy described herein to the individual. In other cases, the methods provided herein include administering an anticancer agent other than endocrine therapy to the individual. Any anticancer agent described herein (e.g., in Section IV below) or known in the art may be used in conjunction with this method.

[0241] This article provides a method for treating an individual with breast cancer (e.g., HR+ breast cancer (e.g., ER+ breast cancer (e.g., luminal A or luminal B breast cancer)), DCIS, and / or metastatic or locally advanced breast cancer), comprising (i) determining an ER pathway activity score from a sample from the individual (e.g., a tissue sample, such as a tumor tissue sample, such as FFPE, FF, archived, fresh, or frozen tumor tissue sample), wherein the ER pathway activity score is determined to be at or above a reference ER pathway activity score (e.g., a reference ER pathway activity score in a reference population, such as a reference ER pathway activity score at or above -1.0); and (ii) administering an effective amount of the endocrine therapy described herein to the individual.

[0242] This article provides a method for treating an individual with breast cancer (e.g., HR+ breast cancer (e.g., ER+ breast cancer (e.g., luminal A or luminal B breast cancer)), DCIS, and / or metastatic or locally advanced breast cancer), comprising administering the endocrine therapy described herein to the individual, wherein the individual has been identified by one or more predictive diagnostic methods described in Section III-A above as being more likely to benefit from treatment including endocrine therapy.

[0243] This article provides a method for treating an individual with breast cancer (e.g., HR+ breast cancer (e.g., ER+ breast cancer (e.g., luminal A or luminal B breast cancer)), DCIS, and / or metastatic or locally advanced breast cancer), comprising administering the endocrine therapy described herein to the individual, wherein the individual has been identified as having an ER pathway activity score at or above a reference ER pathway activity score by any of the predictive diagnostic methods described in Section III-A above.

[0244] This article provides a method for treating an individual with breast cancer (e.g., HR+ breast cancer (e.g., ER+ breast cancer (e.g., luminal A or luminal B breast cancer)), DCIS, and / or metastatic or locally advanced breast cancer), comprising (i) determining an E2-inducing score from a sample from the individual (e.g., a tissue sample, such as a tumor tissue sample, such as FFPE, FF, archived, fresh, or frozen tumor tissue sample), wherein the E2-inducing score is determined to be at or above a reference E2-inducing score (e.g., a reference E2-inducing score in a reference population, such as a reference E2-inducing score at or above -2.0); and (ii) administering an effective amount of the endocrine therapy described herein to the individual.

[0245] This article provides a method for treating an individual with breast cancer (e.g., HR+ breast cancer (e.g., ER+ breast cancer (e.g., luminal A-type breast cancer or luminal B-type breast cancer)), DCIS, and / or metastatic or locally advanced breast cancer), comprising administering the endocrine therapy described herein to the individual, wherein the individual has been identified as having an E2 induction score that reaches or exceeds a reference E2 induction score by any of the predictive diagnostic methods described in Section III-A above.

[0246] This article also provides a method for treating an individual with breast cancer (e.g., HR+ breast cancer (e.g., ER+ breast cancer (e.g., luminal A or luminal B breast cancer)), DCIS, and / or metastatic or locally advanced breast cancer), comprising (i) determining an ER pathway activity score from a sample from the individual (e.g., a tissue sample, such as a tumor tissue sample, such as FFPE, FF, archived, fresh, or frozen tumor tissue sample), wherein the ER pathway activity score is determined to be lower than a reference ER pathway activity score (e.g., a reference ER pathway activity score in a reference population, such as a reference ER pathway activity score below -1.0); and (ii) administering an effective amount of anticancer therapy to the individual, other than endocrine therapy.

[0247] This article provides a method for treating an individual with breast cancer (e.g., HR+ breast cancer (e.g., ER+ breast cancer (e.g., luminal A or luminal B breast cancer)), DCIS, and / or metastatic or locally advanced breast cancer), comprising administering an effective amount of anticancer therapy to the individual, wherein the individual has been identified by one or more predictive diagnostic methods described in Section III-A above as unlikely to benefit from treatment including endocrine therapy.

[0248] This article provides a method for treating an individual with breast cancer (e.g., HR+ breast cancer (e.g., ER+ breast cancer (e.g., luminal A or luminal B breast cancer)), DCIS, and / or metastatic or locally advanced breast cancer), comprising administering anticancer therapy other than endocrine therapy to the individual, wherein the individual has been identified by one or more predictive diagnostic methods described in Section III-A above as being more likely to benefit from treatment including anticancer therapy other than endocrine therapy.

[0249] This article provides a method for treating an individual with breast cancer (e.g., HR+ breast cancer (e.g., ER+ breast cancer (e.g., luminal A or luminal B breast cancer)), DCIS, and / or metastatic or locally advanced breast cancer), comprising administering an effective amount of anticancer therapy to the individual, wherein the individual has been identified as having an ER pathway activity score below the reference ER pathway activity score by any of the predictive diagnostic methods described in Section III-A above.

[0250] This article provides a method for treating an individual with breast cancer (e.g., HR+ breast cancer (e.g., ER+ breast cancer (e.g., luminal type A or luminal type B breast cancer)), DCIS, and / or metastatic or locally advanced breast cancer), comprising (i) determining an E2-inducible score from a sample from the individual (e.g., a tissue sample, such as a tumor tissue sample, such as FFPE, FF, archived, fresh, or frozen tumor tissue sample), wherein the E2-inducible score is determined to be lower than a reference E2-inducible score (e.g., a reference E2-inducible score in a reference population, such as a reference E2-inducible score lower than -2.0); and (ii) administering an effective amount of anticancer therapy, other than endocrine therapy, to the individual.

[0251] This article provides a method for treating an individual with breast cancer (e.g., HR+ breast cancer (e.g., ER+ breast cancer (e.g., luminal A-type or luminal B-type breast cancer)), DCIS, and / or metastatic or locally advanced breast cancer), comprising administering an effective amount of anticancer therapy to the individual in addition to endocrine therapy, wherein the individual has been identified as having an E2 induction score below the reference E2 induction score by any of the predictive diagnostic methods described in Section III-A above.

[0252] In any of the foregoing circumstances, the reference ER pathway activity score can be the ER pathway activity score in a reference population of individuals with HR+ breast cancer (e.g., ER+ breast cancer (e.g., luminal A or luminal B breast cancer)), DCIS, and / or metastatic or locally advanced breast cancer). In some cases, the reference population is a group of individuals who have not received treatment including endocrine therapy (including those described herein). In some cases, the reference ER pathway activity score can be a pre-assigned reference ER pathway activity score. In some cases, the reference ER pathway activity score can be at or above -1.0 (e.g., -1.0, -0.9, -0.8, -0.7, -0.6, -0.5, -0.4, -0.3, and -0.2 or higher). For example, in some cases, the reference ER pathway activity score can be at or above -0.9. In some cases, the reference ER pathway activity score can be at or above -0.8. In some cases, the reference ER pathway activity score can be at or above -0.7. In some cases, the reference ER pathway activity score can be at or above -0.6. In some cases, the reference ER pathway activity score can reach or exceed -0.5. In some cases, the reference ER pathway activity score can reach or exceed -0.4. In some cases, the reference ER pathway activity score can reach or exceed -0.3. In some cases, the reference ER pathway activity score can reach or exceed -0.2. In some cases, the reference ER pathway activity score can be between about -1.0 and about -0.2 (e.g., between about -0.9 and about -0.2, for example, between about -0.8 and about -0.2, for example, between about -0.7 and about -0.2, for example, between about -0.6 and about -0.2, for example, between about -0.5 and about -0.2, for example, between about -0.4 and about -0.2, or for example, between about -0.3 and about -0.2).

[0253] In any of the foregoing circumstances, the ER pathway activity score of samples from an individual (e.g., tissue samples, such as tumor tissue samples, such as formalin-fixed and paraffin-embedded (FFPE), fresh-frozen (FF), archived, fresh, or frozen tumor tissue samples) can reach or exceed -1.0 (e.g., -1.0, -0.9, -0.8, -0.7, -0.6, -0.5, -0.4, -0.3, -0.2, or higher). For example, in some cases, the ER pathway activity score can reach or exceed -0.9. In some cases, the ER pathway activity score can reach or exceed -0.8. In some cases, the ER pathway activity score can reach or exceed -0.7. In some cases, the ER pathway activity score can reach or exceed -0.6. In some cases, the ER pathway activity score can reach or exceed -0.5. In some cases, the ER pathway activity score can reach or exceed -0.4. In some cases, the ER pathway activity score can reach or exceed -0.3. In some cases, the ER pathway activity score can reach or exceed -0.2. In other cases, the ER pathway activity score can be between about -1.0 and about -0.2 (e.g., between about -0.9 and about -0.2, for example, between about -0.8 and about -0.2, for example, between about -0.7 and about -0.2, for example, between about -0.6 and about -0.2, for example, between about -0.5 and about -0.2, for example, between about -0.4 and about -0.2, or for example, between about -0.3 and about -0.2). In some cases, the ER activity score from the sample can be less than -1.0.

[0254] In any of the foregoing circumstances, the reference E2-inducing score can be the E2-inducing score in a reference population of individuals with HR+ breast cancer (e.g., ER+ breast cancer (e.g., luminal A or luminal B breast cancer)), DCIS, and / or metastatic or locally advanced breast cancer. In some cases, the reference population is a group of individuals who have not received treatment including the endocrine therapies described herein. In some cases, the reference E2-inducing score can be a pre-assigned reference E2-inducing score. In some cases, the reference E2-inducing score can be at or above -2.0 (e.g., -2.0, -1.0, -0.9, -0.8, -0.7, -0.6, -0.5, -0.4, -0.3, -0.2, or higher). For example, in some cases, the reference E2-inducing score can be at or above -1.0. In some cases, the reference E2-inducing score can be at or above -0.9. In some cases, the reference E2-inducing score can be at or above -0.8. In some cases, the reference E2-inducing score can be at or above -0.7. In some cases, the reference E2 induced score can reach or exceed -0.6. In some cases, the reference E2 induced score can reach or exceed -0.5. In some cases, the reference E2 induced score can reach or exceed -0.4. In some cases, the reference E2 induced score can reach or exceed -0.3. In some cases, the reference E2 induced score can reach or exceed -0.2. In some cases, the reference E2 induced score can reach or exceed -0.1. In some cases, the reference E2 induced score can be between about -2.0 and about -0.1 (e.g., between about -1.0 and about -0.1, for example, between about -0.7 and about -0.1, for example, between about -0.6 and about -0.1, for example, between about -0.5 and about -0.1, for example, between about -0.4 and about -0.1, for example, between about -0.3 and about -0.1, or for example, between about -0.2 and about -0.1).

[0255] In any of the foregoing circumstances, the E2 induction score of samples from an individual (e.g., tissue samples, such as tumor tissue samples, such as formalin-fixed and paraffin-embedded (FFPE), fresh-frozen (FF), archived, fresh, or frozen tumor tissue samples) may reach or exceed -2.0 (e.g., -2.0, -1.0, -0.9, -0.8, -0.7, -0.6, -0.5, -0.4, -0.3, -0.2, -0.1, or higher). In some cases, the E2 induction score may reach or exceed -1.0. In some cases, the E2 induction score may reach or exceed -0.9. In some cases, the E2 induction score may reach or exceed -0.8. For example, in some cases, the E2 induction score may reach or exceed -0.7. In some cases, the E2 induction score may reach or exceed -0.6. In some cases, the E2 induction score may reach or exceed -0.5. In some cases, the E2-induced score can reach or exceed -0.4. In some cases, the E2-induced score can reach or exceed -0.3. In some cases, the E2-induced score can reach or exceed -0.2. In some cases, the E2-induced score can reach or exceed -0.1. In some cases, the E2-induced score can be between about -2.0 and about -0.1 (e.g., between about -1.0 and about -0.1, for example, between about -0.7 and about -0.1, for example, between about -0.6 and about -0.1, for example, between about -0.5 and about -0.1, for example, between about -0.4 and about -0.1, for example, between about -0.3 and about -0.1, or for example, between about -0.2 and about -0.1). In some cases, the E2-induced score from the sample can be less than -2.0.

[0256] The methods provided herein may include determining ER pathway activity scores from samples from individuals (e.g., tissue samples, such as tumor tissue samples, such as FFPE, FF, archived, fresh, or frozen tumor tissue samples). In some cases, the sample may be an FFPE tumor tissue sample. In some cases, the sample may be an FF tumor tissue sample.

[0257] In any of the aforementioned cases, an individual may have HR+ breast cancer. In some cases, HR+ cancer can be ER+ breast cancer. In some cases, an individual may have ER+ breast cancer, selected from, for example, luminal type A breast cancer or luminal type B breast cancer. In some cases, the breast cancer may be advanced breast cancer or metastatic breast cancer.

[0258] In some cases involving the determination of ER pathway activity scores and / or E2 induction scores using any of the foregoing methods or assays on samples from an individual (e.g., tissue samples, such as tumor tissue samples, such as formalin-fixed and paraffin-embedded (FFPE), fresh-frozen (FF), archived, fresh, or frozen tumor tissue samples), the individual has previously been treated with the endocrine therapy described herein. In other cases, the individual has not previously received endocrine therapy.

[0259] In some cases, the method further includes generating reports for individuals or other individuals or entities, caregivers, physicians, oncologists, hospitals, clinics, third-party payers, insurance companies, pharmaceutical or biotechnology companies, or government agencies, such as electronic reports, web-based reports, or paper reports. In some cases, the report includes outputs from a method that incorporates assessments of ER pathway activity and / or E2 induction scores.

[0260] C. Exemplary methods for determining E2 induction, E2 inhibition, and ER pathway activity scores

[0261] The methods and assays provided herein may include determining E2 induction, E2 inhibition, and / or ER pathway activity scores based on the expression levels of predetermined genomes (e.g., biomarkers) in samples (e.g., tissue samples, such as tumor tissue samples, such as FFPE, FF, archived, fresh, or frozen tumor tissue samples) from individuals (e.g., individuals with breast cancer (e.g., HR+ breast cancer (e.g., ER+ breast cancer (e.g., luminal A or luminal B breast cancer), DCIS, and / or metastatic or locally advanced breast cancer)). In some cases, the predetermined genome is any of the genomes listed in Tables 1-3. In some cases, the predetermined genome is the genomes listed in Tables 1 and 4 (e.g., 14 gene signatures). In some cases, the predetermined genome is the genomes listed in Tables 2 and 5 (e.g., 19 gene signatures). In some cases, the predetermined genome is the genomes listed in Tables 3 and 6 (e.g., 41 gene signatures). In some cases, the predetermined genome is the genomes listed in Tables 1 and 4 (e.g., 14 gene signatures) without including other genes. In some cases, the predetermined genome is the genome listed in Tables 2 and 5 (e.g., 19 gene features), excluding other genes. In other cases, the predetermined genome is the genome listed in Tables 3 and 6 (e.g., 41 gene features), excluding other genes.

[0262] In some embodiments, the ER pathway activity score is calculated using eight gene features by subtracting the E2 repression score, determined by the average z-score expression of the five E2-inducible genes listed in Table 3, from the E2-inducible score.

[0263] In some embodiments, the ER pathway activity score is calculated using nine gene features by subtracting the E2 repression score, determined by the average z-score expression of the five E2-inducing genes listed in Table 3, from the E2-inducing score; and by subtracting the E2 repression score, determined by the average z-score expression of the four E2-repressing genes listed in Table 6, from the E2-inducing score; and in some embodiments, the ER pathway activity score is calculated using nine gene features by subtracting the average z-score expression of the three E2-repressing genes listed in Table 6 from the E2-inducing score; and in some embodiments, the ER pathway activity score is calculated using nine gene features.

[0264] In some embodiments, the ER pathway activity score is calculated using 10 gene features by subtracting the E2 suppression score, determined by the average z-score expression of the seven E2-inducing genes listed in Table 3 from the E2-inducing score from the average z-score expression of the three E2-repressing genes listed in Table 6, from the E2-inducing score determined by the average z-score expression of the six E2-inducing genes listed in Table 3 from the E2-repressing score determined by the average z-score expression of the four E2-repressing genes listed in Table 6, from the E2-inducing score determined by the average z-score expression of the six E2-inducing genes listed in Table 3. In some embodiments, the ER pathway activity score is calculated using 10 gene features by subtracting the E2 suppression score, determined by the average z-score expression of the five E2-inducing genes listed in Table 6 from the E2-inducing score determined by the average z-score expression of the five E2-repressing genes listed in Table 3 from the E2-inducing score determined by the average z-score expression of the five E2-repressing genes listed in Table 6, from the E2-inducing score determined by the average z-score expression of the five E2-inducing genes listed in Table 3.

[0265] In some embodiments, the ER pathway activity score is calculated using 11 gene features by subtracting the E2 suppression score, determined by the average z-score expression of the three E2 repressor genes listed in Table 6, from the E2 induction score determined by the average z-score expression of the eight E2-inducing genes listed in Table 3. In some embodiments, the ER pathway activity score is calculated using 11 gene features by subtracting the E2 suppression score, determined by the average z-score expression of the four E2 repressor genes listed in Table 6, from the E2 induction score determined by the average z-score expression of the seven E2-inducing genes listed in Table 3. In some embodiments, the ER pathway activity score is calculated using 11 gene features by subtracting the E2 suppression score, determined by the average z-score expression of the five E2 repressor genes listed in Table 6, from the E2 induction score determined by the average z-score expression of the six E2-inducing genes listed in Table 3.

[0266] In some embodiments, the ER pathway activity score is calculated using 12 gene features by subtracting the E2 suppression score, determined by the average z-score expression of the nine E2-inducing genes listed in Table 3 from the E2-inducing score from the average z-score expression of the three E2-repressing genes listed in Table 6. In some embodiments, the ER pathway activity score is calculated using 12 gene features by subtracting the E2 suppression score, determined by the average z-score expression of the four E2-repressing genes listed in Table 6 from the E2-inducing score, determined by the average z-score expression of the eight E2-inducing genes listed in Table 3. In some embodiments, the ER pathway activity score is calculated using 12 gene features by subtracting the E2 suppression score, determined by the average z-score expression of the five E2-repressing genes listed in Table 6 from the E2-inducing score, determined by the average z-score expression of the seven E2-inducing genes listed in Table 3. In some embodiments, the ER pathway activity score is calculated using 12 gene features by subtracting the E2 repression score, determined by the average z-score expression of the six E2 repression genes listed in Table 6, from the E2 induction score determined by the average z-score expression of the six E2 inducible genes listed in Table 3.

[0267] In some embodiments, the ER pathway activity score is calculated using 13 gene features by subtracting the E2 suppression score, determined by the average z-score expression of the three E2 repressor genes listed in Table 6, from the E2 induction score determined by the average z-score expression of the ten E2-inducing genes listed in Table 3. In some embodiments, the ER pathway activity score is calculated using 13 gene features by subtracting the E2 suppression score, determined by the average z-score expression of the four E2 repressor genes listed in Table 6, from the E2 induction score determined by the average z-score expression of the nine E2-inducing genes listed in Table 3. In some embodiments, the ER pathway activity score is calculated using 13 gene features by subtracting the E2 suppression score, determined by the average z-score expression of the five E2 repressor genes listed in Table 6, from the E2 induction score determined by the average z-score expression of the eight E2-inducing genes listed in Table 3. In some embodiments, the ER pathway activity score is calculated using 13 gene features by subtracting the E2 repression score, determined by the average z-score expression of the seven E2-inducible genes listed in Table 3, from the E2 induction score.

[0268] In some embodiments, the ER pathway activity score is calculated using 14 gene features by subtracting the E2 suppression score, determined by the average z-score expression of the 11 E2-inducing genes listed in Table 3, from the E2-inducing score; and the E2 suppression score, determined by the average z-score expression of the 3 E2-repressing genes listed in Table 6, from the E2-inducing score; in some embodiments, the ER pathway activity score is calculated using 14 gene features by subtracting the average z-score expression of the 4 E2-repressing genes listed in Table 6 from the E2-inducing score; and in some embodiments, the ER pathway activity score is calculated using 14 gene features by subtracting the average z-score expression of the 5 E2-repressing genes listed in Table 6 from the E2-inducing score; and the E2-inducing score is calculated using the average z-score expression of the 9 E2-inducing genes listed in Table 3. In some embodiments, the ER pathway activity score is calculated using 14 gene features by subtracting the E2 suppression score, determined by the average z-score expression of the 8 E2-inducing genes listed in Table 6, from the E2-inducing score determined by the average z-score expression of the 8 E2-inducing genes listed in Table 3. In some embodiments, the ER pathway activity score is calculated using 14 gene features by subtracting the E2 suppression score, determined by the average z-score expression of the 6 E2-suppressing genes listed in Table 4, from the E2-inducing score determined by the average z-score expression of the 8 E2-inducing genes listed in Table 1. In some embodiments, the ER pathway activity score is calculated using 14 gene features by subtracting the E2 suppression score, determined by the average z-score expression of the 7 E2-inducing genes listed in Table 6, from the E2-inducing score determined by the average z-score expression of the 7 E2-inducing genes listed in Table 3.

[0269] In some embodiments, the ER pathway activity score is calculated using 15 gene features by subtracting the E2 suppression score, determined by the average z-score expression of the 12 E2-inducing genes listed in Table 6, from the E2-inducing score determined by the average z-score expression of the 12 E2-inducing genes listed in Table 3. In some embodiments, the ER pathway activity score is calculated using 15 gene features by subtracting the E2 suppression score, determined by the average z-score expression of the 4 E2-suppressing genes listed in Table 6, from the E2-inducing score determined by the average z-score expression of the 11 E2-inducing genes listed in Table 3. In some embodiments, the ER pathway activity score is calculated using 15 gene features by subtracting the E2 suppression score, determined by the average z-score expression of the 5 E2-suppressing genes listed in Table 6, from the E2-inducing score determined by the average z-score expression of the 10 E2-inducing genes listed in Table 3. In some embodiments, the ER pathway activity score is calculated using 15 gene features by subtracting the E2 suppression score, determined by the average z-score expression of the 9 E2-inducible genes listed in Table 3, from the E2 induction score; and by subtracting the E2 suppression score, determined by the average z-score expression of the 6 E2-repressive genes listed in Table 6, from the E2 induction score; and in some embodiments, the ER pathway activity score is calculated using 15 gene features by subtracting the average z-score expression of the 7 E2-repressive genes listed in Table 6 from the E2 induction score; and by the E2 suppression score, determined by the average z-score expression of the 8 E2-inducible genes listed in Table 3.

[0270] In some embodiments, the ER pathway activity score is calculated using 16 gene features by subtracting the E2 suppression score, determined by the average z-score expression of the 13 E2-inducing genes listed in Table 3, from the E2-inducing score; and the E2 suppression score, determined by the average z-score expression of the 3 E2-repressing genes listed in Table 6, from the E2-inducing score; in some embodiments, the ER pathway activity score is calculated using 16 gene features by subtracting the average z-score expression of the 4 E2-repressing genes listed in Table 6 from the E2-inducing score; and in some embodiments, the ER pathway activity score is calculated using 16 gene features by subtracting the average z-score expression of the 5 E2-repressing genes listed in Table 6 from the E2-inducing score; and the E2-inducing score is calculated using the average z-score expression of the 11 E2-inducing genes listed in Table 3. In some embodiments, the ER pathway activity score is calculated using 16 gene features by subtracting the E2 suppression score, determined by the average z-score expression of the 10 E2-inducing genes listed in Table 3, from the E2-inducing score from the average z-score expression of the 6 E2-repressing genes listed in Table 6. In some embodiments, the ER pathway activity score is calculated using 16 gene features by subtracting the E2 suppression score, determined by the average z-score expression of the 9 E2-inducing genes listed in Table 3, from the average z-score expression of the 7 E2-repressing genes listed in Table 6. In some embodiments, the ER pathway activity score is calculated using 16 gene features by subtracting the E2 suppression score, determined by the average z-score expression of the 8 E2-inducing genes listed in Table 6, from the average z-score expression of the 8 E2-inducing genes listed in Table 3.

[0271] In some embodiments, the ER pathway activity score is calculated using 17 gene features by subtracting the E2 suppression score, determined by the average z-score expression of the 14 E2-inducing genes listed in Table 3, from the E2 induction score; and the E2 suppression score, determined by the average z-score expression of the 3 E2-repressing genes listed in Table 6, from the E2 induction score; in some embodiments, the ER pathway activity score is calculated using 17 gene features by subtracting the average z-score expression of the 4 E2-repressing genes listed in Table 6 from the E2 induction score; and in some embodiments, the ER pathway activity score is calculated using 17 gene features by subtracting the average z-score expression of the 5 E2-repressing genes listed in Table 6 from the E2 induction score; and the E2 induction score is calculated using the average z-score expression of the 12 E2-inducing genes listed in Table 3. In some embodiments, the ER pathway activity score is calculated using 17 gene features by subtracting the E2 suppression score, determined by the average z-score expression of the 11 E2-inducing genes listed in Table 3, from the E2 induction score; and the E2 suppression score, determined by the average z-score expression of the 6 E2-repressing genes listed in Table 6, from the E2 induction score; in some embodiments, the ER pathway activity score is calculated using 17 gene features by subtracting the average z-score expression of the 7 E2-repressing genes listed in Table 6 from the E2 induction score; and in some embodiments, the ER pathway activity score is calculated using 17 gene features by subtracting the average z-score expression of the 8 E2-repressing genes listed in Table 6 from the E2 induction score; and the E2 induction score is calculated using the average z-score expression of the 9 E2-inducing genes listed in Table 3.

[0272] In some embodiments, the ER pathway activity score is calculated using 18 gene features by subtracting the E2 suppression score, determined by the average z-score expression of the 15 E2-inducing genes listed in Table 3, from the E2-inducing score; and the E2 suppression score, determined by the average z-score expression of the 3 E2-repressing genes listed in Table 6, from the E2-inducing score; in some embodiments, the ER pathway activity score is calculated using 18 gene features by subtracting the average z-score expression of the 4 E2-repressing genes listed in Table 6 from the E2-inducing score; and in some embodiments, the ER pathway activity score is calculated using 18 gene features by subtracting the average z-score expression of the 5 E2-repressing genes listed in Table 6 from the E2-inducing score; and the E2-inducing score is calculated using the average z-score expression of the 13 E2-inducing genes listed in Table 3. In some embodiments, the ER pathway activity score is calculated using 18 gene features by subtracting the E2 suppression score, determined by the average z-score expression of the 6 E2 repressor genes listed in Table 6, from the E2 induction score determined by the average z-score expression of the 12 E2-inducing genes listed in Table 3. In some embodiments, the ER pathway activity score is calculated using 18 gene features by subtracting the E2 suppression score, determined by the average z-score expression of the 7 E2 repressor genes listed in Table 6, from the E2 induction score determined by the average z-score expression of the 11 E2-inducing genes listed in Table 3. In some embodiments, the ER pathway activity score is calculated using 18 gene features by subtracting the E2 suppression score, determined by the average z-score expression of the 8 E2 repressor genes listed in Table 6, from the E2 induction score determined by the average z-score expression of the 10 E2-inducing genes listed in Table 3. In some embodiments, the ER pathway activity score is calculated using 18 gene features by subtracting the E2 repression score determined by the average z-score expression of the nine E2 repression genes listed in Table 6 from the E2 induction score determined by the average z-score expression of the nine E2 inducible genes listed in Table 3.

[0273] In some embodiments, the ER pathway activity score is calculated using 19 gene features by subtracting the E2 suppression score, determined by the average z-score expression of the 16 E2-inducing genes listed in Table 3, from the E2 induction score; and the E2 suppression score, determined by the average z-score expression of the 3 E2-repressing genes listed in Table 6, from the E2 induction score; in some embodiments, the ER pathway activity score is calculated using 19 gene features by subtracting the average z-score expression of the 4 E2-repressing genes listed in Table 6 from the E2 induction score; and in some embodiments, the ER pathway activity score is calculated using 19 gene features by subtracting the average z-score expression of the 5 E2-repressing genes listed in Table 6 from the E2 induction score; and the E2 induction score is calculated using the average z-score expression of the 14 E2-inducing genes listed in Table 3. In some embodiments, the ER pathway activity score is calculated using 19 gene features by subtracting the E2 suppression score, determined by the average z-score expression of the 6 E2 repressor genes listed in Table 6, from the E2 induction score determined by the average z-score expression of the 13 E2-inducing genes listed in Table 3. In some embodiments, the ER pathway activity score is calculated using 19 gene features by subtracting the E2 suppression score, determined by the average z-score expression of the 7 E2 repressor genes listed in Table 6, from the E2 induction score determined by the average z-score expression of the 12 E2-inducing genes listed in Table 3. In some embodiments, the ER pathway activity score is calculated using 19 gene features by subtracting the E2 suppression score, determined by the average z-score expression of the 8 E2 repressor genes listed in Table 6, from the E2 induction score determined by the average z-score expression of the 11 E2-inducing genes listed in Table 3. In some embodiments, the ER pathway activity score is calculated using 19 gene features by subtracting the E2 suppression score, determined by the average z-score expression of the 11 E2-inducing genes listed in Table 5, from the E2-inducing score determined by the average z-score expression of the 11 E2-inducing genes listed in Table 2. In some embodiments, the ER pathway activity score is calculated using 19 gene features by subtracting the E2 suppression score, determined by the average z-score expression of the 9 E2-suppressing genes listed in Table 6, from the E2-inducing score determined by the average z-score expression of the 10 E2-inducing genes listed in Table 3.

[0274] In some embodiments, the ER pathway activity score is calculated using 20 gene features by subtracting the E2 suppression score, determined by the average z-score expression of the 17 E2-inducing genes listed in Table 3, from the E2-inducing score; and the E2 suppression score, determined by the average z-score expression of the 3 E2-repressing genes listed in Table 6, from the E2-inducing score; in some embodiments, the ER pathway activity score is calculated using 20 gene features by subtracting the average z-score expression of the 4 E2-repressing genes listed in Table 6 from the E2-inducing score; and in some embodiments, the ER pathway activity score is calculated using 20 gene features by subtracting the average z-score expression of the 5 E2-repressing genes listed in Table 6 from the E2-inducing score; and the E2-inducing score is calculated using the average z-score expression of the 15 E2-inducing genes listed in Table 3. In some embodiments, the ER pathway activity score is calculated using 20 gene features by subtracting the E2 suppression score, determined by the average z-score expression of the 6 E2 repressor genes listed in Table 6, from the E2 induction score determined by the average z-score expression of the 14 E2-inducing genes listed in Table 3. In some embodiments, the ER pathway activity score is calculated using 20 gene features by subtracting the E2 suppression score, determined by the average z-score expression of the 7 E2 repressor genes listed in Table 6, from the E2 induction score determined by the average z-score expression of the 13 E2-inducing genes listed in Table 3. In some embodiments, the ER pathway activity score is calculated using 20 gene features by subtracting the E2 suppression score, determined by the average z-score expression of the 8 E2 repressor genes listed in Table 6, from the E2 induction score determined by the average z-score expression of the 12 E2-inducing genes listed in Table 3. In some embodiments, the ER pathway activity score is calculated using 20 gene features by subtracting the E2 suppression score, determined by the average z-score expression of the 11 E2-inducing genes listed in Table 6, from the E2-inducing score determined by the average z-score expression of the 11 E2-inducing genes listed in Table 3. In some embodiments, the ER pathway activity score is calculated using 20 gene features by subtracting the E2 suppression score, determined by the average z-score expression of the 10 E2-inducing genes listed in Table 6, from the E2-inducing score determined by the average z-score expression of the 10 E2-inducing genes listed in Table 3.

[0275] In some embodiments, the ER pathway activity score is calculated using 21 gene features by subtracting the E2 suppression score, determined by the average z-score expression of the 18 E2-inducing genes listed in Table 3, from the E2 induction score; and the E2 suppression score, determined by the average z-score expression of the 3 E2-repressing genes listed in Table 6, from the E2 induction score; in some embodiments, the ER pathway activity score is calculated using 21 gene features by subtracting the average z-score expression of the 4 E2-repressing genes listed in Table 6 from the E2 induction score; and in some embodiments, the ER pathway activity score is calculated using 21 gene features by subtracting the average z-score expression of the 5 E2-repressing genes listed in Table 6 from the E2 induction score; and the E2 induction score is calculated using the average z-score expression of the 16 E2-inducing genes listed in Table 3. In some embodiments, the ER pathway activity score is calculated using 21 gene features by subtracting the E2 suppression score, determined by the average z-score expression of the 6 E2 repressor genes listed in Table 6, from the E2 induction score determined by the average z-score expression of the 15 E2-inducing genes listed in Table 3. In some embodiments, the ER pathway activity score is calculated using 21 gene features by subtracting the E2 suppression score, determined by the average z-score expression of the 7 E2 repressor genes listed in Table 6, from the E2 induction score determined by the average z-score expression of the 14 E2-inducing genes listed in Table 3. In some embodiments, the ER pathway activity score is calculated using 21 gene features by subtracting the E2 suppression score, determined by the average z-score expression of the 8 E2 repressor genes listed in Table 6, from the E2 induction score determined by the average z-score expression of the 13 E2-inducing genes listed in Table 3. In some embodiments, the ER pathway activity score is calculated using 21 gene features by subtracting the E2 suppression score, determined by the average z-score expression of the 12 E2-inducible genes listed in Table 3, from the E2 induction score; and by subtracting the E2 suppression score, determined by the average z-score expression of the 9 E2-repressive genes listed in Table 6, from the E2 induction score; and in some embodiments, the ER pathway activity score is calculated using 21 gene features by subtracting the average z-score expression of the 10 E2-repressive genes listed in Table 6 from the E2 induction score; and by the E2 suppression score.

[0276] In some embodiments, the ER pathway activity score is calculated using 22 gene features by subtracting the E2 suppression score, determined by the average z-score expression of the 19 E2-inducing genes listed in Table 3, from the E2-inducing score; and the E2 suppression score, determined by the average z-score expression of the 3 E2-repressing genes listed in Table 6, from the E2-inducing score; in some embodiments, the ER pathway activity score is calculated using 22 gene features by subtracting the average z-score expression of the 4 E2-repressing genes listed in Table 6 from the E2-inducing score; and in some embodiments, the ER pathway activity score is calculated using 22 gene features by subtracting the average z-score expression of the 5 E2-repressing genes listed in Table 6 from the E2-inducing score; and the E2-inducing score is calculated using the average z-score expression of the 17 E2-inducing genes listed in Table 3. In some embodiments, the ER pathway activity score is calculated using 22 gene features by subtracting the E2 suppression score, determined by the average z-score expression of the 6 E2 repressor genes listed in Table 6, from the E2 induction score determined by the average z-score expression of the 16 E2-inducing genes listed in Table 3. In some embodiments, the ER pathway activity score is calculated using 22 gene features by subtracting the E2 suppression score, determined by the average z-score expression of the 7 E2 repressor genes listed in Table 6, from the E2 induction score determined by the average z-score expression of the 15 E2-inducing genes listed in Table 3. In some embodiments, the ER pathway activity score is calculated using 22 gene features by subtracting the E2 suppression score, determined by the average z-score expression of the 8 E2 repressor genes listed in Table 6, from the E2 induction score determined by the average z-score expression of the 14 E2-inducing genes listed in Table 3. In some embodiments, the ER pathway activity score is calculated using 22 gene features by subtracting the E2 suppression score, determined by the average z-score expression of the 9 E2 repressor genes listed in Table 6, from the E2 induction score determined by the average z-score expression of the 13 E2-inducing genes listed in Table 3. In some embodiments, the ER pathway activity score is calculated using 22 gene features by subtracting the E2 suppression score, determined by the average z-score expression of the 10 E2 repressor genes listed in Table 6, from the E2 induction score determined by the average z-score expression of the 12 E2-inducing genes listed in Table 3. In some embodiments, the ER pathway activity score is calculated using 22 gene features by subtracting the E2 suppression score, determined by the average z-score expression of the 11 E2-inducing genes listed in Table 6, from the E2 induction score determined by the average z-score expression of the 11 E2 repressor genes listed in Table 3.

[0277] In some embodiments, the ER pathway activity score is calculated using 23 gene features by subtracting the E2 suppression score, determined by the average z-score expression of the 20 E2-inducing genes listed in Table 3, from the E2-inducing score from the average z-score expression of the 3 E2-repressing genes listed in Table 6. In some embodiments, the ER pathway activity score is calculated using 23 gene features by subtracting the E2 suppression score, determined by the average z-score expression of the 19 E2-inducing genes listed in Table 3, from the average z-score expression of the 4 E2-repressing genes listed in Table 6. In some embodiments, the ER pathway activity score is calculated using 23 gene features by subtracting the E2 suppression score, determined by the average z-score expression of the 18 E2-inducing genes listed in Table 3, from the average z-score expression of the 5 E2-repressing genes listed in Table 6. In some embodiments, the ER pathway activity score is calculated using 23 gene features by subtracting the E2 suppression score, determined by the average z-score expression of the 6 E2 repressor genes listed in Table 6, from the E2 induction score determined by the average z-score expression of the 17 E2-inducing genes listed in Table 3. In some embodiments, the ER pathway activity score is calculated using 23 gene features by subtracting the E2 suppression score, determined by the average z-score expression of the 7 E2 repressor genes listed in Table 6, from the E2 induction score determined by the average z-score expression of the 16 E2-inducing genes listed in Table 3. In some embodiments, the ER pathway activity score is calculated using 23 gene features by subtracting the E2 suppression score, determined by the average z-score expression of the 8 E2 repressor genes listed in Table 6, from the E2 induction score determined by the average z-score expression of the 15 E2-inducing genes listed in Table 3. In some embodiments, the ER pathway activity score is calculated using 23 gene features by subtracting the E2 suppression score, determined by the average z-score expression of the 9 E2 repressor genes listed in Table 6, from the E2 induction score determined by the average z-score expression of the 14 E2-inducing genes listed in Table 3. In some embodiments, the ER pathway activity score is calculated using 23 gene features by subtracting the E2 suppression score, determined by the average z-score expression of the 10 E2 repressor genes listed in Table 6, from the E2 induction score determined by the average z-score expression of the 13 E2-inducing genes listed in Table 3. In some embodiments, the ER pathway activity score is calculated using 23 gene features by subtracting the E2 suppression score, determined by the average z-score expression of the 11 E2 repressor genes listed in Table 6, from the E2 induction score determined by the average z-score expression of the 12 E2-inducing genes listed in Table 3.

[0278] In some embodiments, the ER pathway activity score is calculated using 24 gene features by subtracting the E2 suppression score, determined by the average z-score expression of the 21 E2-inducing genes listed in Table 3, from the E2-inducing score; and the E2 suppression score, determined by the average z-score expression of the 3 E2-repressing genes listed in Table 6, from the E2-inducing score; in some embodiments, the ER pathway activity score is calculated using 24 gene features by subtracting the average z-score expression of the 4 E2-repressing genes listed in Table 6 from the E2-inducing score; and in some embodiments, the ER pathway activity score is calculated using 24 gene features by subtracting the average z-score expression of the 5 E2-repressing genes listed in Table 6 from the E2-inducing score; and in some embodiments, the ER pathway activity score is calculated using 24 gene features by subtracting the average z-score expression of the 5 E2-repressing genes listed in Table 6 from the E2-inducing score; and the E2-inducing score is calculated using the average z-score expression of the 19 E2-inducing genes listed in Table 3. In some embodiments, the ER pathway activity score is calculated using 24 gene features by subtracting the E2 suppression score, determined by the average z-score expression of the 6 E2 repressor genes listed in Table 6, from the E2 induction score determined by the average z-score expression of the 18 E2-inducing genes listed in Table 3. In some embodiments, the ER pathway activity score is calculated using 24 gene features by subtracting the E2 suppression score, determined by the average z-score expression of the 7 E2 repressor genes listed in Table 6, from the E2 induction score determined by the average z-score expression of the 17 E2-inducing genes listed in Table 3. In some embodiments, the ER pathway activity score is calculated using 24 gene features by subtracting the E2 suppression score, determined by the average z-score expression of the 8 E2 repressor genes listed in Table 6, from the E2 induction score determined by the average z-score expression of the 16 E2-inducing genes listed in Table 3. In some embodiments, the ER pathway activity score is calculated using 24 gene features by subtracting the E2 suppression score, determined by the average z-score expression of the 9 E2 repressor genes listed in Table 6, from the E2 induction score determined by the average z-score expression of the 15 E2-inducing genes listed in Table 3. In some embodiments, the ER pathway activity score is calculated using 24 gene features by subtracting the E2 suppression score, determined by the average z-score expression of the 10 E2 repressor genes listed in Table 6, from the E2 induction score determined by the average z-score expression of the 14 E2-inducing genes listed in Table 3. In some embodiments, the ER pathway activity score is calculated using 24 gene features by subtracting the E2 suppression score, determined by the average z-score expression of the 11 E2 repressor genes listed in Table 6, from the E2 induction score determined by the average z-score expression of the 13 E2-inducing genes listed in Table 3.In some embodiments, the ER pathway activity score is calculated using 24 gene features by subtracting the E2 suppression score determined by the average z-score expression of the 12 E2 repressor genes listed in Table 6 from the E2 induction score determined by the average z-score expression of the 12 E2 inducible genes listed in Table 3.

[0279] In some embodiments, the ER pathway activity score is calculated using 25 gene features by subtracting the E2 suppression score, determined by the average z-score expression of the 22 E2-inducing genes listed in Table 3, from the E2-inducing score; and the E2 suppression score, determined by the average z-score expression of the 3 E2-repressing genes listed in Table 6, from the E2-inducing score; in some embodiments, the ER pathway activity score is calculated using 25 gene features by subtracting the average z-score expression of the 4 E2-repressing genes listed in Table 6 from the E2-inducing score; and in some embodiments, the ER pathway activity score is calculated using 25 gene features by subtracting the average z-score expression of the 5 E2-repressing genes listed in Table 6 from the E2-inducing score; and the E2-inducing score is calculated using the average z-score expression of the 20 E2-inducing genes listed in Table 3. In some embodiments, the ER pathway activity score is calculated using 25 gene features by subtracting the E2 suppression score, determined by the average z-score expression of the 19 E2-inducing genes listed in Table 3, from the E2 induction score; and the E2 suppression score, determined by the average z-score expression of the 6 E2-repressing genes listed in Table 6, from the E2 induction score; in some embodiments, the ER pathway activity score is calculated using 25 gene features by subtracting the average z-score expression of the 7 E2-repressing genes listed in Table 6 from the E2 induction score; and in some embodiments, the ER pathway activity score is calculated using 25 gene features by subtracting the average z-score expression of the 8 E2-repressing genes listed in Table 6 from the E2 induction score; and the E2 induction score is calculated using the average z-score expression of the 17 E2-inducing genes listed in Table 3. In some embodiments, the ER pathway activity score is calculated using 25 gene features by subtracting the E2 suppression score, determined by the average z-score expression of the 9 E2 repressor genes listed in Table 6, from the E2 induction score determined by the average z-score expression of the 16 E2-inducing genes listed in Table 3. In some embodiments, the ER pathway activity score is calculated using 25 gene features by subtracting the E2 suppression score, determined by the average z-score expression of the 10 E2 repressor genes listed in Table 6, from the E2 induction score determined by the average z-score expression of the 15 E2-inducing genes listed in Table 3. In some embodiments, the ER pathway activity score is calculated using 25 gene features by subtracting the E2 suppression score, determined by the average z-score expression of the 11 E2 repressor genes listed in Table 6, from the E2 induction score determined by the average z-score expression of the 14 E2-inducing genes listed in Table 3.In some embodiments, the ER pathway activity score is calculated using 25 gene features by subtracting the E2 suppression score determined by the average z-score expression of the 12 E2 repressor genes listed in Table 6 from the E2 induction score determined by the average z-score expression of the 13 E2 inducible genes listed in Table 3.

[0280] In some embodiments, the ER pathway activity score is calculated using 26 gene features by subtracting the E2 suppression score, determined by the average z-score expression of the 23 E2-inducing genes listed in Table 3, from the E2 induction score; and the E2 suppression score, determined by the average z-score expression of the 3 E2-repressing genes listed in Table 6, from the E2 induction score; in some embodiments, the ER pathway activity score is calculated using 26 gene features by subtracting the average z-score expression of the 4 E2-repressing genes listed in Table 6 from the E2 induction score; and in some embodiments, the ER pathway activity score is calculated using 26 gene features by subtracting the average z-score expression of the 5 E2-repressing genes listed in Table 6 from the E2 induction score; and the E2 induction score is calculated using the average z-score expression of the 21 E2-inducing genes listed in Table 3. In some embodiments, the ER pathway activity score is calculated using 26 gene features by subtracting the E2 suppression score, determined by the average z-score expression of the 6 E2 repressor genes listed in Table 6, from the E2 induction score determined by the average z-score expression of the 20 E2-inducing genes listed in Table 3. In some embodiments, the ER pathway activity score is calculated using 26 gene features by subtracting the E2 suppression score, determined by the average z-score expression of the 7 E2 repressor genes listed in Table 6, from the E2 induction score determined by the average z-score expression of the 19 E2-inducing genes listed in Table 3. In some embodiments, the ER pathway activity score is calculated using 26 gene features by subtracting the E2 suppression score, determined by the average z-score expression of the 8 E2 repressor genes listed in Table 6, from the E2 induction score determined by the average z-score expression of the 18 E2-inducing genes listed in Table 3. In some embodiments, the ER pathway activity score is calculated using 26 gene features by subtracting the E2 suppression score, determined by the average z-score expression of the 9 E2 repressor genes listed in Table 6, from the E2 induction score determined by the average z-score expression of the 17 E2-inducing genes listed in Table 3. In some embodiments, the ER pathway activity score is calculated using 26 gene features by subtracting the E2 suppression score, determined by the average z-score expression of the 10 E2 repressor genes listed in Table 6, from the E2 induction score determined by the average z-score expression of the 16 E2-inducing genes listed in Table 3. In some embodiments, the ER pathway activity score is calculated using 26 gene features by subtracting the E2 suppression score, determined by the average z-score expression of the 11 E2 repressor genes listed in Table 6, from the E2 induction score determined by the average z-score expression of the 15 E2-inducing genes listed in Table 3.In some embodiments, the ER pathway activity score is calculated using 26 gene features by subtracting the E2 suppression score, determined by the average z-score expression of the 12 E2 repressor genes listed in Table 6, from the E2 induction score determined by the average z-score expression of the 14 E2-inducible genes listed in Table 3. In some embodiments, the ER pathway activity score is calculated using 26 gene features by subtracting the E2 suppression score, determined by the average z-score expression of the 13 E2-inducible genes listed in Table 6, from the E2 induction score determined by the average z-score expression of the 13 E2-inducible genes listed in Table 3.

[0281] In some embodiments, the ER pathway activity score is calculated using 27 gene features by subtracting the E2 suppression score determined by the average z-score expression of the 4 E2 repressor genes listed in Table 6 from the E2 induction score determined by the average z-score expression of the 23 E2 inducible genes listed in Table 3.

[0282] In some embodiments, the ER pathway activity score is calculated using 28 gene features by subtracting the E2 suppression score determined by the average z-score expression of the 5 E2 repressor genes listed in Table 6 from the E2 induction score determined by the average z-score expression of the 23 E2 inducible genes listed in Table 3.

[0283] In some embodiments, the ER pathway activity score is calculated using 29 gene features by subtracting the E2 repression score determined by the average z-score expression of the 6 E2 repression genes listed in Table 6 from the E2 induction score determined by the average z-score expression of the 23 E2 inducible genes listed in Table 3.

[0284] In some embodiments, the ER pathway activity score is calculated using 30 gene features by subtracting the E2 repression score determined by the average z-score expression of the 7 E2 repression genes listed in Table 6 from the E2 induction score determined by the average z-score expression of the 23 E2 inducible genes listed in Table 3.

[0285] In some embodiments, the ER pathway activity score is calculated using 31 gene features by subtracting the E2 suppression score determined by the average z-score expression of the 8 E2 repressor genes listed in Table 6 from the E2 induction score determined by the average z-score expression of the 23 E2 inducible genes listed in Table 3.

[0286] In some embodiments, the ER pathway activity score is calculated using 32 gene features by subtracting the E2 repression score determined by the average z-score expression of the 9 E2 repression genes listed in Table 6 from the E2 induction score determined by the average z-score expression of the 23 E2 inducible genes listed in Table 3.

[0287] In some embodiments, the ER pathway activity score is calculated using 33 gene features by subtracting the E2 suppression score determined by the average z-score expression of the 10 E2 repressor genes listed in Table 6 from the E2 induction score determined by the average z-score expression of the 23 E2 inducible genes listed in Table 3.

[0288] In some embodiments, the ER pathway activity score is calculated using 34 gene features by subtracting the E2 suppression score determined by the average z-score expression of the 11 E2 repressor genes listed in Table 6 from the E2 induction score determined by the average z-score expression of the 23 E2 inducible genes listed in Table 3.

[0289] In some embodiments, the ER pathway activity score is calculated using 35 gene features by subtracting the E2 suppression score determined by the average z-score expression of the 12 E2 repressor genes listed in Table 6 from the E2 induction score determined by the average z-score expression of the 23 E2 inducible genes listed in Table 3.

[0290] In some embodiments, the ER pathway activity score is calculated using 36 gene features by subtracting the E2 suppression score determined by the average z-score expression of the 13 E2 repressor genes listed in Table 6 from the E2 induction score determined by the average z-score expression of the 23 E2 inducible genes listed in Table 3.

[0291] In some embodiments, the ER pathway activity score is calculated using 37 gene features by subtracting the E2 suppression score determined by the average z-score expression of the 14 E2 repressor genes listed in Table 6 from the E2 induction score determined by the average z-score expression of the 23 E2 inducible genes listed in Table 3.

[0292] In some embodiments, the ER pathway activity score is calculated using 38 gene features by subtracting the E2 suppression score determined by the average z-score expression of the 15 E2 repressor genes listed in Table 6 from the E2 induction score determined by the average z-score expression of the 23 E2 inducible genes listed in Table 3.

[0293] In some embodiments, the ER pathway activity score is calculated using 39 gene features by subtracting the E2 suppression score determined by the average z-score expression of the 16 E2 repressor genes listed in Table 6 from the E2 induction score determined by the average z-score expression of the 23 E2 inducible genes listed in Table 3.

[0294] In some embodiments, the ER pathway activity score is calculated using 40 gene features by subtracting the E2 suppression score determined by the average z-score expression of the 17 E2 repressor genes listed in Table 6 from the E2 induction score determined by the average z-score expression of the 23 E2 inducible genes listed in Table 3.

[0295] In some embodiments, the ER pathway activity score is calculated using 41 gene features by subtracting the E2 suppression score determined by the average z-score expression of the 18 E2 repressor genes listed in Table 6 from the E2 induction score determined by the average z-score expression of the 23 E2 inducible genes listed in Table 3.

[0296] In some embodiments, the ER pathway activity score is calculated using 14 gene features by subtracting the E2 suppression score, determined by the average z-score expression of the eight E2-inducing genes listed in Table 4, from the E2-inducing score determined by the average z-score expression of the eight E2-inducing genes listed in Table 1. In some embodiments, the ER pathway activity score is calculated using 19 gene features by subtracting the E2 suppression score, determined by the average z-score expression of the eight E2-inducing genes listed in Table 5, from the E2-inducing score determined by the average z-score expression of the 11 E2-inducing genes listed in Table 2. In some embodiments, the ER pathway activity score is calculated using 41 gene features by subtracting the E2 suppression score, determined by the average z-score expression of the 18 E2-inducing genes listed in Table 6, from the E2-inducing score determined by the average z-score expression of the 23 E2-inducing genes listed in Table 3. The ER pathway activity score can be used as a surrogate biomarker for ER pathway activity in an individual tumor.

[0297] In any method or assay provided herein for determining the expression level of a predetermined genome from samples from individuals (e.g., tissue samples, such as tumor tissue samples, such as formalin-fixed and paraffin-embedded (FFPE), fresh-frozen (FF), archived, fresh, or frozen tumor tissue samples), it should be understood that the expression level of the predetermined genome can be normalized to, for example, a reference gene, such as a housekeeping gene. In some cases, the reference gene is SDHA, GUSB, PPIA, and / or UBC. In some cases, the expression level of more than one target gene (e.g., any of the predetermined genomes listed in Tables 1-6) can be determined by aggregation methods known to those skilled in the art and also disclosed herein, including, for example, by calculating the median or mean of all expression levels of the target gene. Prior to aggregation, the expression level of each target gene can be normalized using statistical methods known to those skilled in the art and disclosed herein. These methods include, for example, normalizing to the expression levels of one or more housekeeping genes, normalizing to the median or mean expression level of each gene in all reference populations, normalizing to the total library size, or normalizing to the median or mean expression level of all measured genes. In some cases, prior to aggregation of all multiple target genes, the normalized expression level of each target gene can be normalized using statistical methods known to those skilled in the art and disclosed herein. These methods include, for example, calculating a Z-score for the normalized expression level of each target gene, or scaling the normalized expression level of each gene to a corresponding scaling factor for those expression levels in the reference population.

[0298] Samples from individuals may be FFPE samples, FF samples, fresh samples, frozen samples, or archived samples. In some cases, the samples are FFPE samples. In other cases, the samples are FF samples. The expression level of the intended genome can be quantitatively determined based on any suitable criteria known in the art, including but not limited to measurements of mRNA, DNA, cDNA, and / or gene copy number levels in an individual.

[0299] Table 1: Eight E2-inducible genes among the 14 gene characteristics

[0300] E2-induced AMZ1 C5AR2 CELSR2 FKBP4 GREB1 OLFM1 SLC9A3R1 TFF1

[0301] Table 2: Eleven E2-induced genes among the 19 gene characteristics

[0302] E2-induced AMZ1 AREG C5AR2 CELSR2 FKBP4 FMN1 GREB1 OLFM1 RBM24 SLC9A3R1 TFF1

[0303] Table 3: Twenty-three E2-inducible genes among 41 gene characteristics

[0304]

[0305]

[0306] Table 4: Six E2 repressor genes among 14 gene characteristics

[0307] E2 inhibition BCAS1 CCNG2 IL1R1 PNPLA7 SEMA3E STON1

[0308] Table 5: Eight E2 repressor genes among the 19 gene characteristics

[0309]

[0310]

[0311] Table 6: Eighteen E2 repressor genes among 41 gene characteristics

[0312] E2 inhibition BAMBI BCAS1 CCNG2 DDIT4 EGLN3 FAM171B GRM4 IL1R1 LIPH NBEA PNPLA7 PSCA SEMA3E SSPO STON1 TGFB3 TP53INP1 TP53INP2

[0313] In some cases of any of the foregoing methods and assays, gene expression levels can be nucleic acid expression levels (e.g., RNA expression levels (e.g., mRNA expression levels) or DNA expression levels). Any suitable method for determining nucleic acid expression levels can be used, for example, as described in Section VII below. In some cases, RNA-seq (e.g., using RNA...) is used. plan or plan Nucleic acid expression levels can be determined using RT-qPCR, qPCR, multiplex qPCR or RT-qPCR, microarray analysis, SAGE, MassARRAY techniques, or combinations thereof.

[0314] Methods for assessing mRNA in cells are well-known and include, for example, RNA sequencing (RNA-seq), whole-genome sequencing (WGS), serial analysis of gene expression (SAGE), and various nucleic acid amplification assays (such as RT-PCR using complementary primers specific to a predetermined genome (e.g., qRT-PCR)). Additionally, such methods may include one or more steps that allow one to determine the level of a target mRNA in a biological sample (e.g., by simultaneously examining the level of a comparative control mRNA sequence of a “housekeeping” gene such as a member of the actin family). Optionally, the sequence of the amplified target cDNA can be determined. Optional methods include protocols for examining or detecting mRNA (e.g., target mRNA) in tissue or cell samples using microarray technology. Using a nucleic acid microarray, test and control mRNA samples from test and control tissue samples are reverse transcribed and labeled to generate cDNA probes. The probes are then hybridized to a nucleic acid array immobilized on a solid support. The array is configured so that the order and position of each component of the array are known. For example, genes whose expression is associated with increased or decreased clinical benefit from treatments including immunotherapy and inhibitory matrix antagonists can be selected and arranged on a solid support. Hybridization of a labeled probe with a specific array component indicates that the sample from which the probe was derived expresses the gene.

[0315] In some cases of any of the methods and assays, samples (e.g., tissue samples, such as tumor tissue samples, such as FFPE, FF, archived, fresh, or frozen tumor tissue samples) are obtained from the individual prior to the administration of the endocrine therapy described herein (e.g., minutes, hours, days, weeks, months, or years prior). In other words, the sample may be a baseline sample. In some cases of any of the foregoing methods, the sample is obtained from the individual after the administration of endocrine therapy (e.g., minutes, hours, or days prior). In some cases, samples from the individual are obtained within thirty hours after the administration of endocrine therapy. In some cases, multiple samples are obtained from the same individual at different time points (e.g., before and after the administration of endocrine therapy).

[0316] In any of the aforementioned cases, an individual may have HR+ breast cancer. In some cases, HR+ cancer can be ER+ breast cancer. In some cases, an individual may have ER+ breast cancer, selected from, for example, luminal type A breast cancer or luminal type B breast cancer. In some cases, the breast cancer may be advanced breast cancer or metastatic breast cancer.

[0317] In some cases involving the determination of ER pathway activity scores and / or E2 induction scores from samples from an individual (e.g., tissue samples, such as tumor tissue samples, such as formalin-fixed and paraffin-embedded (FFPE), fresh-frozen (FF), archived, fresh, or frozen tumor tissue samples), the individual has previously been treated with the endocrine therapy described herein. In other cases, the individual has not previously received endocrine therapy.

[0318] In some cases, the method further includes generating reports for individuals or other individuals or entities, caregivers, physicians, oncologists, hospitals, clinics, third-party payers, insurance companies, pharmaceutical or biotechnology companies, or government agencies, such as electronic reports, web-based reports, or paper reports. In some cases, the report includes outputs from a method that incorporates assessments of ER pathway activity and / or E2 induction scores.

[0319] IV. Anticancer agents

[0320] This article provides methods for treating individuals with breast cancer (e.g., HR+ breast cancer (e.g., ER+ breast cancer (e.g., luminal A or luminal B breast cancer)) and / or metastatic or locally advanced breast cancer). Any of the foregoing methods can be based on the determination of E2 induction scores and / or ER pathway activity scores from samples (e.g., tissue samples, such as tumor tissue samples, such as FFPE, FF, archived, fresh, or frozen tumor tissue samples) from the individual.

[0321] In some of the foregoing methods, the anticancer therapeutic agents used in the methods described herein can be administered via, for example, orally, intramuscularly, subcutaneously, intravenously, intradermally, percutaneously, intra-arterially, intraperitoneally, intralesionally, intracranially, intra-articularly, intraprostatically, intrapleurally, intratracheally, intrathecally, intranasally, intravaginally, intrarectally, locally, intratumorally, intraperitoneally, subconjunctivally, intracysticly, mucosally, intraperitoneally, intraumbilically, intraocularly, intraorbitally, intravitreally (e.g., via intravitreal injection), via eye drops, locally, transdermally, parenterally, via inhalation, via injection, via implantation, via infusion, via continuous infusion, via local perfusion to directly immerse target cells, via catheter, via irrigation, as a cream, or as a lipid composition. In some of the foregoing methods, the anticancer therapeutic agents used in the methods described herein can be administered orally. For example, in some cases, the endocrine therapy described herein can be administered orally or intramuscularly. In some cases, SERM can be administered orally or intramuscularly. In some cases, SERD can be administered orally or intramuscularly. In some cases of any of the foregoing methods, the anticancer therapeutic agents used in the methods described herein may be administered intramuscularly. For example, in some cases, the endocrine therapy described herein may be administered orally. In some cases, SERM may be administered orally. In some cases, SERD may be administered orally. The anticancer therapeutic agents used in the methods described herein may also be administered systemically or locally. The method of administration may vary depending on a variety of factors (e.g., the anticancer therapeutic agent to be administered and the severity of the condition, disease, or symptom to be treated (e.g., breast cancer)).

[0322] Anticancer agents, including endocrine agents (and any additional therapeutic agents) described herein, may be formulated, administered, and applied in accordance with good medical practice. Factors to be considered in this context include the specific disease being treated, the specific mammal being treated, the individual patient's clinical condition, the cause of the disease, the site of delivery, the method of administration, the timing of administration, and other factors known to the practicing physician. Anticancer agents are not mandatory, but may optionally be formulated and / or administered concurrently with one or more agents currently used for the prevention or treatment of the disease in question. The effective amount of such other agents depends on the amount of anticancer drug present in the formulation, the type of disease or treatment, and other factors discussed above. These are generally used at the same dosage and route of administration as described herein, or at approximately 1% to 99% of the dosage described herein, or at any dosage and via any route determined empirically / clinically to be appropriate.

[0323] For the prevention or treatment of breast cancer, such as HR+ breast cancer (e.g., ER+ breast cancer (e.g., luminal type A or luminal type B breast cancer)), DCIS, and / or metastatic or locally advanced breast cancer, the appropriate dose of the anticancer agent (e.g., endocrine therapy) described herein (when used alone or in combination with one or more other additional therapeutic agents) will depend on the type of disease to be treated, the severity and course of the disease, whether the anticancer agent is administered for prophylactic or therapeutic purposes, prior therapy, the individual's clinical history and response to the anticancer agent, and the attending physician's discretion. The anticancer agent is appropriately administered to the individual either once or in a series of treatments. For repeated administration over several days or longer, depending on the condition, treatment typically continues until the desired suppression of disease symptoms occurs. An initial higher loading dose may be administered, followed by one or more lower doses. However, other dosing regimens may be useful. Progression of the therapy can be easily monitored using routine techniques and assays. In some cases, the dose of endocrine therapy provided herein is from about 1 mg / kg to about 100 mg / kg. In another instance, the dosage of the endocrine therapy described herein is from about 100 mg / kg to about 1000 mg / kg. In yet another instance, the dosage of the endocrine therapy described herein is from about 1000 mg / kg to about 2000 mg / kg. Some of the endocrine therapies described herein may be administered according to a cyclical administration procedure known in the art—for example, continuous administration for 20, 21, 22, 23, 24, 25, 26, 27, or 28 days or more followed by a rest period of 1, 2, 3, 4, 5, 6, 7, or more days. In yet another instance, the endocrine therapy described herein is administered according to the package insert.

[0324] A. Endocrine therapy

[0325] In some of the aforementioned cases, endocrine therapy may be administered to an individual.

[0326] Exemplary endocrine therapies used in the methods described herein include compounds that modulate estrogen receptor activity. In some cases, the compounds described herein include selective estrogen receptor modulators (SERMs), selective estrogen receptor degraders (SERDs), aromatase inhibitors (AIs), or combinations thereof.

[0327] In some cases, endocrine therapy includes aromatase inhibitors. Aromatase inhibitors can be agents known in the art. For example, in one case, an aromatase inhibitor is letrozole, anastrozole, exemestane, or testrolide, or a pharmaceutical salt thereof, or a combination thereof.

[0328] In another case, endocrine therapy includes SERM.

[0329] Endocrine therapy may comprise a compound that is a tetrasubstituted olefin compound known to have antagonistic activity against ER. For example, endocrine therapy may be tamoxifen, including its derivatives such as hydroxytamoxifen. In one case, endocrine therapy includes nafoxidin. In another case, endocrine therapy includes clomiphene, toremifene, raloxifene, diacetylcholine, bardoxifene, bromhexetine, cyclofennig, lasoxifene, omexifen, acoboxifene, ilesetron, brilanestrant, oflomiphene, droloxifen, etexil, or opemifene, or pharmaceutical salts thereof, or combinations thereof. In yet another case, endocrine therapy includes G1T48 or pharmaceutical salts thereof.

[0330] In yet another case, endocrine therapy includes SERD.

[0331] In one case, endocrine therapy includes fulvestrant.

[0332]

[0333] Or its medicinal salt.

[0334] On one hand, endocrine therapy includes compounds having formula (1):

[0335]

[0336] in;

[0337] Z is -OH or -OR 10 ;

[0338] R 2 It is C 1-4 Alkyl, C 1-4 fluoroalkyl, C 1-4 deuteryl, C 3-6 cycloalkyl or C 1-4 Alkylene-W;

[0339] W represents hydroxyl, halogen, CN, and C. 1-4 Alkyl, C 1-4 Haloalkyl, C 1-4 Alkoxy, C 1-4 Halogenated alkoxy or C 3-6 Cycloalkyl;

[0340] R 3 Each is independently a halogen, C 1-4 Alkyl or C 1-4 fluoroalkyl;

[0341] R 4 Each is independently a halogen, -CN, or -OR. 9 、-S(O)2R 10 C1-4 Alkyl, C 1-4 fluoroalkyl or C 1-4 Heteroalkyl;

[0342] R 5 Each is independently a halogen, -CN, or -OR. 9 、-S(O)2R 10 C 1-4 Alkyl, C 1-4 fluoroalkyl or C 1-4 Heteroalkyl;

[0343] R 6 It is H, C 1-4 Alkyl or halogen;

[0344] R 7 It is H, C 1-4 Alkyl or halogen;

[0345] R 9 It is H, C 1-6 Alkyl, C 1-6 fluoroalkyl or C 3-6 Cycloalkyl;

[0346] R 10 It is C 1-6 alkyl;

[0347] m is 0, 1, or 2;

[0348] n is 0, 1, 2, 3, or 4; and

[0349] p is 0, 1, or 2.

[0350] In another case of the compound of formula (1), Z is -OH or -OR. 10 ;R 2 It is C 1-4 Alkyl, C 1-4 fluoroalkyl, C 1-4 deuteryl, C 3-6 cycloalkyl or C 1-4 Alkylene-W, wherein W is a hydroxyl group, a halogen, a CN group, or a C group. 1-4 Alkyl; R 3 Each is independently a halogen, C 1-4 Alkyl or C 1-4 fluoroalkyl; R 4 Each is independently a halogen, -CN, or -OR. 9 、-S(O)2R 10 C 1-4 Alkyl, C 1-4 fluoroalkyl or C 1-4 Heteroalkyl; R 5 Each is independently a halogen, -CN, or -OR. 9-S(O)2R10, C 1-4 Alkyl, C 1-4 fluoroalkyl or C 1-4 Heteroalkyl; R 6 For H, C 1-4 Alkyl or halogen; R 7 It is H, C 1-4 Alkyl or halogen; R 9 It is H, C 1-6 Alkyl, C 1-6 fluoroalkyl or C 3-6 cycloalkyl; R 10 It is C 1-6 Alkyl; m is 0, 1, or 2; n is 0, 1, 2, 3, or 4; and p is 0, 1, or 2.

[0351] In another case of the compound of formula (1), Z is -OH. In another case of the compound of formula (1), Z is -OR. 10 In another case of the compound of formula (1), Z is -OH, -OCH3 or -OCH2CH3.

[0352] In another case of the compound of formula (1), R 6 It is H, -CH3, F, or Cl. In another case of the compound of formula (1), R 6 It is H. In another case of the compound of formula (1), R 7 It is H, -CH3, F, or Cl. In another case of the compound of formula (1), R 7 It’s H.

[0353] In another case of the compound of formula (1), R 3 Independently, halogen, C 1-4 Alkyl or C 1-4 Fluoroalkyl. In another case of the compound of formula (1), R 3 Each is independently F, Cl, or -CH3. In another case of the compound of formula (1), R 4 Each is independently a halogen, -CN, -OH, or -OR. 9 、-S(O)2R 10 C 1-4 Alkyl, C 1-4 fluoroalkyl or C 1-4 Heteroalkyl. In another case of compounds of formula (1), R 4 Each is independently a halogen, -CN, -OH, -S(O)2CH3, -S(O)2CH2CH3, -CH3, -CH2CH3, -CF3, -CH2OH, -OCF3, -OCH3, or -OCH2CH3. In another case of the compound of formula (1), R 4Each of these can be independently F, Cl, -CN, -OH, -CH3, -CH2CH3, -CF3, -CH2OH, -OCF3, -OCH3, or -OCH2CH3. In another case of the compound of formula (1), R 4 Each is independently F or Cl. In another case of the compound of formula (1), R 5 Each is independently a halogen, C 1-4 Alkyl or C 1-4 Fluoroalkyl. In another case of the compound of formula (1), R 5 Each can be F, Cl, or -CH3 independently.

[0354] In another case of the compound of formula (1), m is 0 or 1. In another case of the compound of formula (1), m is 0. In another case of the compound of formula (1), m is 1. In another case of the compound of formula (1), n ​​is 0, 1, or 2. In another case of the compound of formula (1), n ​​is 0. In another case of the compound of formula (1), n ​​is 1. In another case of the compound of formula (1), n ​​is 2. In another case of the compound of formula (1), p is 0 or 1. In another case of the compound of formula (1), p is 0. In another case of the compound of formula (1), p is 1.

[0355] In another case of the compound of formula (1), Z is -OH; R 6 It is H, -CH3, F, or Cl; R 7 It is H, -CH3, F, or Cl; R 3 Each is independently a halogen, C 1-4 Alkyl or C 1-4 fluoroalkyl; R 4 Each is independently a halogen, -CN, or -OR. 9 、-S(O)2R 10 C 1-4 Alkyl, C 1-4 fluoroalkyl or C 1-4 Heteroalkyl; R 5 Each is independently a halogen, C 1-4 Alkyl or C 1-4 Fluoroalkyl; m is 0 or 1; n is 0, 1 or 2; and p is 0 or 1.

[0356] In another case of the compound of formula (1), R 2 It is C 1-4 Alkyl, C 1-4 fluoroalkyl, C 1-4 deuteryl, C 3-6 cycloalkyl or C 1-4 Alkylene-W; W is hydroxyl, halogen, CN, C 1-4 Alkoxy or C3-6 Cycloalkyl. In another case of compounds of formula (1), R 2 It is C 1-4 Alkyl, C 1-4 fluoroalkyl or C 1-4 Deuteryl group. In another case of the compound of formula (1), R 2 It is C 1-4 Alkyl group. In another case of compounds of formula (1), R 2 The following are possible meanings: -CH3, -CH2CH3, -CH2CH2CH3, -CH(CH3)2, -CH2CH2CH2CH3, -CH2CH(CH3)2, -CH2F, -CHF2, -CF3, -CH2CF3, -CD3, -CH2CD3, -CD2CD3, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, -CH2-W, or CH2CH2-W; W is hydroxyl, F, Cl, -CN, -OCH3, -OCH2CH3, -OCH2CH2CH3, -OCH(CH3)2, cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl. In another case of the compound of formula (1), W is hydroxyl, F, Cl, -CN, cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl. In another case of the compound of formula (1), R 2 It is -CH3, -CH2CH3, -CH2CH2CH3, -CH(CH3)2, -CH2CH2CH2CH3, -CH2CH(CH3)2, -CH2F, -CHF2, -CF3, -CH2CF3, -CD, -CH2CD3, -CD2CD3, -CH2-W, or -CH2CH2-W. In another case of the compound of formula (1), R 2 It is -CH3, -CH2CH3, -CH2F, -CHF2, -CF3, -CH2CF3, -CD3, -CD2CD3, -CH2CD3 or cyclopropyl.

[0357] In another case of the compound of formula (1), Z is -OH; R 6 It is H; R 7 H is 0; m is 0; n is 0, 1, or 2; and p is 0.

[0358] In another case of a compound of formula (1), the compound of formula (1) has the structure of formula (1a), or a medicinal salt thereof, or an N-oxide thereof:

[0359]

[0360] Equation (1a).

[0361] On the other hand, endocrine therapy includes compounds listed in U.S. Patent No. 8,299,112, such as those in Table 1 therein, the entire contents of which are incorporated herein by reference for all purposes.

[0362] On the other hand, endocrine therapy includes compounds having the following formula: (E)3-(4-((E)-1-(1H-indazol-5-yl)-2-phenylbut-1-en-1-yl)phenyl)acrylate; (E)-3-(4-((E)-1-(1H-indazol-5-yl)-2-phenylbut-1-en-1-yl)phenyl)acrylate; (E)-3-(4-((E)-1-(1H-benzo[d][1,2,3]triazol-5-yl)-2-phenylbut-1-en-1-yl)phenyl)acrylate; (E)-3-(4-((E)-2-(4-fluorophenyl)-1-(1H-indazol-5-yl)but-1-en-1-yl)phenyl)acrylate; (E (E)-3-(4-((E)-2-(4-chlorophenyl)-1-(1H-indazol-5-yl)but-1-en-1-yl)phenyl)acrylic acid; (E)-3-(4-((E)-1-(1H-indazol-5-yl)-2-(3-methoxyphenyl)but-1-en-1-yl)phenyl)acrylic acid; (E)-3-(4-((E)-2-(3-(hydroxymethyl)phenyl)-1-(1H-indazol-5-yl)but-1-en-1-yl)phenyl)acrylic acid; (E)-3-(4-((E)-2-(4-(hydroxymethyl)phenyl)-1-(1H-indazol-5-yl)but-1-en-1-yl)phenyl)acrylic acid; (E)-3-(4-((E)-2-(4-chlorophenyl)phenyl)-1-(1H-indazol-5-yl)but-1-en-1-yl)phenyl)acrylic acid; (E)-3-(4-((E)-2-(4-chlorophenyl)phenyl)-1-(1H-indazol-5-yl)but-1-en-1-yl)phenyl)acrylic acid; -(2-(hydroxymethyl)phenyl)-1-(1H-indazol-5-yl)but-1-en-1-yl)phenyl)acrylic acid; (E)-3-(4-((E)-1-(1H-indazol-5-yl)-2-(o-tolyl)but-1-en-1-yl)phenyl)acrylic acid; (E)-3-(4-((E)-1-(1H-indazol-5-yl)-2-(m-tolyl)but-1-en-1-yl)phenyl)acrylic acid; (E)-3-(4-((E)-1-(1H-indazol-5-yl)-2-(p-tolyl)but-1-en-1-yl)phenyl)acrylic acid; (E)-3-(4-((E)-1-(1H-indazol-5-yl)-2-(2-methoxy) (E)-3-(4-((E)-1-(1H-indazol-5-yl)-2-(4-methoxyphenyl)but-1-en-1-yl)phenyl)acrylic acid; ((E)-3-(4-((E)-2-(2-chlorophenyl)-1-(1H-indazol-5-yl)but-1-en-1-yl)phenyl)acrylic acid; (E)-3-(4-((E)-2-(3-chlorophenyl)-1-(1H-indazol-5-yl)but-1-en-1-yl)phenyl)acrylic acid; (E)-3-(4-((E)-2-(2-fluorophenyl)-1-(1H-indazol-5-yl)but-1-en-1-yl)phenyl)acrylic acid;(E)-3-(4-((E)-2-(3-fluorophenyl)-1-(1H-indazol-5-yl)but-1-en-1-yl)phenyl)acrylic acid; (E)-3-(4-((E)-2-(2-ethylphenyl)-1-(1H-indazol-5-yl)but-1-en-1-yl)phenyl)acrylic acid; (E)-3-(4-((E)-1-(1H-indazol-5-yl)-2-(2-(trifluoromethyl)phenyl)but-1-en-1-yl)phenyl)acrylic acid; (E)-3-(4-((E)-4-chloro-1-(1H-indazol-5-yl)-2-phenylbut-1-en-1-yl)phenyl)acrylic acid; (E)-3-(4-((E)-2-(2-ethylphenyl)-1-(1H-indazol-5-yl)-2-phenylbut-1-en-1-yl)phenyl)acrylic acid; (E)-3-(4-((E)-2-(2-ethylphenyl)-1-(1H-indazol-5-yl)-2-phenylbut-1-en-1-yl)phenyl)acrylic acid; (E)-3-(4-((E)-2-(2-cyanophenyl)-1-(1H-indazol-5-yl)but-1-en-1-yl)phenyl)acrylic acid; (E)-3-(4-((E)-2-(2,4-difluorophenyl)-1-(1H-indazol-5-yl)but-1-en-1-yl)phenyl)acrylic acid; (E)-3-(4-((E)-2-(2-chloro-3-fluorophenyl)-1-(1H-indazol-5-yl)but-1-en-1-yl)phenyl)acrylic acid; (E)-3-(4-((E)-2-(2-chloro-3-fluorophenyl)-1-(1H-indazol-5-yl)but-1-en-1-yl)phenyl)acrylic acid; (E)-3-(4-((E)-2-cyclopropyl-1-(1H-indazol-5-yl)) (E)-2-phenylvinyl)phenyl)acrylic acid; (E)-3-(4-((E)-2-(4-fluoro-2-methylphenyl)-1-(1H-indazol-5-yl)but-1-en-1-yl)phenyl)acrylic acid; (E)-3-(4-((E)-2-(2,6-difluorophenyl)-1-(1H-indazol-5-yl)but-1-en-1-yl)phenyl)acrylic acid; (E)-3-(4-((E)-2-(2,6-dichlorophenyl)-1-(1H-indazol-5-yl)but-1-en-1-yl)phenyl)acrylic acid; (E)-3-(4-((E)-4,4,4-trideuterium-1-(1H-indazol-5-yl)-2-phenylbut-1-en-1-yl)phenyl)acrylic acid; (E)-3-(4-((E)-4,4,4-trideuterium-1-(1H-indazol-5-yl)-2-phenylbut-1-en-1-yl)phenyl)acrylic acid; (E)-3-(4-((E)-2-(4-fluoro-3-methylphenyl)-1-(1H-indazol-5-yl)but-1-en-1-yl)phenyl)acrylic acid; (E)-3-(4-((E)-2-(5-fluoro-2-methylphenyl)-1-(1H-indazol-5-yl)but-1-en-1-yl)phenyl)acrylic acid; (E)-3-(4-((E)-2-(2,3-difluorophenyl)-1-(1H-indazol-5-yl)but-1-en-1-yl)phenyl)acrylic acid; (E)-3-(4-((E)-2-(2,5-difluorophenyl)-1-(1H-indazol-5-yl)but-1-en-1-yl)phenyl)acrylic acid;(E)-3-(4-((E)-2-(2-chloro-5-fluorophenyl)-1-(1H-indazol-5-yl)but-1-en-1-yl)phenyl)acrylic acid; (E)-3-(4-((E)-2-(2-chloro-6-methylphenyl)-1-(1H-indazol-5-yl)but-1-en-1-yl)phenyl)acrylic acid; (E)-3-(4-((E)-1-(7-chloro-1H-indazol-5-yl)-2-phenylbut-1-en-1-yl)phenyl)acrylic acid; (E)-3-(4-((E)-1-(4-methyl-1H-indazol-5-yl)-2-phenylbut-1-en-1-yl)phenyl)acrylic acid; (E)-3-(4-((E)-1-(4-methyl-1H-indazol-5-yl)-2-phenylbut-1-en-1-yl)phenyl)acrylic acid; (E)-3-(4-((E)-1-(7- (E)-3-(4-(E)-1-(6-methyl-1H-indazol-5-yl)-2-phenylbut-1-en-1-yl)phenyl)acrylic acid; (E)-3-(4-(E)-1-(3-methyl-1H-indazol-5-yl)-2-phenylbut-1-en-1-yl)phenyl)acrylic acid; (E)-3-(4-(E)-1-(3-chloro-1H-indazol-5-yl)-2-phenylbut-1-en-1-yl)phenyl)acrylic acid; (E)-3-(4-(E)-1-(3-chloro-1H-indazol-5-yl)-2-phenylbut-1-en-1-yl)phenyl)acrylic acid; (E)-3-(4-(E)-2-(4-chloro-2-methylphenyl)-1-(1H-indazol-5-yl)but-1-ene) -1-yl)phenyl)acrylic acid; (E)-3-(4-((E)-1-(1H-indazol-5-yl)-2-phenylprop-1-en-1-yl)phenyl)acrylic acid; (E)-3-(4-((E)-1-(1H-indazol-5-yl)-2-phenylpent-1-en-1-yl)phenyl)acrylic acid; (E)-3-(4-((E)-2-(3-cyanophenyl)-1-(1H-indazol-5-yl)but-1-en-1-yl)phenyl)acrylic acid; (E)-3-(4-((E)-2-(4-cyanophenyl)-1-(1H-indazol-5-yl)but-1-en-1-yl)phenyl)acrylic acid; (E)-3-(4-((E)-4-hydroxy-1-(1 H-Indazol-5-yl)-2-phenylbut-1-en-1-yl)phenyl)acrylic acid; (E)-3-(4-((E)-1-(1H-Indazol-5-yl)-4-methoxy-2-phenylbut-1-en-1-yl)phenyl)acrylic acid; (E)-3-(4-((Z)-1-(1H-Indazol-5-yl)-3-methoxy-2-phenylprop-1-en-1-yl)phenyl)acrylic acid; (E)-3-(4-((E)-1-(4-fluoro-1H-Indazol-5-yl)-2-phenylbut-1-en-1-yl)phenyl)acrylic acid; (E)-3-(4-((E)-1-(1H-Indole-5-yl)-2-phenylbut-1-en-1-yl)phenyl)acrylic acid;(E)-3-(4-((E)-1-(6-chloro-1H-indazol-5-yl)-2-phenylbut-1-en-1-yl)phenyl)acrylic acid; (E)-3-(4-((E)-1-(1H-indazol-5-yl)-4-methyl-2-phenylpent-1-en-1-yl)phenyl)acrylic acid; (E)-3-(4-((E)-1-(1H-benzo[d][1,2,3]triazol-5-yl)-2-(2-chloro-4-fluorophenyl)but-1-en-1-yl)phenyl)acrylic acid; (E)-3-(4-((E)-1-(4-chloro-1H-indazol-5-yl)-2-phenylbut-1-en-1-yl)phenyl)acrylic acid; (E)-3-(4-((E)-2-cyclo) pentyl-1-(1H-indazol-5-yl)-2-phenylvinyl)phenyl)acrylic acid; (E)-3-(4-((E)-2-cyclohexyl-1-(1H-indazol-5-yl)-2-phenylvinyl)phenyl)acrylic acid; (E)-3-(4-((E)-1-(1H-indazol-5-yl)-3-methyl-2-phenylbut-1-en-1-yl)phenyl)acrylic acid; (E)-3-(4-((E)-3-cyclopropyl-1-(1H-indazol-5-yl)-2-phenylprop-1-en-1-yl)phenyl)acrylic acid; (E)-3-(4-((E)-2-(2-chlorophenyl)-2-cyclopropyl-1-(1H-indazol-5-yl)vinyl)phenyl)acrylic acid; (E) -3-(4-((E)-1-(6-fluoro-1H-indazol-5-yl)-2-phenylbut-1-en-1-yl)phenyl)acrylic acid; (E)-3-(4-((E)-1-(1H-benzi[d]imidazol-5-yl)-2-phenylbut-1-en-1-yl)phenyl)acrylic acid; (E)-3-(4-((E)-1-(1H-indazol-5-yl)-2-phenylhex-1-en-1-yl)phenyl)acrylic acid; (E)-3-(4-((E)-3-cyclopentyl-1-(1H-indazol-5-yl)-2-phenylprop-1-en-1-yl)phenyl)acrylic acid; (E)-3-(4-((E)-2-(2-chloro-4-fluorophenyl)-1-(4-fluoro-1H-indazol-5-yl)-2-phenylprop-1-en-1-yl)phenyl)acrylic acid; (E)-3-(4-((E)-2-(2-chloro-4-fluorophenyl)-1-(4-fluoro-1H-indazol-5-yl)-2-phenylprop-1-en-1-yl)phenyl)acrylic acid; (E)-3-(4-((E)-1-(7-fluoro-1H-indola-5-yl)-2-phenylbut-1-en-1-yl)phenyl)acrylic acid; (E)-3-(4-((E)-1-(7-fluoro-1H-indola-5-yl)-2-phenylbut-1-en-1-yl)phenyl)acrylic acid; (E)-3-(4-((E)-2-(2-chloro-4-fluorophenyl)-1-(1H-indola-5-yl)-4-methylpent-1-en-1-yl)phenyl)acrylic acid; (E)-3-(4-((Z)-3,3-difluoro-1-(1H-indola-5-yl)-2-phenylprop-1-en-1-yl)phenyl)acrylic acid;(E)-3-(4-((E)-2-(2-chloro-4-fluorophenyl)-1-(7-fluoro-1H-indazol-5-yl)but-1-en-1-yl)phenyl)acrylic acid; (E)-3-(4-((E)-4-fluoro-1-(1H-indazol-5-yl)-2-phenylbut-1-en-1-yl)phenyl)acrylic acid; (E)-3-(4-((E)-4-chloro-2-(2-chloro-4-fluorophenyl)-1-(1H-indazol-5-yl)but-1-en-1-yl)phenyl)acrylic acid; (E)-3-(4-((Z)-3,3,3-trifluoro-1-(1H-indazol-5-yl)-2-phenylprop-1-en-1-yl)phenyl)acrylic acid; (E)-3 -(4-((E)-1-(4-fluoro-1H-indazol-5-yl)-2-(4-fluoro-2-methylphenyl)but-1-en-1-yl)phenyl)acrylic acid; (E)-3-(4-((E)-2-(4-chloro-2-methylphenyl)-1-(4-fluoro-1H-indazol-5-yl)but-1-en-1-yl)phenyl)acrylic acid; (E)-3-(4-((E)-2-cyclopropyl-1-(4-fluoro-1H-indazol-5-yl)-2-(4-fluoro-2-methylphenyl)vinyl)phenyl)acrylic acid; (E)-3-(4-((E)-2-(4-chloro-2-methylphenyl)-2-cyclopropyl-1-(4-fluoro-1H-indazol-5-yl)vinyl) (E)-3-(4-((E)-1-(4-chloro-1H-indazol-5-yl)-2-(2-chloro-4-fluorophenyl)but-1-en-1-yl)phenyl)acrylic acid; (E)-3-(4-((Z)-2-(2-chloro-4-fluorophenyl)-3,3-difluoro-1-(1H-indazol-5-yl)prop-1-en-1-yl)phenyl)acrylic acid; (E)-3-(4-((E)-2-cyclopropyl-1-(4-fluoro-1H-indazol-5-yl)-2-phenylvinyl)phenyl)acrylic acid; (E)-3-(4-((E)-4-chloro-1-(4-fluoro-1H-indazol-5-yl)-2-phenylbut-1-en-1-yl)phenyl) Acrylic acid; (E)-3-(4-((E)-4-chloro-2-(2-chloro-4-fluorophenyl)-1-(4-fluoro-1H-indazol-5-yl)but-1-en-1-yl)phenyl)acrylic acid; (E)-3-(4-((E)-4-fluoro-2-(4-fluorophenyl)-1-(1H-indazol-5-yl)but-1-en-1-yl)phenyl)acrylic acid; (E)-3-(4-((E)-4-fluoro-1-(4-fluoro-1H-indazol-5-yl)-2-phenylbut-1-en-1-yl)phenyl)acrylic acid; (E)-3-(4-((E)-1-(1H-indazol-5-yl)-5-methoxy-2-phenylpent-1-en-1-yl)phenyl)acrylic acid;(E)-3-(4-((E)-1-(1H-indazol-5-yl)-6-methoxy-2-phenylhex-1-en-1-yl)phenyl)acrylic acid; (E)-3-(4-((E)-2-(2-chloro-4-fluorophenyl)-1-(1H-indazol-5-yl)-3-methylbut-1-en-1-yl)phenyl)acrylic acid; (E)-3-(4-((E)-1-(1H-indazol-5-yl)-2-(3-(trifluoromethoxy)phenyl)but-1-en-1-yl)phenyl)acrylic acid; (E)-3-(4-((E)-2-cyclobutyl-1-(1H-indazol-5-yl)-2-phenylvinyl)phenyl)acrylic acid; (E)-3-(4-((E)-2-cyclobutyl-1-(1H-indazol-5-yl)-2-phenylvinyl)phenyl)acrylic acid; (E)-3-(4-( (E)-2-(2-chloro-4-fluorophenyl)-2-cyclobutyl-1-(1H-indazol-5-yl)vinyl)phenyl)acrylic acid; (E)-3-(4-((E)-1-(3-fluoro-1H-indazol-5-yl)-2-phenylbut-1-en-1-yl)phenyl)acrylic acid; (E)-3-(4-((E)-2-cyclobutyl-1-(3-fluoro-1H-indazol-5-yl)-2-phenylvinyl)phenyl)acrylic acid; (E)-3-(4-((E)-2-(2-chloro-4-fluorophenyl)-1-(3-fluoro-1H-indazol-5-yl)but-1-en-1-yl)phenyl)acrylic acid; (E)-3-(4-((E)-2-(2-chloro-4-fluorophenyl)-1-(3-fluoro-1H-indazol-5-yl)but-1-en-1-yl)phenyl)acrylic acid; (E)-3-(4-((E)-2-(2-chloro-4-fluoro) (E)-2-cyclobutyl-1-(3-fluoro-1H-indazol-5-yl)vinyl)phenyl)acrylic acid; (E)-3-(4-((E)-2-(4-fluorophenyl)-1-(1H-indazol-5-yl)but-1-en-1-yl)phenyl)ethyl acrylate; (E)-3-(4-((E)-1-(1H-indazol-5-yl)-2-(2-methoxyphenyl)but-1-en-1-yl)phenyl)ethyl acrylate; (E)-3-(4-((E)-1-(1H-indazol-5-yl)-2-(4-methoxyphenyl)but-1-en-1-yl)phenyl)ethyl acrylate; (E)-3-(4-((E)-1-(1H-indazol-5-yl)-2-(4-methoxyphenyl)but-1-en-1-yl)phenyl)ethyl acrylate; (E)-3-(4-((E)-1-(1H-indazol-5-yl)-2-(4-methoxyphenyl)but-1-en-1-yl)phenyl)ethyl acrylate; (E)-3-(4-((Z)-1-(1H-indazol-5-yl)-2-phenylbut-1-en-1-yl)-3-methylphenyl)acrylic acid; (E)-3-(4-((E)-1-(1H-indazol-5-yl)-2-phenylbut-1-en-1-yl)-2-methylphenyl)acrylic acid; (E)-3-(4-((Z)-1-(1H-indazol-5-yl)-2-phenylbut-1-en-1-yl)-2-chlorophenyl)acrylic acid; (Z)-3-(4-((E)-1-(1H-indazol-5-yl)-2-phenylbut-1-en-1-yl)phenyl)-2-fluoroacrylic acid;(Z)-3-(4-((E)-1-(1H-indazol-5-yl)-2-phenylbut-1-en-1-yl)phenyl)-2-chloroacrylic acid; (E)-3-(4-((Z)-1-(1H-indazol-5-yl)-2-phenylbut-1-en-1-yl)-3-fluorophenyl)acrylic acid; (E)-3-(4-((Z)-1-(1H-indazol-5-yl)-2-phenylbut-1-en-1-yl)-2-fluorophenyl)acrylic acid; (E)-3-(4-((Z)-1-(1H-indazol-5-yl)-2-phenylbut-1-en-1-yl)-2-(trifluoromethyl)phenyl)acrylic acid; (E)-3-(4-((Z)-1-(1H-indazol-5-yl)-2-phenyl)-2-chloroacrylic acid; (E)-3-(4-((Z)-1-(1H-indazol-5-yl)-2-phenyl)-2-chloroacrylic acid; (E)-3-(4-((Z)-1-(1H-indazol-5-yl)-2-phenylbut-1-en-1-yl)-2-methoxyphenyl)acrylic acid; (E)-3-(4-((E)-2-(2-chloro-4-fluorophenyl)-1-(1H-indazol-5-yl)but-1-en-1-yl)phenyl)acrylate ethyl hydrochloride; (E)-3-(4-((E)-2-(2-chloro-4-fluorophenyl)-1-(1H-indazol-5-yl)but-1-en-1-yl)phenyl)acrylic acid; (E)-3-(4-((E)-2-(2-chloro-4-fluorophenyl)-1-(1H-indazol-5-yl)but-1-en-1-yl)phenyl)acrylic acid; (E)-3-(4-((E)-2-(2,4-dichlorophenyl)-1-(1H-indazol-5-yl)but-1-en-1-yl) Ethyl phenyl acrylate; (E)-3-(4-((E)-2-(2,4-dichlorophenyl)-1-(1H-indazol-5-yl)but-1-en-1-yl)phenyl)acrylic acid; s(E)-3-(4-((E)-2-(4-chloro-2-(trifluoromethyl)phenyl)-1-(1H-indazol-5-yl)but-1-en-1-yl)phenyl)acrylic acid; (E)-3-(4-((E)-2-(2-chloro-4-fluorophenyl)-2-cyclopropyl-1-(1H-indazol-5-yl)vinyl)phenyl)acrylic acid; (E)-3-(4-((E)-2-(4-fluoro-2-(trifluoromethyl)phenyl)-1-(1H-indazol-5-yl)but-1-en-1-yl)phenyl)propane Acrylic acid; (E)-3-(4-(1-(4-fluoro-1H-indazol-5-yl)-2-(4-fluoro-2-(trifluoromethyl)phenyl)butyl)phenyl)acrylic acid; (E)-3-(4-((E)-2-(2,4-dichlorophenyl)-1-(4-fluoro-1H-indazol-5-yl)but-1-en-1-yl)phenyl)acrylic acid; (E)-3-(4-((E)-2-(4-chloro-2-(trifluoromethyl)phenyl)-1-(4-fluoro-1H-indazol-5-yl)but-1-en-1-yl)phenyl)acrylic acid; (E)-3-(4-((E)-2-(2-chloro-4-fluorophenyl)-4-fluoro-1-(1H-indazol-5-yl)but-1-en-1-yl)phenyl)acrylic acid;(E)-3-(4-((E)-2-(2-chloro-4-methoxyphenyl)-1-(1H-indazol-5-yl)but-1-en-1-yl)phenyl)acrylic acid; (E)-3-(4-((E)-2-(2,4-dichlorophenyl)-4-fluoro-1-(4-fluoro-1H-indazol-5-yl)but-1-en-1-yl)phenyl)acrylic acid; (E)-3-(4-((E)-2-cyclopropyl-2-(2,4-dichlorophenyl)-1-(4-fluoro-1H-indazol-5-yl)vinyl)phenyl)acrylic acid; (E)-3-(4-((E)-2-(2-chloro-4-fluorophenyl)-2-cyclopropyl-1-(4-fluoro-1H-indazol-5-yl)vinyl)phenyl)propylene) Acid; (E)-3-(4-((E)-2-cyclopropyl-2-(2,4-dichlorophenyl)-1-(1H-indazol-5-yl)vinyl)phenyl)acrylic acid; (E)-3-(4-((E)-2-(4-chloro-2-methylphenyl)-2-cyclopropyl-1-(1H-indazol-5-yl)vinyl)phenyl)acrylic acid; (E)-3-(4-((E)-1-(1H-indazol-5-yl)-2-(2-methyl-5-(methylsulfonyl)phenyl)but-1-en-1-yl)phenyl)acrylic acid; (E)-3-(4-((E)-1-(1H-indazol-5-yl)-2-(4-methoxy-2-methylphenyl)but-1-en-1-yl)phenyl)acrylic acid; (E) -3-(4-((E)-2-(2-fluoro-4-methoxyphenyl)-1-(1H-indazol-5-yl)but-1-en-1-yl)phenyl)acrylic acid; (E)-3-(4-((E)-2-(2-chloro-5-methoxyphenyl)-1-(1H-indazol-5-yl)but-1-en-1-yl)phenyl)acrylic acid; (E)-3-(4-((E)-2-(2-fluoro-4-(methylsulfonyl)phenyl)-1-(1H-indazol-5-yl)but-1-en-1-yl)phenyl)acrylic acid; (E)-3-(4-((E)-2-(2,4-dichlorophenyl)-3,3,4,4,4-pentadeuter-1-(1H-indazol-5-yl)but-1-en-1-yl)phenyl)acrylic acid; (E)-3-(4-((E)-2-(2,4-dichlorophenyl)-3,3,4,4,4-pentadeuter-1-(1H-indazol-5-yl)but-1-en-1-yl)phenyl) (E)-3-(4-((E)-1-(1H-indazole-5-yl)-2-(3-(methylsulfonyl)phenyl)but-1-en-1-yl)phenyl)acrylic acid; (E)-3-(4-((E)-2-(2,4-dichlorophenyl)-1-(7-fluoro-1H-indazole-5-yl)but-1-en-1-yl)phenyl)acrylic acid; (E)-3-(4-((E)-2-(2-chloro-3-methoxyphenyl)-1-(1H-indazole-5-yl)but-1-en-1-yl)phenyl)acrylic acid; (E)-3-(4-((E)-2-(2,4-dichlorophenyl)-1-(7-fluoro-1H-indole-5-yl)but-1-en-1-yl)phenyl)acrylic acid;(E)-3-(4-((E)-2-(2-chloro-4-fluorophenyl)-1-(7-fluoro-1H-indole-5-yl)but-1-en-1-yl)phenyl)acrylic acid; (E)-3-(4-((E)-2-(2-chloro-4-fluorophenyl)-3,3,4,4,4-pentadeuter-1-(1H-indazol-5-yl)but-1-en-1-yl)phenyl)acrylic acid; (E)-3-(4-((E)-2-(4-chloro-2-cyanophenyl)-1-(1H-indazol-5-yl)but-1-en-1-yl)phenyl)acrylic acid; (E)-3-(4-((E)-2-(2-cyano-4-fluorophenyl)-1-(1H-indazol-5-yl)but-1-)phenyl)acrylic acid; (E)-3-(4-((E)-2-(2-cyano-4-fluorophenyl)-1-(1H-indazol-5-yl)but-1-)... (E)-3-(4-((E)-2-(2-cyano-4-(trifluoromethyl)phenyl)-1-(1H-indazol-5-yl)but-1-en-1-yl)phenyl)acrylic acid; (E)-3-(4-((E)-2-(2-chloro-4-cyanophenyl)-1-(1H-indazol-5-yl)but-1-en-1-yl)phenyl)acrylic acid; (E)-3-(4-((E)-2-(3-cyano-2-methylphenyl)-1-(1H-indazol-5-yl)but-1-en-1-yl)phenyl)acrylic acid; (E)-3-(4-((E)-2-(4-cyano-2-methylphenyl)-1-(1H-indazol-5-yl)but-1-en-1-yl)phenyl)acrylic acid; (E)-3-(4-((E)-2-(4-cyano-2-methylphenyl)-1-(1H-indazol-5-yl)but-1-en-1-yl)phenyl)acrylic acid; (E)-3-(4-(E)-2-(5-cyano-2-methylphenyl)-1-(1H-indazol-5-yl)but-1-en-1-yl)phenyl)acrylic acid; (E)-3-(4-(E)-2-(2-cyano-4-methoxyphenyl)-1-(1H-indazol-5-yl)but-1-en-1-yl)phenyl)acrylic acid; (E)-3-(4-(E)-2-(3-hydroxyphenyl)-1-(1H-indazol-5-yl)but-1-en-1-yl)phenyl)acrylic acid; (E)-3-(4-(E)-2-(2-hydroxyphenyl)-1-(1H-indazol-5-yl)but-1-en-1-yl)phenyl)acrylic acid; (E)-3-(4-(E)-2-(2-hydroxyphenyl)-1-(1H-indazol-5-yl)but-1- (E)-3-(4-((E)-2-(4-hydroxyphenyl)-1-(1H-indazol-5-yl)but-1-en-1-yl)phenyl)acrylic acid; (E)-3-(4-(1-(1H-indazol-5-yl)-2-phenylbut-1-en-1-yl)phenyl)propionic acid; (E)-3-(4-((E)-1-(1H-indazol-5-yl)-2-(4-(2-methoxyethoxy)phenyl)but-1-en-1-yl)phenyl)acrylic acid; (E)-3-(4-((E)-1-(1H-indazol-5-yl)-2-(4-(3-methoxypropoxy)phenyl)but-1-en-1-yl)phenyl)acrylic acid;(E)-3-(4-((E)-1-(1H-indazol-5-yl)-2-(3-(2-methoxyethoxy)phenyl)but-1-en-1-yl)phenyl)acrylic acid; (E)-3-(4-((E)-1-(1H-indazol-5-yl)-2-(3-(3-methoxypropoxy)phenyl)but-1-en-1-yl)phenyl)acrylic acid; (E)-3-(4-((E)-2-(3-(cyclohexyloxy)phenyl)-1-(4-fluoro-1H-indazol-5-yl)but-1-en-1-yl)phenyl)acrylic acid; (E)-3-(4-((E)-2-(3-butoxyphenyl)-1-(1H-indazol-5-yl)) (E)-3-(4-((E)-1-(1H-indazol-5-yl)-2-(3-(pentoxy)phenyl)but-1-en-1-yl)phenyl)acrylic acid; (E)-3-(4-((E)-2-(3-(hexyloxy)phenyl)-1-(1H-indazol-5-yl)but-1-en-1-yl)phenyl)acrylic acid; (E)-3-(4-((E)-2-(4-butoxyphenyl)-1-(1H-indazol-5-yl)but-1-en-1-yl)phenyl)acrylic acid; (E)-3-(4-((E)-1-(1H-indazol-5-yl)-2-(4-(pentoxy)phenyl))acrylic acid; (E)-3-(4-((E)-2-(4-(hexyloxy)phenyl)-1-(1H-indazol-5-yl)but-1-en-1-yl)phenyl)acrylic acid; (E)-3-(4-((E)-2-(4-(2-hydroxyethoxy)phenyl)-1-(1H-indazol-5-yl)but-1-en-1-yl)phenyl)acrylic acid; (E)-3-(4-((E)-1-(1H-indazol-5-yl)-2-(2-(methylsulfonyl)phenyl)but-1-en-1-yl)phenyl)acrylic acid; (E)-3-(4-((E)-2-(2-chlorophenyl)-1-(1-methyl- 1H-indazole-5-yl)but-1-en-1-yl)phenyl)acrylic acid; (E)-3-(4-((E)-2-cyclobutyl-1-(1-methyl-1H-indazole-5-yl)-2-phenylvinyl)phenyl)acrylic acid; (E)-3-(4-((E)-2-(2-chloro-4-fluorophenyl)-1-(1-methyl-1H-indazole-5-yl)but-1-en-1-yl)phenyl)acrylic acid; (E)-3-(4-((E)-2-(2-chloro-4-fluorophenyl)-1-(1-(difluoromethyl)-1H-indazole-5-yl)but-1-en-1-yl)phenyl)acrylic acid; or pharmaceutical salts thereof or their N-oxides or combinations thereof.

[0363] In one case, endocrine therapy includes brilanestrant (GDC-0810) having the following structure:

[0364]

[0365] Or its medicinal salt.

[0366] On the other hand, endocrine therapy includes compounds listed in USPN 9,499,538 or 9,586,952, each of which is incorporated herein by reference in its entirety for all purposes.

[0367] On the other hand, endocrine therapy includes compounds listed in USPN 7,612,114 or 8,399,520, each of which is incorporated herein by reference in its entirety for all purposes. In one instance, endocrine therapy includes ilextron (RAD1901):

[0368]

[0369] Or its medicinal salt.

[0370] On the other hand, endocrine therapy includes compounds listed in International Patent Application No. WO2018077260, such as in Table 2 therein, the entire contents of which are incorporated herein by reference for all purposes. In one instance, endocrine therapy includes LX-039. In another instance, endocrine therapy includes compounds having the following structure:

[0371]

[0372] Or its medicinal salt.

[0373] On the other hand, endocrine therapy includes compounds listed in International Patent Applications Nos. WO2017136688, WO2017162206, WO2017140669, WO2017216280, WO2017216279, WO2018091153, WO2018019793, and WO2018077630, each of which is incorporated herein by reference in its entirety for all purposes.

[0374] In another case, endocrine therapy includes AZ9496 having the following structure:

[0375]

[0376] Or its medicinal salt.

[0377] In another aspect, endocrine therapy includes compounds listed in U.S. Patent Application No. 20150284357, the entire contents of which are incorporated herein by reference for all purposes. In another aspect, endocrine therapy includes compounds listed in USPN 9,475,791, the entire contents of which are incorporated herein by reference for all purposes. In yet another aspect, endocrine therapy includes compounds listed in International Patent Applications Nos. WO2018081168 or WO2018129387, each of which is incorporated herein by reference for all purposes. In one aspect, endocrine therapy includes compounds having the following formula:

[0378]

[0379] Or stereoisomers or their medicinal salts.

[0380] On the other hand, endocrine therapy includes compounds listed in USPN 8,703,810, such as in the compound table provided therein, the full text of which is incorporated herein by reference for all purposes.

[0381] On one hand, endocrine therapy includes compounds having formula (2):

[0382]

[0383] Equation (2)

[0384] Or its medicinal salt, wherein:

[0385] R 1 It is H, F, C1-C4 alkyl or C1-C4 fluoroalkyl;

[0386] R 3 It is H, halogen, C1-C4 alkyl, C3-C6 cycloalkyl or C1-C4 fluoroalkyl;

[0387] R 4 Each is independently selected from H, halogen, -CN, -OH, -OR 9 、-SR 9 、-S(O)R 10 、-S(O)2R 10 -C(O)R 10 -C(O)OH, -C(O)OR 10 -C(O)NHR 10 -C(O)N(R) 10 )2. Substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C1-C6 fluoroalkyl, substituted or unsubstituted C1-C6 fluoroalkoxy, substituted or unsubstituted C1-C6 alkoxy and substituted or unsubstituted C1-C6 heteroalkyl;

[0388] R 5 Each is independently selected from H, halogen, -CN, -OH, -OR 9 、-SR 9 、-S(O)R 10 、-S(O)2R 10 Substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C1-C6 fluoroalkyl, substituted or unsubstituted C1-C6 fluoroalkoxy, substituted or unsubstituted C1-C6 alkoxy, and substituted or unsubstituted C1-C6 heteroalkyl;

[0389] R 6 Each is independently selected from H, halogen, -CN, -OH, -OR 9 、-SR 9 、-S(O)R 10 、-S(O)2R 10 Substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C1-C6 fluoroalkyl, substituted or unsubstituted C1-C6 fluoroalkoxy, substituted or unsubstituted C1-C6 alkoxy, and substituted or unsubstituted C1-C6 heteroalkyl;

[0390] It is pyrrolidinyl or azahexacyclic butyl;

[0391] R 7 It is an H or C1-C4 alkyl group;

[0392] R 8 Each is independently selected from F, Cl, -CN, -OH, -OR 9 、-SR 9 、-S(O)R 10 、-S(O)2R 10 Substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C1-C6 fluoroalkyl, substituted or unsubstituted C1-C6 fluoroalkoxy, substituted or unsubstituted C1-C6 alkoxy, and substituted or unsubstituted C1-C6 heteroalkyl;

[0393] Or 1 R 8 With R 1 And R 8 Connect to R 1 Intermediate atoms together form 5-, 6-, or 7-membered rings;

[0394] R 9 Each is independently selected from H, -C(O)R 10 -C(O)OR 10 -C(O)NHR 10Substituted or unsubstituted C1-C6 alkyl groups, substituted or unsubstituted C1-C6 heteroalkyl groups, substituted or unsubstituted C1-C6 fluoroalkyl groups, substituted or unsubstituted C3-C6 alkyl groups. 10 Cycloalkyl, substituted or unsubstituted C2-C 10 Heterocyclic alkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -C1-C2 alkylene- (substituted or unsubstituted C3-C 10 cycloalkyl), -C1-C2 alkylene- (substituted or unsubstituted C2-C 10 Heterocyclic alkyl), -C1-C2 alkylene- (substituted or unsubstituted aryl), and -C1-C2 alkylene- (substituted or unsubstituted heteroaryl); or

[0395] R 10 Each is independently selected from substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C1-C6 heteroalkyl, substituted or unsubstituted C1-C6 fluoroalkyl, substituted or unsubstituted C3-C 10 Cycloalkyl, substituted or unsubstituted C2-C 10 Heterocyclic alkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl, -C1-C2 alkylene- (substituted or unsubstituted C3-C 10 cycloalkyl), -C1-C2 alkylene- (substituted or unsubstituted C2-C 10 Heterocyclic alkyl), -C1-C2 alkylene- (substituted or unsubstituted aryl), and -C1-C2 alkylene- (substituted or unsubstituted heteroaryl);

[0396] Y is -O-, -S-, or -NR 11 -;R 11 It is H, -C(O)R 10 substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C1-C6 fluoroalkyl, or substituted or unsubstituted C1-C6 heteroalkyl;

[0397] X is -O-, -S-, -CH2-, -NH- or -(C1-C6 alkyl)-;

[0398] m is 0, 1, 2, 3 or 4;

[0399] n is 0, 1, 2, or 3;

[0400] p is 0, 1, 2, 3, or 4; and

[0401] t can be 1, 2, 3 or 4.

[0402] In one case, the compound of formula (2) is a compound in which R ... 1 It is H or C1-C4 alkyl; R 3It is a C1-C4 alkyl or C1-C4 fluoroalkyl; R 4 Each is independently selected from H, halogen, -CN, -OH, -OR 9 -SR 9 、-S(=O)R 10 -S(=O)2R 10 C1-C4 alkyl, C1-C4 fluoroalkyl, C1-C4 fluoroalkoxy, C1-C4 alkoxy, and C1-C4 heteroalkyl; R 5 Each is independently selected from H, F, Cl, -OH, -CH3, -CF3, -OCF3, and -OCH3; R 6 Each is independently selected from H, F, Cl, -OH, -CH3, -CF3, -OCF3, and -OCH3; R 7 It is H; R 8Each is independently selected from H, F, Cl, -OH, C1-C4 alkyl, C1-C4 fluoroalkyl, C1-C4 fluoroalkoxy, C1-C4 alkoxy, and C1-C4 heteroalkyl; Y is -O- or -S-; X is -O-, -S-, -CH2-, -NH-, or -N(CH3)-; and p is 0, 1, or 2. On the other hand, endocrine therapy includes compounds having the following formula: 3-(3-hydroxyphenyl)-4-methyl-2-(4-((S)-2-((R)-3-methylpyrrolidin-1-yl)propoxy)phenyl)-2H-benzopyran-6-ol; (S)-3-(3-hydroxyphenyl)-4-methyl-2-(4-((S)-2-((R)-3-methylpyrrolidin-1-yl)propoxy)phenyl)-2H-benzopyran-6-ol; (R)-3-(3-hydroxyphenyl)-4-methyl-2-(4-((S)-2-((R)-3-methylpyrrolidin-1-yl)propoxy)phenyl)-2H-benzopyran-6-ol. H-Benzopyran-6-ol; 3-(3-hydroxyphenyl)-4-methyl-2-(4-(2-((R)-3-methylpyrrolidin-1-yl)ethoxy)phenyl)-2H-benzoopyran-6-ol; 3-(3-hydroxyphenyl)-4-methyl-2-(4-((R)-2-((R)-3-methylpyrrolidin-1-yl)propoxy)phenyl)-2H-benzoopyran-6-ol; 3-(3-hydroxyphenyl)-4-methyl-2-(4-(2-((S)-3-methylpyrrolidin-1-yl)ethoxy)phenyl)-2H-benzoopyran-6-ol; 3-(3-hydroxyphenyl)-4-methyl- 2-(4-((S)-2-((S)-3-methylpyrrolidin-1-yl)propoxy)phenyl)-2H-benzopyran-6-ol; 3-(3-hydroxyphenyl)-4-methyl-2-(4-((R)-2-((S)-3-methylpyrrolidin-1-yl)propoxy)phenyl)-2H-benzopyran-6-ol; 2-(4-((S)-2-(3,3-dimethylpyrrolidin-1-yl)propoxy)phenyl)-3-(3-hydroxyphenyl)-4-methyl-2H-benzopyran-6-ol; 2-(4-(2-(3,3-dimethylpyrrolidin-1-yl)ethoxy)phenyl)-3-(3 3-(3-hydroxyphenyl)-4-methyl-2H-benzopyran-6-ol; 3-(3-hydroxyphenyl)-4-methyl-2-(4-(2-((R)-2-methylpyrrolidin-1-yl)ethoxy)phenyl)-2H-benzopyran-6-ol; 3-(3-hydroxyphenyl)-4-methyl-2-(4-((S)-2-((R)-2-methylpyrrolidin-1-yl)propoxy)phenyl)-2H-benzopyran-6-ol; 3-(3-hydroxyphenyl)-4-methyl-2-(4-((S)-2-((S)-2-methylpyrrolidin-1-yl)propoxy)phenyl)-2H-benzopyran-6-ol;3-(3-hydroxyphenyl)-4-methyl-2-(4-((S)-2-((R)-3-methylpyrrolidin-1-yl)propoxy)phenyl)-2H-benzopyran-7-ol; 3-(4-hydroxyphenyl)-4-methyl-2-(4-((S)-2-((R)-3-methylpyrrolidin-1-yl)propoxy)phenyl)-2H-benzopyran-7-ol; 4-methyl-2-(4-((S)-2-((R)-3-methylpyrrolidin-1-yl)propoxy)phenyl)-3-phenyl-2H-benzopyran-6-ol; 3-(4-fluorophenyl)-4-methyl-2-(4-((S)-2-((R)-3-methylpyrrolidin-1-yl)propoxy)phenyl)-2H-benzopyran-6-ol (S)-3-(4-fluorophenyl)-4-methyl-2-(4-((S)-2-((R)-3-methylpyrrolidin-1-yl)propoxy)phenyl)-2H-benzopyrran-6-ol; (R)-3-(4-fluorophenyl)-4-methyl-2-(4-((S)-2-((R)-3-methylpyrrolidin-1-yl)propoxy)phenyl)-2H-benzopyrran-6-ol; 3-(4-hydroxyphenyl)-4-methyl-2-(4-((S)-2-((R)-3-methylpyrrolidin-1-yl)propoxy)phenyl)-2H-benzopyrran-6-ol; 3-(3-fluorophenyl)-4-methyl -2-(4-((S)-2-((R)-3-methylpyrrolidin-1-yl)propoxy)phenyl)-2H-benzopyran-6-ol; 3-(3-fluoro-4-hydroxyphenyl)-4-methyl-2-(4-((S)-2-((R)-3-methylpyrrolidin-1-yl)propoxy)phenyl)-2H-benzopyran-6-ol; 2-(2-fluoro-4-((S)-2-((R)-3-methylpyrrolidin-1-yl)propoxy)phenyl)-3-(3-hydroxyphenyl)-4-methyl-2H-benzopyran-6-ol; 3-(3-hydroxy-4-methylphenyl)-4-methyl-2-(4-((S)-2-((R)-3-methylpyrrolidin-1-yl)propoxy)phenyl)-3-(3-hydroxyphenyl)-4-methyl-2H-benzopyran-6-ol; 3-(3-hydroxy-4-methylphenyl)-4-methyl-2-(4-((S)-2-((R)-3-methylpyrrolidin- 1-yl)propoxy)phenyl)-2H-benzopyran-6-ol; 3-(3-hydroxy-2-methylphenyl)-4-methyl-2-(4-((S)-2-((R)-3-methylpyrrolid-1-yl)propoxy)phenyl)-2H-benzopyran-6-ol; 3-(4-hydroxy-2-methylphenyl)-4-methyl-2-(4-((S)-2-((R)-3-methylpyrrolid-1-yl)propoxy)phenyl)-2H-benzopyran-6-ol; 3-(4-hydroxy-3-methylphenyl)-4-methyl-2-(4-((S)-2-((R)-3-methylpyrrolid-1-yl)propoxy)phenyl)-2H-benzopyran-6-ol;3-(3-fluoro-5-hydroxyphenyl)-4-methyl-2-(4-((S)-2-((R)-3-methylpyrrolidin-1-yl)propoxy)phenyl)-2H-benzopyran-6-ol; 3-(4-chlorophenyl)-4-methyl-2-(4-((S)-2-((R)-3-methylpyrrolidin-1-yl)propoxy)phenyl)-2H-benzopyran-6-ol; 3-(2-fluoro-4-hydroxyphenyl)-4-methyl-2-(4-((S)-2-((R)-3-methylpyrrolidin-1-yl)propoxy)phenyl)-2H-benzopyran-6-ol; 3-(3,4-difluorophenyl)-4-methyl-2-(4-((S)-2-((R)-3)-3 -Methylpyrrolidone-1-yl)propoxy)phenyl)-2H-benzopyran-6-ol; 3-(3,5-difluoro-4-hydroxyphenyl)-4-methyl-2-(4-((S)-2-((R)-3-methylpyrrolidone-1-yl)propoxy)phenyl)-2H-benzopyran-6-ol; 3-(2,4-difluoro-3-hydroxyphenyl)-4-methyl-2-(4-((S)-2-((R)-3-methylpyrrolidone-1-yl)propoxy)phenyl)-2H-benzopyran-6-ol; 3-(3,4-difluoro-5-hydroxyphenyl)-4-methyl-2-(4-((S)-2-((R)-3-methylpyrrolidone-1-yl)propoxy)phenyl)-2H- Benzopyran-6-ol; 3-(2-chloro-4-fluorophenyl)-4-methyl-2-(4-((S)-2-((R)-3-methylpyrrolidin-1-yl)propoxy)phenyl)-2H-benzopyran-6-ol; 3-(2,4-difluorophenyl)-4-methyl-2-(4-((S)-2-((R)-3-methylpyrrolidin-1-yl)propoxy)phenyl)-2H-benzopyran-6-ol; 3-(4-bromophenyl)-4-methyl-2-(4-((S)-2-((R)-3-methylpyrrolidin-1-yl)propoxy)phenyl)-2H-benzopyran-6-ol; 4-methyl-2-(4-((S)-2-((R)-3-methylpyrrolidin-1-yl)propoxy)phenyl) 1-yl)propoxy)phenyl)-3-(o-tolyl)-2H-benzopyran-6-ol; 3-(4-fluoro-3-hydroxyphenyl)-4-methyl-2-(4-((S)-2-((R)-3-methylpyrrolidin-1-yl)propoxy)phenyl)-2H-benzopyran-6-ol; 3-(4-ethynylphenyl)-4-methyl-2-(4-((S)-2-((R)-3-methylpyrrolidin-1-yl)propoxy)phenyl)-2H-benzopyran-6-ol; 4-methyl-2-(4-((S)-2-((R)-3-methylpyrrolidin-1-yl)propoxy)phenyl)-3-(4-(methanesulfonyl)phenyl)-2H-benzopyran-6-ol;3-(2-fluoro-3-hydroxyphenyl)-4-methyl-2-(4-((S)-2-((R)-3-methylpyrrolidin-1-yl)propoxy)phenyl)-2H-benzopyran-6-ol; 5-fluoro-3-(3-hydroxyphenyl)-4-methyl-2-(4-((S)-2-((R)-3-methylpyrrolidin-1-yl)propoxy)phenyl)-2H-benzopyran-6-ol; 3-(2-fluoro-5-hydroxyphenyl)-4-methyl- 2-(4-((S)-2-((R)-3-methylpyrrolidin-1-yl)propoxy)phenyl)-2H-benzopyran-6-ol; 3-(4-fluorophenyl)-4-methyl-2-(4-((S)-2-((R)-2-methylpyrrolidin-1-yl)propoxy)phenyl)-2H-benzopyran-6-ol; 2-(4-((S)-2-((R)-3-fluoropyrrolidin-1-yl)propoxy)phenyl)-3-(3-hydroxyphenyl) 3-(4-hydroxyphenyl)-2-(4-((S)-2-((R)-3-methylpyrrolidin-1-yl)propoxy)phenyl)-4-(trifluoromethyl)-2H-benzopyrran-6-ol; 3-(3-hydroxyphenyl)-2-(4-((S)-2-((R)-3-methylpyrrolidin-1-yl)propoxy)phenyl)-4-(trifluoromethyl)-2H-benzopyrran-6-ol; 3 -(3-hydroxy-4-(trifluoromethyl)phenyl)-4-methyl-2-(4-((S)-2-((R)-3-methylpyrrolidin-1-yl)propoxy)phenyl)-2H-benzopyran-6-ol; 3-(4-hydroxy-3-(trifluoromethyl)phenyl)-4-methyl-2-(4-((S)-2-((R)-3-methylpyrrolidin-1-yl)propoxy)phenyl)-2H-benzopyran-6-ol; or a pharmaceutical salt thereof or a combination thereof.

[0403] In one case, endocrine therapy includes GDC-0927 (SRN-0927) having the following structure:

[0404]

[0405] Or its medicinal salt.

[0406] On the other hand, endocrine therapy includes compounds listed in USPN 9,980,947, such as in Table 1 therein, the entire text of which is incorporated herein by reference for all purposes.

[0407] On one hand, endocrine therapy includes compounds of formula (3):

[0408]

[0409] Or stereoisomers, tautomers, or their medicinal salts, wherein:

[0410] Y 1 It is CR b Or N;

[0411] Y 2 It is -(CH2)-, -(CH2CH2)-, or NR. a ;

[0412] Y 3 It is NR a or C(R) b )2;

[0413] Where Y 1 Y 2 and Y 3 One of them is N or NR a ;

[0414] R a It is H, C1-C6 alkyl, C2-C8 alkenyl, propargyl, C3-C6 cycloalkyl or C3-C6 heterocyclic group, which is optionally substituted by one or more groups independently selected from the group consisting of: F, Cl, Br, I, CN, OH, OCH3 and SO2CH3;

[0415] R b It is H, -O (C1-C3 alkyl), C1-C6 alkyl, C2-C8 alkenyl, propargyl, -(C1-C6 alkyldiyl)-(C3-C6 cycloalkyl), C3-C6 cycloalkyl or C3-C6 heterocyclic, optionally substituted by one or more groups independently selected from the group consisting of: F, Cl, Br, I, CN, -CH2F, -CHF2, -CF3, -CH2CF3, -CH2CHF2, -CH2CH2F, OH, OCH3 and SO2CH3;

[0416] R c It is H, C1-C6 alkyl, allyl or propyne, which is optionally substituted by one or more groups independently selected from the group consisting of: F, Cl, Br, I, CN, OH, OCH3 and SO2CH3;

[0417] Z 1 It is CR a R b C(O) or bond;

[0418] Cy is C6-C 20 Aryldiyl, C3-C 12 Carbocyclic dimethyl, C2-C 20 Heterocyclic dimethyl or C1-C 20 heteroaryldimethyl;

[0419] Z2 It is O, S, NR a C1-C6 alkyl diene, C1-C6 fluoroalkyl diene, O-(C1-C6 alkyl diene), O-(C1-C6 fluoroalkyl diene), C(O) or bond;

[0420] R 1 、R 2 、R 3 and R 4 Independently H, F, Cl, Br, I, -CN, -CH3, -CH2CH3, -CH(CH3)2, -CH2CH(CH3)2, -CH2OH, -CH2OCH3, -CH2CH2OH, -C(CH3 )2OH, -CH(OH)CH(CH3)2, -C(CH3)2CH2OH, -CH2CH2SO2CH3, -CH2OP(O)(OH)2, -CH2F, -CHF2, -CH2NH2, -CH2N HSO2CH3, -CH2NHCH3, -CH2N(CH3)2, -CF3, -CH2CF3, -CH2CHF2, -CH(CH3)CN, -C(CH3)2CN, -CH2CN, -CO2H, - COCH3, -CO2CH3, -CO2C(CH3)3, -COCH(OH)CH3, -CONH2, -CONHCH3, -CONHCH2CH3, -CONHCH(CH3)2, -CON(CH3 )2, -C(CH3)2CONH2, -NH2, -NHCH3, -N(CH3)2, -NHCOCH3, -N(CH3)COCH3, -NHS(O)2CH3, -N(CH3)C(CH3)2CO NH2, -N(CH3)CH2CH2S(O)2CH3, -NO2, =O, -OH, -OCH3, -OCH2CH3, -OCH2CH2OCH3, -OCH2CH2OH, -OCH2CH2N(CH 3) 2, -OP(O)(OH)2, -S(O)2N(CH3)2, -SCH3, -S(O)2CH3, -S(O)3H, cyclopropyl, cyclopropylamide, cyclobutyl, oxetane, azirone, 1-methylazirone-3-yl)oxy, N-methyl-N-oxetane-3-ylamino, azirone-1-ylmethyl, benzyloxyphenyl, pyrrolidine-1-yl, pyrrolidine-1-yl-methyl ketone, piperazine-1-yl, morpholinylmethyl, morpholinyl-methyl ketone or morpholino;

[0421] R 5It is H, C1-C9 alkyl, C3-C9 cycloalkyl, C3-C9 heterocyclic, C6-C9 aryl, C6-C9 heteroaryl, -(C1-C6 alkyldiyl)-(C3-C9 cycloalkyl), -(C1-C6 alkyldiyl)-(C3-C9 heterocyclic), C(O)R b 、C(O)NR a SO2R a or SO2NR a It is optionally influenced by halogen, CN, OR a 、N(R a 2. C1-C9 alkyl, C3-C9 cycloalkyl, C3-C9 heterocyclic, C6-C9 aryl, C6-C9 heteroaryl, C(O)R b 、C(O)NR a SO2R a or SO2NR a One or more substitutions in;

[0422] R 6It is F, Cl, Br, I, -CN, -CH3, -CH2CH3, -CH(CH3)2, -CH2CH(CH3)2, -CH2OH, -CH2OCH3, -CH2CH2OH, -C(CH3)2OH, -CH(OH)CH(CH3)2, -C(CH3)2CH2OH, -CH2CH2SO2CH3, -CH2OP(O)(OH)2, -CH2F, -CHF2, -CH2NH2, -CH2NHSO2 CH3, -CH2NHCH3, -CH2N(CH3)2, -CF3, -CH2CF3, -CH2CHF2, -CH(CH3)CN, -C(CH3)2CN, -CH2CN, -CO2H, -COCH 3. -CO2CH3, -CO2C(CH3)3, -COCH(OH)CH3, -CONH2, -CONHCH3, -CONHCH2CH3, -CONHCH(CH3)2, -CON(CH3)2, - C(CH3)2CONH2, -NH2, -NHCH3, -N(CH3)2, -NHCOCH3, -N(CH3)COCH3, -NHS(O)2CH3, -N(CH3)C(CH3)2CONH2, -N(CH3)CH2CH2S(O)2CH3, -NO2, =O, -OH, -OCH3, -OCH2CH3, -OCH2CH2OCH3, -OCH2CH2OH, -OCH2CH2N(CH3)2 -OP(O)(OH)2, -S(O)2N(CH3)2, -SCH3, -S(O)2CH3, -S(O)3H, cyclopropyl, cyclopropylamide, cyclobutyl, oxetane, azirone, 1-methylazirone-3-yl)oxy, N-methyl-N-oxetane-3-ylamino, azirone-1-ylmethyl, benzyloxyphenyl, pyrrolidine-1-yl, pyrrolidine-1-yl-methyl ketone, piperazine-1-yl, morpholinylmethyl, morpholinyl-methyl ketone or morpholine; and

[0423] m is 0, 1, 2, 3 or 4;

[0424] The alkyl diel, fluoroalkyl diel, aryl diel, carbocyclic diel, heterocyclic diel, and heteroaryl diel are optionally substituted by one or more groups independently selected from the group consisting of: F, Cl, Br, I, -CN, -CH3, -CH2CH3, -CH(CH3)2, -CH2CH(CH3)2, -CH2OH, -CH2OCH3, -CH2CH2OH, -C(CH3)2OH, -CH(OH)CH(CH3)2, -C(CH3)2CH2OH, -CH2CH2 SO2CH3, -CH2OP(O)(OH)2, -CH2F, -CHF2, -CF3, -CH2CF3, -CH2CHF2, -CH2CH2F, -CH(CH3)CN, -C(CH3)2CN, -CH2CN , -CH2NH2, -CH2NHSO2CH3, -CH2NHCH3, -CH2N(CH3)2, -CO2H, -COCH3, -CO2CH3, -CO2C(CH3)3, -COCH(OH)CH3, -CON H2, -CONHCH3, -CON(CH3)2, -C(CH3)2CONH2, -NH2, -NHCH3, -N(CH3)2, -NHCOCH, -N(CH3)COCH3, -NHS(O)2CH3, -N (CH3)C(CH3)2CONH2, -N(CH3)CH2CH2S(O)2CH3, -NO2, =O, -OH, -OCH3, -OCH2CH3, -OCH2CH2OCH3, -OCH2CH2OH, -OC H2CH2N(CH3)2, -OP(O)(OH)2,...

Claims

1. Use of an agent for detecting estrogen receptor pathway activity in an individual with breast cancer in the preparation of a kit for identifying an individual with breast cancer who may benefit from treatment comprising an endocrine therapy agent by the following method, wherein the endocrine therapy agent is selected from the following group: a selective estrogen receptor degrader, a selective estrogen receptor modulator, a selective estrogen receptor covalent antagonist, a selective human estrogen receptor agonist, or an aromatase inhibitor, or a combination of two or more thereof, the method comprising determining an estrogen receptor pathway activity score from a sample from the individual, wherein an estrogen receptor pathway activity score from the sample that is at or above a reference estrogen receptor pathway activity score identifies the individual as an individual who may benefit from treatment comprising an endocrine therapy agent, wherein the estrogen receptor pathway activity score is determined by subtracting an estradiol induction score determined by the average z score expression of at least 8 estradiol-induced genes from an estradiol induction score determined by the average z score expression of at least 6 estradiol-inducible genes. The invention relates to a method for determining an estradiol inhibition score determined by the average z-score expression of estradiol-inducible genes, wherein the at least eight estradiol-inducible genes are selected from the group consisting of AGR3, AMZ1, AREG, C5AR2, CELSR2, CT62, FKBP4, FMN1, GREB1, IGFBP4, NOS1AP, NXPH3, OLFM1, PGR, PPM1J, RAPGEFL1, RBM24, RERG, RET, SGK3, SLC9A3R1, TFF1, and ZNF703, and wherein the at least six estradiol-inducible genes are selected from the group consisting of BAMBI, BCAS1, CCNG2, DDIT4, EGLN3, FAM171B, GRM4, IL1R1, LIPH, NBEA, PNPLA7, PSCA, SEMA3E, SSPO, STON1, TGFB3, TP53INP1, and TP53INP2.

2. Use of an agent for detecting estrogen receptor pathway activity in an individual with breast cancer in the preparation of a kit for selecting an endocrine therapeutic agent for an individual with breast cancer by the following method, wherein the endocrine therapeutic agent is selected from the following group: a selective estrogen receptor degrader, a selective estrogen receptor modulator, a selective estrogen receptor covalent antagonist, a selective human estrogen receptor agonist, or an aromatase inhibitor, or a combination of two or more thereof, the method comprising determining an estrogen receptor pathway activity score from a sample from the individual, wherein the estrogen receptor pathway activity score is calculated by subtracting an estradiol inhibition score determined by the average z-score expression of at least 6 estradiol inhibition genes from an estradiol induction score determined by the average z-score expression of at least 8 estradiol-induced genes, wherein the at least 8 estradiol-induced genes are selected from the following group: AGR3, AMZ1, AREG, C5AR2, CELS R2, CT62, FKBP4, FMN1, GREB1, IGFBP4, NOS1AP, NXPH3, OLFM1, PGR, PPM1J, RAPGEFL1, RBM24, RERG, RET, SGK3, SLC9A3R1, TFF1 and ZNF703, and wherein the at least 6 estradiol-suppressed genes are selected from the following group: BAMBI, BCAS1, CCNG2, DDIT4, EGLN3, FAM171B, GRM4, IL1R1, LIPH, NBEA, PNPLA7, PSCA, SEMA3E, SSPO, STON1, TGFB3, TP53INP1 and TP53INP2, wherein the estrogen receptor pathway activity score from the sample that is at or above a reference estrogen receptor pathway activity score identifies the individual as an individual who may benefit from treatment including an endocrine therapy agent.

3. Use of an endocrine therapy agent in the preparation of a medicament for treating an individual with breast cancer, wherein the endocrine therapy agent is selected from the group consisting of a selective estrogen receptor degrader, a selective estrogen receptor modulator, a selective estrogen receptor covalent antagonist, a selective human estrogen receptor agonist, or an aromatase inhibitor, or a combination of two or more thereof, wherein the individual has been identified as an individual who is more likely to benefit from a treatment comprising an endocrine therapy agent by calculating an estrogen receptor pathway activity score determined from a sample from the individual, wherein the estrogen receptor pathway activity score is calculated by subtracting an estradiol inhibition score determined by the average z-score expression of at least 6 estradiol inhibition genes from an estradiol induction score determined by the average z-score expression of at least 8 estradiol induced genes, wherein the at least 8 estradiol induced genes are The at least 6 estradiol-repressed genes are selected from the group consisting of AGR3, AMZ1, AREG, C5AR2, CELSR2, CT62, FKBP4, FMN1, GREB1, IGFBP4, NOS1AP, NXPH3, OLFM1, PGR, PPM1J, RAPGEFL1, RBM24, RERG, RET, SGK3, SLC9A3R1, TFF1, and ZNF703; wherein the at least 6 estradiol-repressed genes are selected from the group consisting of BAMBI, BCAS1, CCNG2, DDIT4, EGLN3, FAM171B, GRM4, IL1R1, LIPH, NBEA, PNPLA7, PSCA, SEMA3E, SSPO, STON1, TGFB3, TP53INP1, and TP53INP2; wherein an estrogen receptor pathway activity score from the sample that is at or above a reference estrogen receptor pathway activity score identifies the individual as an individual who may benefit from treatment comprising an endocrine therapy agent; and The reference estrogen receptor pathway activity score is any one of the following: (a) an estrogen receptor pathway activity score determined from a sample obtained from the individual prior to administration of a first dose of an endocrine therapy agent; (b) an estrogen receptor pathway activity score determined from a sample from the individual at a previous time point, wherein the previous time point is after administration of a first dose of an endocrine therapy agent; (c) a pre-assigned estrogen receptor pathway activity score; or (d) Reference group.

4. The use according to any one of claims 1 to 3, wherein the reference estrogen receptor pathway activity score is an estrogen receptor pathway activity score in a reference population.

5. The use according to claim 4, wherein the reference population is a population of individuals suffering from hormone receptor-positive breast cancer.

6. Use of an agent for detecting estrogen receptor pathway activity in an individual with breast cancer in the preparation of a kit for monitoring the response of an individual with breast cancer to treatment with an endocrine therapy agent by the following method, wherein the endocrine therapy agent is selected from the following group: a selective estrogen receptor degrader, a selective estrogen receptor modulator, a selective estrogen receptor covalent antagonist, a selective human estrogen receptor agonist, or an aromatase inhibitor, or a combination of two or more thereof, The method include: (a) determining a first estrogen receptor pathway activity score from a sample from the individual at a first time point, the estrogen receptor pathway activity score being calculated by subtracting an estradiol inhibition score determined by the average z-score expression of at least 6 estradiol inhibition genes from an estradiol induction score determined by the average z-score expression of at least 8 estradiol inducible genes, wherein the at least 8 estradiol inducible genes are selected from the group consisting of: , AGR3, AMZ1, AREG, C5AR2, CELSR2, CT62, FKBP4, FMN1, GREB1, IGFBP4, NOS1AP, NXPH3, OLFM1, PGR, PPM1J, RAPGEFL1, RBM24, RERG, RET, SGK3, SLC9A3R1, TFF1, and ZNF703, wherein the at least 6 estradiol-repressed genes are selected from the group consisting of BAMBI, BCAS1, CCNG2, DDIT4, EGLN3, FAM171B, GRM4, IL1R1, LIPH, NBEA, PNPLA7, PSCA, SEMA3E, SSPO, STON1, TGFB3, TP53INP1, and TP53INP2; (b) after step (a), determining a second estrogen receptor pathway activity score from a sample from the individual at a second time point after administration of the endocrine therapy agent; as well as (c) comparing the first estrogen receptor pathway activity score to the second estrogen receptor pathway activity score, wherein a decrease in the second estrogen receptor pathway activity score relative to the first estrogen receptor pathway activity score predicts an individual who is likely to respond to treatment with an endocrine therapy agent.

7. The use according to claim 6, wherein the first estrogen receptor pathway activity score is: (a) an estrogen receptor pathway activity score determined from a sample obtained from the individual prior to administration of a first dose of an endocrine therapy agent; (b) an estrogen receptor pathway activity score determined from a sample from the individual at a previous time point, wherein the previous time point is after administration of a first dose of an endocrine therapy agent; or (c) Pre-assigned estrogen receptor pathway activity score.

8. Use of an agent for detecting estrogen receptor pathway activity in an individual with breast cancer in the preparation of a kit for identifying an individual with breast cancer who may benefit from treatment comprising an endocrine therapy agent by the following method, wherein the endocrine therapy agent is selected from the following group: a selective estrogen receptor degrader, a selective estrogen receptor modulator, a selective estrogen receptor covalent antagonist, a selective human estrogen receptor agonist, or an aromatase inhibitor, or a combination of two or more thereof, the method comprising determining an estradiol induction score from the average z-score expression of at least 23 estradiol-induced genes in a sample from the individual, the The 23 estradiol-inducible genes are selected from the following group: AGR3, AMZ1, AREG, C5AR2, CELSR2, CT62, FKBP4, FMN1, GREB1, IGFBP4, NOS1AP, NXPH3, OLFM1, PGR, PPM1J, RAPGEFL1, RBM24, RERG, RET, SGK3, SLC9A3R1, TFF1 and ZNF703; wherein an estradiol induction score from the sample that reaches or exceeds a reference estradiol induction score identifies the individual as an individual who may benefit from treatment including an endocrine therapy agent.

9. Use of an agent for detecting estrogen receptor pathway activity in an individual with breast cancer in the preparation of a kit for selecting an endocrine therapeutic agent for an individual with breast cancer by the following method, wherein the endocrine therapeutic agent is selected from the following group: a selective estrogen receptor degrader, a selective estrogen receptor modulator, a selective estrogen receptor covalent antagonist, a selective human estrogen receptor agonist, or an aromatase inhibitor, or a combination of two or more thereof, the method comprising determining an estradiol induction score from the average z-score expression of 23 estradiol-induced genes in a sample from the individual, the 23 estradiol-induced genes being selected from the group consisting of: The alcohol-inducible genes are selected from the group consisting of AGR3, AMZ1, AREG, C5AR2, CELSR2, CT62, FKBP4, FMN1, GREB1, IGFBP4, NOS1AP, NXPH3, OLFM1, PGR, PPM1J, RAPGEFL1, RBM24, RERG, RET, SGK3, SLC9A3R1, TFF1 and ZNF703; wherein an estradiol induction score from the sample that is at or above a reference estradiol induction score identifies the individual as one who may benefit from treatment comprising an endocrine therapy agent.

10. Use of an endocrine therapy agent in the preparation of a medicament for treating an individual with breast cancer, wherein the endocrine therapy agent is selected from the group consisting of a selective estrogen receptor degrader, a selective estrogen receptor modulator, a selective estrogen receptor covalent antagonist, a selective human estrogen receptor agonist, or an aromatase inhibitor, or a combination of two or more thereof, wherein the individual has been identified as an individual more likely to benefit from a treatment comprising an endocrine therapy agent by an estradiol induction score determined from the average z-score expression of 23 estradiol-induced genes, the 23 estradiol-induced genes being selected from the group consisting of AGR3, AMZ1, AREG, C5AR2, CELSR2, CT62, FKBP4, FMN1, GREB1, IGFBP4, NOS1AP, NXPH3, OLFM1, PGR, PPM1J, RAPGEFL1, RBM24, RERG, RET, SGK3, SLC9A3R1, TFF1, and ZNF703; wherein an estrogen receptor pathway activity score at or above a reference estrogen receptor pathway activity score identifies the individual as an individual who may benefit from treatment comprising an endocrine therapy agent; and The reference estrogen receptor pathway activity score is any one of the following: (a) an estrogen receptor pathway activity score determined from a sample obtained from the individual prior to administration of a first dose of an endocrine therapy agent; (b) an estrogen receptor pathway activity score determined from a sample from the individual at a previous time point, wherein the previous time point is after administration of a first dose of an endocrine therapy agent; (c) a pre-assigned estrogen receptor pathway activity score; or (d) Reference group.

11. The use according to claim 10, wherein the reference population is a population of individuals suffering from hormone receptor-positive breast tumors.

12. Use of an agent for detecting estrogen receptor pathway activity in an individual with breast cancer in the preparation of a kit for monitoring the response of an individual with breast cancer to treatment with an endocrine therapy agent by the following method, wherein the endocrine therapy agent is selected from the following group: a selective estrogen receptor degrader, a selective estrogen receptor modulator, a selective estrogen receptor covalent antagonist, a selective human estrogen receptor agonist, or an aromatase inhibitor, or a combination of two or more thereof, The method include: (a) determining a first estradiol induction score from the average z-score expression of 23 estradiol-inducible genes in a sample from the individual at a first time point, the 23 estradiol-inducible genes being selected from the group consisting of AGR3, AMZ1, AREG, C5AR2, CELSR2, CT62, FKBP4, FMN1, GREB1, IGFBP4, NOS1AP, NXPH3, OLFM1, PGR, PPM1J, RAPGEFL1, RBM24, RERG, RET, SGK3, SLC9A3R1, TFF1, and ZNF703; (b) after step (a), determining a second estradiol induction score from a sample from the individual at a second time point after administration of the endocrine therapeutic agent; and (c) comparing said first estradiol induction score to said second estradiol induction score, wherein a decrease in said second estradiol induction score relative to said first estradiol induction score predicts an individual who is likely to respond to treatment with an endocrine therapy agent.

13. The use according to claim 12, wherein the first estradiol induction score is: (a) an estradiol induction score determined from a sample obtained from the individual prior to administration of a first dose of an endocrine therapy agent; (b) an estradiol induction score determined from a sample from the individual at a previous time point, wherein the previous time point is after administration of a first dose of an endocrine therapeutic agent; or (c) Pre-assigned estradiol induction scores.

14. The use according to any one of claims 1-3, 6, 8-10 and 12, wherein the breast cancer is estrogen receptor positive breast cancer.

15. The use according to claim 14, wherein the estrogen receptor-positive breast cancer is luminal A breast cancer.

16. The use according to claim 14, wherein the estrogen receptor-positive breast cancer is luminal B breast cancer.

17. The use according to claim 16, wherein the breast cancer is advanced or metastatic breast cancer.

18. Use of an agent for detecting estrogen receptor pathway activity in an individual with breast cancer in the preparation of a kit for identifying the individual as an individual who may benefit from treatment including an endocrine therapy agent by the following method: include: Step 1: Detect the expression levels of the following genes: (a) all estradiol-repressed genes selected from the group consisting of BCAS1, CCNG2, IL1R1, PNPLA7, SEMA3E and STON1, and all estradiol-inducible genes selected from the group consisting of AMZ1, C5AR2, CELSR2, FKBP4, GREB1, OLFM1, SLC9A3R1 and TFF1; or (b) all estradiol-repressed genes selected from BCAS1, CCNG2, IL1R1, NBEA, PNPLA7, SEMA3E, STON1 and TP53INP1, and all estradiol-inducible genes selected from AMZ1, AREG, C5AR2, CELSR2, FKBP4, FMN1, GREB1, OLFM1, RBM24, SLC9A3R1 and TFF1; or (c) all estradiol-repressed genes selected from BAMBI, BCAS1, CCNG2, DDIT4, EGLN3, FAM171B, GRM4, IL1R1, LIPH, NBEA, PNPLA7, PSCA, SEMA3E, SSPO, STON1, TGFB3, TP53INP1 and TP53INP2, and all estradiol-inducible genes selected from AGR3, AMZ1, AREG, C5AR2, CELSR2, CT62, FKBP4, FMN1, GREB1, IGFBP4, NOS1AP, NXPH3, OLFM1, PGR, PPM1J, RAPGEFL1, RBM24, RERG, RET, SGK3, SLC9A3R1, TFF1 and ZNF703; Step 2: Determine the estrogen receptor pathway activity score, wherein the estrogen receptor pathway activity score is calculated by subtracting an estradiol repression score determined by the average z-score expression of all estradiol repressed genes in step 1(a), (b) or (c) from an estradiol induction score determined by the average z-score expression of all estradiol inducible genes in step 1(a), (b) or (c) in a sample from the individual, wherein an estradiol induction score from the sample that is at or above a reference estradiol induction score identifies the individual as an individual who may benefit from treatment comprising an endocrine therapeutic agent.

19. The use according to any one of claims 1-3, 6, 8-10, 12 and 18, wherein the endocrine therapeutic agent is a selective estrogen receptor degrader.

20. The use according to any one of claims 1-3, 6, 8-10, 12 and 18, wherein the selective estrogen receptor degrader is brilanestrant having the following structure: or a pharmaceutically acceptable salt thereof.

21. The use according to any one of claims 1-3, 6, 8-10, 12 and 18, wherein the selective estrogen receptor degrader is GDC-0927 having the following structure: or a pharmaceutically acceptable salt thereof.

22. The use according to any one of claims 1-3, 6, 8-10, 12 and 18, wherein the endocrine therapeutic agent is selected from a compound having the following formula: or a pharmaceutically acceptable salt thereof.

23. The use according to any one of claims 1-3, 6, 8-10, 12 and 18, wherein the endocrine therapeutic agent is a compound having the following formula:

24. The use according to any one of claims 1-3, 6, 8-10, 12 and 18, wherein the endocrine therapeutic agent is a compound having the following formula: or a pharmaceutically acceptable salt thereof.

25. The use according to any one of claims 1-3, 6, 8-10, 12 and 18, wherein the endocrine therapeutic agent is a compound having the following formula: or a pharmaceutically acceptable salt thereof.

26. The use according to any one of claims 1-3, 6, 8-10, 12 and 18, wherein the endocrine therapeutic agent is a compound having the following formula: or a pharmaceutically acceptable salt thereof.

27. The use according to any one of claims 1-3, 6, 8-10, 12 and 18, wherein the endocrine therapeutic agent is selected from a compound having the following formula: or a pharmaceutically acceptable salt thereof.

28. The use according to any one of claims 1-3, 6, 8-10, 12 and 18, wherein The endocrine therapeutic agent is a compound having the formula: or a pharmaceutically acceptable salt thereof.

29. The use according to any one of claims 1-3, 6, 8-10, 12 and 18, wherein The individual is a human.